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Summary 
Thyroid cancer is responsible for more deaths than all other endocrine cancers 
combined, and its incidence is rising. In contrast to other cancers, thyroid carcinomas 
rarely display mutations in p53. p53 is a potent tumour suppressor, and serves to inhibit 
cell transformation. Interestingly, the thyroid gland is also sensitive to the effects of 
ionising radiation, where WT p53 would normally play a protective role. However, there is 
evidence to suggest that aberrant expression of cellular oncogenes can result in the 
functional inactivation of WT p53. PBF is a proto-oncogene found to be overexpressed in 
thyroid tumours. PBF overexpression causes transformation in vitro and tumourigenesis 
in vivo. Work within this thesis describes the functional relationship between PBF and 
p53 in thyroid cancer. We provide evidence for a direct interaction between PBF and p53 
in thyroid cancer cells, and our data demonstrate that oncogenic expression of PBF 
adversely affects p53 homeostasis by increasing its degradation, with PBF potentially 
serving as a co-factor in a complex with p53 and HDM2. Surprisingly, PBF had no effect 
on p53-mediated transcription using focused microarrays. Nonetheless, overexpression 
of PBF conferred a significant survival advantage following DNA damage, indicating that 
PBF might potentially facilitate neoplastic growth and tumourigenesis. Besides regulation 
of transcription, p53 performs a wide range of biological functions. PBF may therefore 
serve to promote p53 inactivation independently of its role as a transcription factor. 
Overall, these data indicate that oncogenic expression of PBF may result in a novel 
mechanism of p53 inactivation, where PBF binds to p53 and accelerates its degradation 
in complex with HDM2. These events cause an increase in cell survival following DNA 
damage, thereby potentially promoting tumourigenesis in thyroid cancers expressing WT 
p53. 
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 Pathogenesis of thyroid cancer  1.1.
1.1.1. Epidemiology and classification 
Thyroid cancer is the most frequently diagnosed endocrine malignancy and is 
responsible for more deaths than all other endocrine cancers combined (Davies et al, 
2002; Chen et al, 2009; Albores-Saavedra et al, 2007). Thyroid cancers are fairly 
uncommon in the general population, accounting for around 1 % of all newly 
diagnosed malignant disease, which equates to 0.5 % of cancers in males and 1.5 % 
of cancers in females (Chen et al, 2009). The incidence of thyroid cancer is higher in 
older patients, those with family history, and a history of exposure to ionising 
radiation (Sharma et al, 2010; Johnston et al, 2012). However, the worldwide 
incidence of thyroid cancer has been gradually increasing and has almost tripled 
between 1975 and 2008 in the UK and other industrialised countries (Burgess & 
Tucker, 2006; Albores-Saavedra et al, 2007; Nikiforov & Nikiforova, 2011). Whilst 
females are approximately three times more likely to develop thyroid malignancy, the 
rate of incidence in males has increased at a similar level (Figure 1.1).  
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Figure 1.1: Chart representing the rise in incidence of thyroid cancer between 1975 
and 2008. The chart data displays European Age-Standardised Incidence Rates per 
100,000 Population, by Sex, in Great Britain. Whilst females are 3 times more likely 
to develop the disease, male incidence rate has risen similarly to females (cancer 
research UK). 
 
The significant rise in thyroid cancer incidence has been attributed to recent 
advances in diagnostic techniques, where thyroid ultrasonography provides 
significant ascertainment bias. Moreover, the steady increase in the use of radiation 
to the head or neck for diagnosis or treatment (for example through the use of 
computed tomography (CT) scans), may present a significant risk of thyroid 
malignancy (Baker & Bhatti, 2006). Whilst differentiated thyroid cancers mostly have 
good prognosis, the rise in incidence of this disease is higher than for any other 
human cancer. Furthermore, in comparison to other malignancies, thyroid cancer has 
the second most rapidly increasing mortality rate (Johnston et al, 2012; Figure 1.2). 
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Figure 1.2: Charts representing the SEER incidence and mortality rates for thyroid 
cancer. A: thyroid cancer presents with the greatest rise in incidence compared to 
other human cancers B: In comparison to other malignancies thyroid cancer also has 
the second highest increase in mortality rate (Data taken from the National Institute 
of Health, SEER). 
 
The thyroid is comprised of two main cell types; with thyroid follicular epithelial cells 
forming the majority. These cells are responsible for the uptake of iodine at the 
basolateral membrane and produce thyroglobulin and the thyroid hormones thyroxine 
(T4) and triiodothyronine (T3). Parafollicular C cells residing in the connective tissue 
adjacent to the follicles are involved in the production and secretion of calcitonin 
(Nikiforov & Nikiforova, 2011).  The vast majority of thyroid cancers arise from thyroid 
follicular cells, with only a small minority (3-5 %) originating from parafollicular or C-
cells. Thyroid cancers originating from follicular epithelial cells can be subdivided into 
well-differentiated papillary carcinomas, follicular carcinomas, and undifferentiated 
anaplastic carcinomas. Anaplastic carcinomas can develop spontaneously, although 
many arise via stepwise dedifferentiation of both papillary and follicular carcinomas 
(Nikiforov & Nikiforova, 2011; Nikiforova & Nikiforov, 2009). 
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 Regulation of normal thyroid cell growth 1.1.1.1.
In order to maintain the functional and structural integrity of the follicular unit, the 
proliferative renewal of thyroid cells is paramount. Therefore the control of normal 
thyroid epithelial cell growth and associated proliferation of cells in the surrounding 
connective tissue and capillaries must be tightly controlled (Kimura et al, 2001). 
Normal thyroid cell growth is mediated primarily by 2 potentially synergistic 
mechanisms involving Thyroid stimulating hormone (TSH) and cyclic AMP (cAMP) 
signalling, and the Insulin-like growth factor 1 (IGF-1) (Brenner-Gati et al, 1988). 
TSH is produced by the anterior pituitary gland in response to thyroptropin releasing 
hormone (TRH), which is in turn produced within the hypothalamus. Additionally, the 
hypothalamus produces and secretes somatostatin which is responsible for inhibiting 
the production and secretion of TSH. TSH stimulates the thyroid gland to produce 
and secrete thyroid hormones T3 and T4. Circulating blood levels of T3 and T4 
provide an auto regulatory negative feedback loop to further monitor thyroid follicular 
cell growth and hormone production. For example, when circulating T3/T4 levels are 
low, the production of TSH is increased; conversely when T3 and T4 levels are high, 
TSH production is decreased (Lewis et al, 2004; Medina et al, 1999, 2000). The TSH 
receptor is expressed on the cell surface of thyroid follicular cells, and following 
interaction with TSH, is activated and stimulates the production of adenylate cyclase, 
ultimately serving to promote thyroid cell growth and proliferation via the cAMP 
pathway. cAMP is an important intracellular second messenger and mediates thyroid 
cell growth primarily through activation of protein kinase A (PKA) and stimulation 
mTOR protein kinase, which ultimately serve to activate specific transcription factors 
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involved in cell cycle progression and DNA synthesis (Deleu et al, 1999; Goretzki et 
al, 1987; Kimura et al, 2001). 
In addition to TSH stimulation of thyroid growth, IGF-1 is able to stimulate thyroid 
growth via independent mechanisms. However, it is thought that TSH and IGF-1 
perform synergistically in vivo to mediate successful thyroid cell growth and 
proliferation (Brenner-Gati et al, 1988; Zaballos & Santisteban, 2012). IGF-1 
stimulates mitogenic activity in thyroid follicular epithelium via activation of the 
phosphoinositol-3 kinase (PI3K) pathway. Specifically binding of IGF-1 to the IGF1R 
activates the receptor's intrinsic tyrosine kinase activities, which results in the 
phosphorylation of the IRSs (Insulin Receptor Substrates) (Deleu et al, 1999; 
Zaballos & Santisteban, 2012). Tyrosine-phosphorylated IRSs interact with the 
cytoplasmic protein PI3K through its SH2 (Src Homology -2) domains. PI3K 
activation then leads to the transduction of the functional effects of IGFs (Zheng et al, 
2002).  
Whilst it is well established that normal thyroid growth and proliferation hinges upon 
TSH and IGF-1 signalling, the exact molecular mechanisms and specific endpoints 
regarding mitogenic signals remain poorly characterised. Furthermore, the extent to 
which TSH and IGF-1 can independently or synergistically drive thyroid cell growth, 
remains uncertain (Zaballos & Santisteban, 2012) 
1.1.2. The molecular biology of thyroid cancer 
In a similar manner to other cancer types, thyroid cancer initiation and progression 
occurs through stepwise accumulation of different genetic and epigenetic events 
within the cell. Such events include activating and inactivating somatic mutations, 
alterations in gene expression patterns, dysregulation of microRNAs and aberrant 
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control of gene methylation (Nikiforov & Nikiforova, 2011). Amongst these alterations, 
somatic mutations are by far the most common and thoroughly understood. Indeed 
thyroid cancer represents a neoplastic condition where critical genes are frequently 
mutated via two distinct molecular mechanisms: point mutations or chromosome 
rearrangements (Ciampi & Nikiforov, 2007). Point mutations refer to the replacement 
of a single nucleotide base with another; and may also include insertions or deletions 
of a single nucleotide base pair within a gene sequence (Namba et al, 1990). 
Chromosomal rearrangements represent abnormalities caused by breakage and 
fusion of different parts of homologous or non-homologous chromosomes (Fugazzola 
et al, 1995). Interestingly, it has been suggested that these 2 types of somatic 
mutations associate with different aetiological aspects of thyroid carcinogenesis. It 
has become increasingly apparent that thyroid tumours arise due to genetic 
alterations leading to aberrant activation of the MAPK pathway (Xing, 2007; Nikiforov 
& Nikiforova, 2011 and Figure 1.3). This pathway is of central importance to the 
regulation of cell growth, differentiation and survival in response to growth factors, 
hormones, and cytokines all of which interact with receptor tyrosine kinases present 
on the cell surface (MacCorkle & Tan, 2005). In over 70 % of thyroid papillary 
carcinomas genetic alterations occur in genes coding for the receptor tyrosine 
kinases, RET and NTRK1, and also 2 intracellular manipulators of the MAPK 
pathway: the GTP-binding protein RAS and the serine threonine kinase BRAF. 
Interestingly these mutations rarely overlap in the same tumour, suggesting that 
activation of this signalling pathway is a crucial initiating event for thyroid 
transformation (Romei et al, 2012).  
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Figure 1.3: Schematic overview of the MAPK signalling pathway. Extracellular 
mitogenic signals, for example growth factors, activate membrane bound receptors to 
initiate an intracellular signalling cascade. Upon activation, Ras interacts with 
members of the Raf protein kinase family (for example the B-type Raf kinase, BRAF). 
Activated BRAF causes the phosphorylation and activation of MEK1/2, which 
sequentially phosphorylates and activates ERK1/2; ERK1/2 brings about the 
phosphorylation and activation of numerous downstream proteins, which ultimately 
lead to increased expression of genes involved in cell proliferation, growth, survival 
and tumourigenesis. Thyroid papillary carcinomas may also present with the 
RET/PTC fusion protein, which brings about aberrant activation of the MAPK 
pathway upstream of Ras. BRAF is commonly mutated in thyroid papillary 
carcinomas, leading to aberrant activation of the MAPK pathway (adapted from Xing, 
2007). 
1.1.3. RET/PTC rearrangements 
The RET proto-oncogene is located on chromosome 10q11.2 and encodes a 
receptor tyrosine kinase. The RET gene encodes three functional domains, including 
an extracellular ligand binding domain, transmembrane region, and an intracellular 
tyrosine kinase domain. Receptor tyrosine kinases are activated following ligand: 
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receptor interaction. RET-TKs are responsive to growth factors belonging to the glial 
cell-line derived neutrophic factor family (Pachnis et al, 1993). Upon ligand binding, 
RET-TKs undergo dimerization, autophosphorylation of specific tyrosine residues in 
the intracellular domain, and activation of the MAPK signalling cascade (Ciampi & 
Nikiforov, 2007 and Figure 1.3).  
The Ret proto-oncogene is normally expressed in cells deriving from the neural crest, 
the kidney and the enteric nervous system (Pachnis et al, 1993). In papillary thyroid 
cancer the RET proto-oncogene is rendered constitutively active by fusion of the 
RET-TK domain with the 5’ terminal sequence of one of a number of different 
heterologous genes via rearrangements that generate a series of transforming 
oncogenes collectively described as RET/PTCs (Hamatani et al, 2008). RET/PTC 
rearrangements occur in up to 20 % of thyroid papillary carcinomas, and such 
rearrangements present with increased metastatic potential. Furthermore, murine 
transgenic models of RET/PTC rearrangements demonstrate the potential of 
RET/PTCs to stimulate activation of the MAPK pathway, thereby increasing the risk 
of thyroid transformation and tumourigenesis (Kim & Zhu, 2009). 
1.1.4. RAS mutations  
The 3 human RAS genes (HRAS, NRAS and KRAS) encode homologous G-proteins 
that function via propagation of intracellular signals following activation by membrane 
bound receptors (Nikiforov & Nikiforova, 2011). Point mutations within important 
domains of the Ras protein are known to either increase its affinity for GTP 
(mutations in codons 12/13 of KRAS), or inactivate its autocatalytic GTPase function 
(mutation of codon 61 of HRAS and NRAS). These mutations give rise to constitutive 
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RAS function and aberrant stimulation of downstream targets within the MAPK and 
PI3K pathways, thus promoting tumourigenesis (Figure 1.3).  
In contrast to other molecular markers, RAS mutations are not restricted to any 
particular histological subtype of thyroid cancer. For instance, in thyroid papillary 
carcinomas, Ras mutations are present in 15-20 % of tumours (Suarez et al, 1990; 
Nikiforov & Nikiforova, 2011). Interestingly, thyroid papillary carcinomas housing RAS 
mutations frequently present with follicular variant histology. RAS mutations are much 
more highly associated with conventional follicular thyroid carcinomas, where these 
mutations are present in 40-50 % of cases (Motoi et al, 2000; Nikiforov & Nikiforova, 
2011), and to a lesser extent within follicular adenomas, where the prevalence of 
RAS mutations account for 20-40 % of cases (Manenti et al, 1994). Furthermore, 
RAS mutations are also present in up to 35 % of poorly differentiated and up to 50 % 
of anaplastic carcinomas, suggesting that RAS mutations may promote tumour 
aggressiveness and relatively poor prognosis (Garcia-Rostan et al, 2003; Basolo et 
al, 2000). 
1.1.5. BRAF mutations  
Another potent modulator of the MAP kinase pathway is the B-type RAF kinase 
(BRAF). Mutations in BRAF have been extensively implicated with aberrant 
regulation of the MAP-K signalling pathway and have a characterised role in human 
cancers (Davies et al, 2002). Interestingly, amongst other human cancers, thyroid 
cancers demonstrate a high prevalence of BRAF mutations, making this gene of 
central importance to the initiation and progression of thyroid malignancies (Dhomen 
& Marais, 2007). Since the discovery of BRAF mutations in human cancers, more 
than 40 different mutations in BRAF have been identified. Missense point mutations 
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in the kinase domain of the BRAF gene are located throughout exons 11 and 15, and 
in over 80 % of cases the T1799A mutation is responsible for cell transformation 
(Davies et al, 2002). The T1799A mutation translates to a V600E amino acid 
substitution within the BRAF protein product, leading to its constitutive activation. The 
V600E mutation is thought to render the BRAF kinase constitutively active because 
the normal valine residue which lies adjacent to the activation phosphorylation site at 
serine 599, is mutated to a negatively charged glutamate residue, thereby mimicking 
activation at this site (Dhillon & Kolch, 2004; Mercer & Pritchard, 2003). Therefore the 
molecular and cellular consequences of the V600E mutation in BRAF result in a 
constitutively active BRAF kinase by disrupting the interaction of the activation 
domain with the ATP-binding P-loop, which normally renders BRAF inactive (Wan et 
al, 2004). 
BRAF mutations occur in up to 45 % of thyroid papillary carcinomas and in up to 40 
% of insular anaplastic carcinomas (Xing, 2007). Such observations imply that BRAF 
mutations (e.g. BRAFV600E) are an early transforming event in thyroid tumourigenesis, 
and predispose thyroid tumours to increasing dedifferentiation and aggressiveness. 
Finally, in a mouse model of targeted BRAFV600E overexpression, mice developed 
significant goiters and an increased prevalence of thyroid papillary carcinomas 
compared to their wild-type counterparts (Charles et al, 2011; Chakravarty et al, 
2011). Such studies highlight the transforming potential of the V600E mutation in 
BRAF. 
1.1.6. Nuclear receptor mutants 
The PAX8/PPARγ rearrangement arises from the fusion between a fragment of the 
thyroid transcription factor gene 8 (PAX8), and the peroxisome proliferator activator 
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receptor γ1 (PPARγ) gene, encoding a DNA-binding nuclear receptor that functions 
to regulate adipocyte differentiation and lipid metabolism (Evans et al, 2004; Gregory 
Powell et al, 2004). Whilst the mechanisms of PAX8/PPARγ are particularly poorly 
understood, the genetic rearrangement occurs in 30-35 % of follicular thyroid 
carcinomas (Nikiforova et al, 2003). Furthermore, it has been documented that 
mutations in the thyroid hormone receptor (TR) α1 and β1 transcripts play a role in 
thyroid papillary cancer progression (Puzianowska-Kuznicka et al, 2002).  
1.1.7. Other oncogenes in thyroid cancer  
In addition to BRAF and RAS mutations, a number of additional oncogenic mutations 
have been identified in poorly differentiated and anaplastic carcinomas, but not in 
well-differentiated tumour types, suggesting these mutations are late events in 
thyroid tumourigenesis. The catenin (cadherin-associated protein) beta 1 (CTNNB1) 
gene encodes a β-catenin involved in cell-adhesion and Wnt signalling, and a point 
mutation in this gene has been found in up to 60 % of anaplastic carcinomas (Garcia-
Rostan et al, 1999; García & Santisteban, 2002; Kurihara et al, 2004). In addition, 
studies have demonstrated that poorly differentiated and anaplastic carcinomas 
harbour mutations of PI3K pathways components including phosphoinositide-3-
kinase catalytic alpha polypeptide (PIK3CA) itself (10-20 %), phosphatise and tensin 
homologue (PTEN) (5-15%) and v-akt murine thymoma viral oncogene homolog 1 
(AKT1) (5-10%) (Ricarte-Filho et al, 2009; García-Rostán et al, 2005; Santarpia et al, 
2008; Dahia et al, 1997). 
1.1.8. The prognosis of thyroid cancer 
Retrospective studies have enabled the recognition of certain factors that negatively 
affect the prognosis of thyroid cancer and such risk is assessed in patients with DTC 
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using a prognostic scoring system. Tumour size, Node metastases and distant 
Metastases (TNM) is the most frequently used system and is summarised in Table 
1-1. While most patients have a good prognosis following surgery and administration 
of radioiodine, BTA guidelines suggest 10 year disease specific mortality for stage I 
as 1.7 %, rising to 60.9 % for stage IV disease (British Thyroid Association and Royal 
College of Physicians 2007; Loh et al. 1997). However, 5-30 % of patients will 
develop locoregional recurrence (British Thyroid Association and Royal College of 
Physicians 2007; Jonklaas et al, 2006; Mazzaferri, 1993), with subsequent five year 
survival of 87 %. If distant metastases are present, five year survival falls to 72 % 
(Jonklaas et al. 2006). Accuracy of the staging and grading systems used in 
differentiated thyroid cancer has increased (D’Avanzo et al, 2004). Factors 
associated with a worse prognosis are male gender, age greater than 40 years and 
tumours of the follicular subtype or greater than 1 cm in size (British Thyroid 
Association and Royal College of Physicians 2007; Mazzaferri, 1993). 
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Table 1-1: A table summarising Tumour size, Node metastases and Distance 
metastases (TNM) as a scoring system to predict mortality rates. (Compiled from the 
British Thyroid Association and Royal College of Physicians 2007 and D’Avanzo et 
al, 2004). 
 
The gold standard for diagnosing thyroid malignancy remains FNA cytology (FNAC). 
However, recent advances in molecular analysis of FNA help to provide 
individualised treatment strategies to patients. Currently, indeterminate cytology 
indicating an inability to conclusively discern benign from malignant nodules is found 
in 10-20 % of patients with thyroid nodules and malignancy is diagnosed in only 20 % 
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of these. Consequently, unnecessary surgery is performed in 60-90 % of these 
patients (Baloch et al, 2002, 2008; Mazzaferri, 1993). Advances in the molecular 
analysis of the mutational markers described above (see Section 1.1.2), represent 
opportunities to identify specific cancer subtypes, and to provide highly improved 
diagnostic accuracy to avoid unnecessary surgical procedures. For example, the 
collective results of 22 studies of thyroidal FNA samples revealed that in 1,117 
nodules deemed positive for the BRAFV600E mutation, 99.3 % were then histologically 
classified as papillary carcinomas, demonstrating the great accuracy of BRAFV600E 
mutations as an indicator of cancer (Nikiforov & Nikiforova, 2011; Nikiforova & 
Nikiforov, 2009; Kim et al, 2011). 
1.1.9. Ionising radiation and thyroid cancer 
The thyroid gland (especially the developing thyroid in children and adolescents), has 
been reported to be highly sensitive to the carcinogenic effects of ionising radiation 
(Takeichi et al, 1991; Nikiforov et al, 1996; Hamatani et al, 2008). Data regarding the 
increased prevalence of thyroid papillary carcinomas of atomic bomb survivors in 
Hiroshima and Nagasaki, and of populations affected by the Chernobyl nuclear 
disaster, provide irrefutable evidence that ionising radiation is a significant risk factor 
for thyroid papillary carcinomas (Kazakov et al, 1992; Astakhova et al, 1998; Takeichi 
et al, 1991; Imaizumi et al, 2006; Hamatani et al, 2008). For instance, the Chernobyl 
nuclear power plant accident resulted in exposure of populations in the Ukraine, 
Belarus and the Russian Federation to significant volumes of radionuclides (I131, I133 
and Cs137). The primary source of radiation to the thyroid was incorporated into the 
food chain through radioiodine contaminated milk and other food products, resulting 
in cellular damage through β-emissions. Specificity to the thyroid occurs due to the 
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expression of the sodium iodide symporter (NIS) at the basolateral membrane of 
thyroid follicular cells, thereby resulting in the accumulation of radioiodides. Children 
in affected areas received relatively high doses of irradiation due to the small size of 
the thyroid and the above average consumption of contaminated milk. This exposure 
in children and adolescents in contaminated areas correlated with a significant 
increase in thyroid cancer incidence (Kazakov et al, 1992; Astakhova et al, 1998; 
Nikiforov et al, 1996; Nikiforov & Gnepp, 1994; Fagin, 2005). 
Whilst BRAF mutation(s) appear to be the most common genetic change in sporadic 
papillary carcinomas, the RET/PTC proto-oncogene appears to play a much more 
prevalent role in radiation induced thyroid cancer. For example, in the most 
contaminated regions resulting from the Chernobyl nuclear disaster, the resulting 
prevalence of paediatric thyroid papillary carcinoma was increased by ~100-fold in 
the highest affected areas, compared to the incident rate before the disaster (Fagin, 
2005; Hamatani et al, 2008). Genetic analysis of post Chernobyl tumours suggests 
that RET/PTC rearrangements are highly prevalent; found in 66-87 % of radiation 
induced papillary tumours compared to a maximum of ~40 % in sporadic paediatric 
tumours and only 15-12 % in adult  sporadic tumours (Klugbauer et al, 1995; 
Fugazzola et al, 1995; Ciampi & Nikiforov, 2007). Further to these observations, 
irradiation of human thyroid carcinoma cell lines and human foetal thyroid cells led to 
an increased rate of RET/PTC translocations in a dose dependent manner. These 
findings provide direct in vitro evidence that irradiation causes RET/PTC 
rearrangements in thyroid follicular cells (Ito et al, 1993).   
More recently, in 2011, another nuclear disaster took place in Fukushima Japan in 
wake of the Tohoku earthquake and tsunami on 11th March 2011. Fukushima 
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represents the largest nuclear disaster since Chernobyl of 1986. Whilst this disaster 
resulted in significant atmospheric efflux of radioiodides, the exposure rates for the 
surrounding population differ significantly from Chernobyl for the following reasons: 
The reactors in Chernobyl had no containment vessel, and fires burned for many 
days resulting in persistent discharge of radioiodides into the atmosphere (Wakeford, 
2011a). Furthermore, radioiodides were distributed over larger areas, ingested by 
grass eating cows, and subsequently ingested as milk by millions of children. These 
factors resulted in populations around Chernobyl receiving massive doses of 
irradiation. In contrast, Fukashima appears to have resulted in significantly lower 
doses of public exposure (Boice, 2012; Wakeford, 2011b; Dauer et al, 2011). For 
example, the Fukushima plant incorporated containment vessels around each 
reactor, and the prevailing winds primarily deposited radioiodides into the ocean. In 
addition, successful evacuation of individuals in affected areas and monitoring of 
local food products and water supply was undertaken (Boice, 2012). Such 
preventative measures including the distribution of stable iodine pills ensured that 
individual exposure was minimal. Nonetheless some radioiodides were deposited 
over populated areas, suggesting that the Fukushima disaster may have a significant 
effect on thyroid cancer incidence in the future (Yasumura, 2011).  
 p53 is the guardian of the genome 1.2.
1.2.1. The discovery of p53 
p53 was initially discovered following investigations into the oncogenicity of DNA 
tumour viruses (Levine & Oren, 2009). DNA tumour viruses archetypally express a 
small number of viral encoded proteins which stimulate an immune response within 
the host, leading to the production of virus specific antibodies. Such antibodies were 
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exploited to investigate and monitor viral proteins encoded by the viral genome. 
Subsequent investigations revealed that certain proteins (for example the SV40 large 
T antigen), were important in the transforming potential of virus infected cells. Sera 
from animals possessing SV40-induced tumours were utilised to immunoprecipitate 
the SV40 large T antigen, where interestingly, a non-viral protein with a predicted 
molecular mass of 53 kDa was found to be co-immunoprecipitated (Linzer & Levine, 
1979; Lane & Crawford, 1979; Kress et al, 1979; Levine & Oren, 2009). Thus it 
appeared that the SV40 large T antigen was engaging in a specific interaction with 
an unknown cellular protein of 53 kDa. Future studies revealed that the term p53 is 
actually a misnomer, with the molecular mass of the p53 protein being only 47.3 kDa. 
This gross overestimate has since been attributed to the proline rich region within the 
protein that hinders the migration of the protein through SDS-PAGE (Levine & Oren, 
2009).  
1.2.2. p53 the tumour suppressor protein 
Shortly after its initial discovery, p53 was wrongly characterised as an oncogene. 
Since SV40 appeared to drive the overexpression and cellular accumulation of p53 in 
transformed cells, it followed logically that p53 was a positive mediator of cell 
transformation (Sarnow et al, 1982; Linzer et al, 1979). Furthermore, it was 
determined that p53 expression was elevated in tumours, but not in non-transformed 
cells, further lending weight to the hypothesis that increased p53 expression 
promoted cell transformation and tumourigenesis (Rotter, 1983; DeLeo et al, 1979; 
Levine & Oren, 2009). This hypothesis logically (but wrongly) identified p53 as an 
oncogene. The eventual characterisation of p53 as bona fide tumour suppressor was 
initially hindered following experiments using the first successful clones of the p53 
Chapter 1: General introduction 
19 
 
gene from transformed cells. Interestingly, when the sequences of a number of these 
p53 clones were sequenced it was observed that no 2 clones were identical. 
Subsequent sequencing of p53 from normal cells revealed that most, if not all of the 
clones contained inactivating mutations of p53 (Finlay et al, 1988; Halevy et al, 1991; 
Eliyahu et al, 1988). Moreover, TP53 was shown to be lost or inactivated in a number 
of malignancies, both human and murine, and is now known to be the most 
frequently altered gene in human tumours. Finally, it was discovered that the rare 
disease Li Fraumeni syndrome, which results in a severely increased susceptibility to 
a number of types of cancers, arises from inactivating germline mutations in p53 
(Varley et al, 1997). These observations provided irrefutable evidence that p53 is a 
tumour suppressor protein and not an oncogene.  
1.2.3. The molecular structure of p53 
Mammalian p53 family members, including p53, p63 and p73 represent an 
evolutionarily ancient group of transcription factors which may date back as far as the 
divergence of animalia and fungi some 2 billion years ago (Nedelcu & Tan, 2007). 
Sequencing and characterisation of p53 have revealed a number of important 
domains within the p53 protein that are crucial to its function. 
 p53 transactivation domain 1.2.3.1.
Full length wild-type p53 contains 2 tandem, but functionally independent, C-terminal 
transcription activation domains (TADs). The first, AD1, lies between residues 1-42, 
and the second, AD2, spans residues 64-92 and encompasses a proline rich domain 
(PRO) from residues 64-92 (Figure 1.4). Both AD1 and AD2 are able to interact with 
the basal cellular transcription machinery and also histone acetyl transferases 
(HATs). Furthermore, both AD1 and AD2 are able to independently drive 
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transcription when fused to an exogenous DNA binding domain (DBD) (Candau et al, 
1997). Interestingly, AD1 and AD2 appear to promote distinct subsets of genes to 
bring about different biological processes; for example, investigations into mutants of 
p53 containing deleted or non-functional AD1 revealed that this domain was critical 
for p53-mediated cell cycle arrest in response to genotoxic insult (Zhu et al, 1998). 
However, mutated or deleted AD1 still allows for p53-mediated apoptosis, since the 
presence of a functional AD2 domain still allows for interaction of p53 with its 
canonical response elements, and AD1 mutants can still transactivate the potent pro-
apoptotic gene BAX (Zhu et al, 1998; Johnson et al, 2005). These findings suggest 
that the tandem transcriptional activation domains AD1 and AD2 are responsible for 
bringing about growth arrest and apoptosis respectively. 
 
 
Figure 1.4: Schematic representation of the p53 protein, showing important functional 
domains (not to scale). The p53 protein is 393 amino acids in length, with an N-
terminal acidic transcription activation domain (TAD), also known as AD1+ AD2 
which activate transcription factors (residues 1-42 + 43-92); a proline rich domain 
(PRO), is important for p53 apoptotic functions (residues 64-92); a central DNA 
binding domain (DBD) containing important arginine residues and a zinc atom 
(residues 102-292); a tetramerisation domain (TD) required for p53 oligermerisation 
following activation (residues 307-355) - this region also contains a nuclear 
localisation signal (NLS); and a C-terminal regulation domain (RD – residues 355-
393). 
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 p53 DNA binding domain 1.2.3.2.
The DNA binding domain (DBD) of p53 encompasses residues 102-292 (Figure 1.4). 
Within these residues lie 4 distinct regions that are highly conserved between 
species and other p53 family members. These are: conserved region II (residues 
117–142), conserved region III (residues 171–181), conserved region IV (residues 
234–256), and conserved region V (residues 270–286) (Harms & Chen, 2006). 
These conserved regions play a critical role in the interaction of tetrameric p53 with 
p53 consensus sequences (Olivier et al, 2002). The recognised p53 response 
element contains 2 decamers consisting of the following sequence: RRRCWWGYYY, 
which are separated by a spacer of 0-13 bp, where R=purine, C=cytosine, 
W=adenine or thymidine, G=guanine, and Y=pyrimidine (el-Deiry et al, 1992). 
Several studies indicate that a monomer binds the pentameric sequence and that a 
tetramer binds the full consensus site. To bind DNA, the larger part of the DBD forms 
an antiparallel β-sandwich (two β-sheets packed together). This serves as a scaffold 
that supports the structures important for the interaction with DNA. These structures 
include two large loops and a loop-sheet-helix motif (Cho et al, 1994). The two large 
loops are held together by a zinc atom which is coordinated by three cysteine 
residues and one histidine residue (C176, H179, C238, and C242). C176 and H179 
are situated in loop 2 which covers conserved region III. C238 and C242 are 
positioned in loop 3 which encompasses region IV. Loop 3 also contains S241 and 
R248, which interact with the DNA phosphate backbone and the minor groove, 
respectively. The loop-sheet-helix motif spans conserved region V; this motif contains 
residues that contact the DNA phosphate backbone (R273, A276, R283) as well as 
the major groove (C277 and R280). Another amino acid residue, K120, is located 
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within conserved region II and is crucial for the interaction with the major groove and 
the DNA phosphate backbone (Harms & Chen, 2006; Cho et al, 1994; Viadiu, 2008). 
The ability of p53 to bind to DNA appears to be of great significance to its function as 
a tumour suppressor. This statement is supported by the fact that many tumours 
harbour mutations that alter the affinity of p53 for its consensus sequence. For 
example, more than 80 % of p53 mutations apparent in human tumours are found in 
this central DBD (residues 93-292) (Olivier et al, 2002). These mutations include 
contact site alterations, where crucial residues for p53-DNA interactions are mutated, 
and conformational mutations which alter the shape of the anti-parallel β-sandwich, 
thereby reducing the proximity of the important DNA binding regions of p53 (Harms & 
Chen, 2006). 
 p53 tetramerisation domain 1.2.3.3.
As previously mentioned, to bind with high affinity to its consensus sequence, and 
therefore mediate transcription, p53 must do so as a tetramer. The tetramerisation 
domain (TD) spanning residues 325-356 is responsible for formation of p53 into 
tetramers (Harms & Chen, 2006 and see Figure 1.4). The secondary structure of the 
TD is a β-pleated sheet linked to an α-helix, where p53 monomers form dimers 
through antiparallel β-sheet: antiparallel α-helix interaction (Kamada et al, 2011; 
Mateu & Fersht, 1998). p53 then forms a terameric structure by forming as a dimer of 
dimers by utilising parallel helix:helix interactions. The tetrameric structure is 
maintained through formation of a hydrophobic core produced by the helix:helix 
interaction (Mateu & Fersht, 1998, Figure 1.5). Although the TD is not a mutational 
hotspot, mutation of this domain has been observed in some Li-Fraumeni syndrome 
families (Petitjean et al, 2007). The L344P mutation lies within the α-helix that is 
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important for the dimer–dimer interaction and results in monomeric p53 (Scoumanne 
et al, 2005; Zambetti, 2007; see Figure 1.5).  
 
Figure 1.5: Schematic representation of four p53 monomers orientated into 
tetrameric conformation. p53 initially forms dimers by interaction of antiparallel β-
pleated sheets and antiparallel α-helices. Tetramers form as a dimer of dimers by 
interaction of parallel α-helices to form a stable hydrophobic core. Critical residues 
such as L344 have been observed to be mutated in Li-Fraumeni syndrome resulting 
in monomeric p53 –highlighting the importance of p53 tetramer formation in its 
function as a tumour suppressor (image adapted from Scoumanne et al, 2005). 
 
 p53 nuclear localisation signal 1.2.3.4.
To exert its effects as a transcription factor, p53 must shuttle between the cytoplasm 
and the nucleus. Tetrameric p53 cannot pass freely through the nuclear pore space 
due to its size, and therefore utilises nuclear import and export signals in order to 
cross the nuclear membrane. Accordingly, p53 possess a bipartite nuclear 
localisation signal located between residues 305-322 (Figure 1.4) and also 2 nuclear 
export signals at the C-terminus and N-terminus of the protein (Scoumanne et al, 
2005; Harms & Chen, 2006; Viadiu, 2008). It is interesting to note that whilst NLS 
and NES mutations appear relatively rare, p53 subcellular localisation can be 
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affected by post translational modifications (Liang & Clarke, 1999). Furthermore, 
many viral infections, such as cytomegalovirus infection, result in p53 sequestration, 
thereby inhibiting p53 function (Wang et al, 2001).  
 p53 regulatory domain 1.2.3.5.
The last 30 amino acids (residues 362-393), make up the regulatory domain of p53 
(Figure 1.4). This domain is comprised of a relatively large number of lysine and 
arginine residues, and therefore is basic in nature (Brady & Attardi, 2010). The basic 
region of p53 has affinity for DNA binding in a non-sequence-specific manner and 
also promotes linear diffusion serving as a landing pad to enhance p53 detection of 
specific response elements. In addition, the p53 regulatory domain is subject to a 
large number of post-translational modifications including acetylation, methylation, 
phosphorylation, SUMOylation, neddylation and ubiquitination (Harms & Chen, 2006; 
Viadiu, 2008; Liu & Kulesz-Martin, 2006). The C-terminus of p53 is unfolded, acting 
as a flexible linker by acquisition of more stable secondary structure following 
interaction with other proteins that regulate p53 expression and function (Brady & 
Attardi, 2010; Bell et al, 2002) 
1.2.4. The molecular function of p53 
p53 is unique amongst the other p53 family members in its potency as a tumour 
suppressor. Further to co-ordinating effective tumour suppression by mediating 
crucial cellular responses to cell stress and DNA damage, p53 has an emerging 
repertoire of roles in diverse range of physiological processes. Such processes 
include fertility, cell metabolism, mitochondrial function and stem cell maintenance 
(Hu et al, 2007; Kanfi et al, 2008; Matoba et al, 2006; Gatza et al, 2007; Junttila & 
Evan, 2009). To function effectively as a tumour suppressor, p53 is required to 
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unerringly distinguish between normal and potentially neoplastic cell growth by 
promoting the former and preventing the latter (Vogelstein et al, 2000). The following 
paragraphs highlight the molecular mechanisms and cellular biology of p53 tumour 
suppressor function.  
p53 is a sequence specific transcription factor and is widely considered “the guardian 
of the genome”, owing mostly to its central role in the organisation of cellular 
responses to genotoxic stress (Wu & Levine, 1997). Under normal conditions, the 
levels of p53 are tightly controlled within the cell and levels remain low via direct 
regulation of p53 protein stability (Vogelstein et al 2000). p53 is primarily turned over 
via ubiquitin mediated proteolysis. Ubiquitination is co-ordinated by a group of 
enzymes known as ubiquitin ligases. Specifically, E3 ubiquitin ligases are responsible 
for the direct ubiquitination of target proteins (Ardley & Robinson, 2005). The activity 
of E3 ligases is augmented by the activity of ubiquitin activating enzymes (E1 
ligases) and ubiquitin conjugating enzymes (E2 ligases). For instance, E1 ligases 
initiate the ubiquitination process by binding specifically to two ubiquitin monomers, 
making ubiquitin molecules functionally available for transfer to E2 ligases (Nandi et 
al, 2006, Schulman & Harper, 2009). E2 ligases functionally interact with specific E3 
ligases; E3 ligases are responsible for the sequential addition of mono-ubiquitin tags, 
from the E2 ligase to the target protein (Ardley & Robinson, 2005, 3; Nandi et al, 
2006, Risseeuw et al, 2003) Several E3 ligases are known to promote p53 
degradation, including HDM2, COP-1, PIRH2, TOPORS and ARF-BP1 (Brooks & Gu, 
2006). Of these enzymes, HDM2 is by far the most extensively studied, and the 
observation that HDM2 null mice die early in development due to p53-dependent 
massive apoptosis highlights the critical role that this protein plays in p53 
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homeostasis (Jones et al, 1995; Montes de Oca Luna et al, 1995). HDM2 contains a 
number of functional domains including an N-terminal p53 binding domain; NLS and 
NES regions important for nuclear shuttling (which are also sites of phosphorylation); 
an acidic region crucial for the ubiquitination and degradation of p53 and HDM2 (also 
a site of extensive phosphorylation); a zinc finger domain, important for contacting 
ribosomal proteins; and a RING finger domain critical for mediating the ubiquitination 
of substrates (Meek & Hupp, 2010 and Figure 1.6). Mechanistically, HDM2 binds 
directly to, and prevents p53 function by masking specific sites that are essential for 
interaction with transcriptional co-activators (Brooks & Gu, 2006). Furthermore, 
HDM2 contains a self and p53 specific ubiquitin ligase that covalently attaches 
monoubiquitin tags to specific lysine residues within the C-terminus of p53 (Honda et 
al, 1997). This site specific ubiquitination targets the p53 protein for degradation 
within nuclear and cytoplasmic 26s proteasomes (Sionov & Haupt, 1999; Brooks & 
Gu, 2006; Meek, 2004). The function of HDM2 is thought to be highly facilitated by 
MDMX. The MDMX protein shares significant structural homology with HDM2 and 
appears to have both dependent and independent roles in the modulation of p53 
activity (Marine et al, 2007; Meek & Hupp, 2010). For instance, MDMX binds directly 
to the N-terminus of p53, and significantly represses p53 transcriptional activity. 
However, MDMX lacks intrinsic ubiquitin ligase activity and hence cannot directly 
influence p53 ubiquitination. MDMX is able to indirectly regulate p53 ubiquitination by 
activating the ubiquitin ligase function of HDM2 by forming HDM2:MDMX 
heterodimers by virtue of their mutual RING finger domains (Kawai et al, 2007).  
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Figure 1.6: Schematic demonstrating DNA damage induced post-translational 
modification of p53 and HDM2 (not to scale). Important regions of p53 are the 
transactivation domain (TAD), proline rich region (PRO) and regulatory domain (RD). 
Important regions of HDM2 include nuclear localisation domains (NLS/NES), the 
acidic domain and the RING finger domain. Phosphorylation sites are represented by 
red and blue circles respectively. In each case, target residue numbers are 
documented and text boxes summarise the biological outcomes of each of the 
indicated modification sites (adapted from Meek, 2004; Meek & Anderson, 2009). 
 
Central to the HDM2 regulation of p53 levels is the fact that the HDM2 gene itself can 
be induced by p53 in response to cellular stress. Such induction creates an 
autoregulatory negative feedback loop, which keeps p53 levels low in the absence of 
cellular stresses. In addition, this relationship ensures that responses arbitrated by 
p53 are limited with regard to their extent and duration; for example after a relatively 
benign cellular insult (Wu & Levine, 1997).  
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As mentioned previously, the levels of p53 protein are kept at low levels in the 
absence of cellular stress; nonetheless, the p53 gene is continually transcribed and 
translated, so that the levels of p53 within the cell are determined by the rate at which 
it is degraded rather than the rate at which it is made (Vogelstein et al, 2000). This 
allows for a rapid p53 response upon stimulus by relevant stress signals (Meek, 
2004). p53 is rapidly stabilised and activated in response to a plethora of genetic 
insults. Of the diverse stimuli that elicit a p53 response, the molecular mechanism by 
which p53 is activated following DNA damage are perhaps the most fully understood 
(Meek, 2004). Stabilisation of p53 is achieved by uncoupling the direct interaction of 
p53 with its negative regulator HDM2. This event is mediated principally by multisite 
phosphorylation of both p53 and HDM2, and results in the inhibition of the 
degradation of p53 (Fang et al, 2000). Indeed human p53 has been reported to be 
post translationally modified in at least 18 different sites (Appella & Anderson, 2000, 
2001). For example, in response to DNA damage caused by exposure to ionising 
radiation, p53 is modified initially through phosphorylation of ser-15 by the protein 
kinase ATM (Saito et al, 2002). This initial phosphorylation event primes the p53 
molecule for numerous additional post translational modifications such as 
phosphorylation of thr-18 by CK1 (reviewed in Appella & Anderson, 2000 and Figure 
1.6). In the case of the DNA damage response, such modification of p53 results in 
the activation of p53 as a transcription factor, which as a tetramer, binds DNA and 
drives the expression of a multitude of genes responsible for cell-cycle inhibition, 
apoptosis, genetic stability and inhibition of blood vessel formation (Vogelstein et al, 
2000 and Figure 1.7). In nearly all mammalian cell types, the direct effect of p53 
stimulation is an initial block in the progression of the cell cycle and this effect is 
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brought about by the p53 driven expression of the potent cyclin dependent kinase 
inhibitor p21WAF1/CIP. p21 inhibits the phosphorylation events mediated by cyclin 
dependent kinases which would otherwise result in smooth progression though the 
cell cycle (Waldman et al, 1995). Indeed, the classical G1/S phase boundary arrest 
observed after activation of the p53 response is the result of the inhibition of 
CDK2/cyclin E by p21 (Waldman et al, 1995). This G1/S arrest is critical in preventing 
the replication of damaged DNA (Figure 1.7). 
The example above is just one of an exhaustive list of important events that can 
positively or negatively regulate cell fate to prevent cell transformation and maintain 
the integrity of the genome (see Figure 1.7). 
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Figure 1.7: Schematic overview of the classical p53 transcriptional response to DNA 
damage. DNA damage activates specific kinases that post-translationally modify p53 
and HDM2, allowing for p53 activation. Activated p53 undergoes further post-
translational modifications that further stabilise p53, allowing it to form tetramers. 
Tetrameric p53 undergoes nuclear translocation, where it binds to p53 response 
elements and drives the transcription of target genes to bring about cellular 
responses that ultimately serve to protect against malignant progression (Vogelstein 
et al, 2000). 
 
1.2.5. The importance of p53 in human cancer 
Clearly loss or mutation of p53 is strongly associated with an increased susceptibility 
to cancer and most functions of p53 have been considered in light of how p53 might 
protect from malignant progression (Vousden & Lane, 2007). As such, p53 has 
become one of the most studied genes in human disease, primarily because most 
human cancers have defects in the p53 pathway (Murray-Zmijewski et al, 2008). In 
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fact, gene mutations inactivate p53 in around 50 % of human cancers, although the 
mutation rate varies dramatically from up to ~70 % of lung cancers, ~60 % of colon 
cancers, but only 10-12 % of leukaemias (see the IARC TP53 mutation database for 
further information). Further to this p53 can be functionally inactivated by oncogenic 
expression of its negative regulators, including HDM2, MDMX, and ARF (Brooks & 
Gu, 2006; Meek & Anderson, 2009; Hu et al, 2006; Sherr, 2006). More recently, 
expression of novel viral and cellular oncogenes have been observed to be 
functionally activated in a number of human tumours, further highlighting the 
importance of wild-type p53 inactivation in human cancers. The following section 
provides some examples of the molecular mechanisms of p53 functional inactivation 
caused by viral and cellular oncogenes.  
1.2.6. Mechanisms of p53 inactivation by viral oncogenes 
The E6 protein from human papilloma virus (HPV) in cervical carcinoma, for example, 
degrades p53 by ubiquitin mediated proteolysis (Kyo et al, 1991; Mishra & Jana, 
2008). Another pertinent example includes hepatocarcinoma resulting from hepatitis 
B infections. 90% of these viruses encode HBXAg; this protein has affinity for the N-
terminal domain of p53 and as a result is able to inhibit its transcriptional activity 
(Truant et al, 1995). Finally, the well characterised SV40 viral T antigen associates 
with a region of the p53 protein responsible for DNA binding and results in the 
prevention of active p53 from associating with the promoter of target genes (Mietz et 
al, 1992).  
1.2.7. p53 inactivation by cellular oncogenes 
As mentioned previously, oncogenic expression of the regulators of p53 expression 
and activity can aberrantly affect the p53 pathway, and HDM2, the master regulator 
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of p53, is no exception. The HDM2 gene is amplified in a variety of tumours, and 
HDM2 overexpression without amplification is a common mechanism of p53 
inactivation in certain cancers, including breast cancer (Bond et al, 2005; Osman et 
al, 1999; Hu et al, 2006). Furthermore, MDMX, a protein that shares significant 
homology to HDM2, has been extensively implicated in the functional inactivation of 
p53. Unlike HDM2, MDMX does not have intrinsic E3 ligase activity and does not 
promote p53 degradation. However, MDMX binds to HDM2 through C-terminal RING 
domain interaction (Shvarts et al, 1996, 1997; Tanimura et al, 1999; Sharp et al, 
1999) and stimulates the ability of HDM2 to ubiquitinate and degrade p53. MDMX 
overexpression has been found in a number of primary tumours or tumour cell lines 
with wild-type p53 (Riemenschneider et al, 1999; Danovi et al, 2004; Marine et al, 
2007), suggesting that MDMX may contribute to p53 inactivation during 
tumourigenesis.  
1.2.8. p53 in thyroid cancer 
TP53 mutations are very common in human malignancies, accounting for 50 % of all 
known cases (Vogelstein et al, 2000). However, mutations in TP53 are much rarer in 
thyroid carcinomas, where they account for only 10 % of cases (Olivier et al, 2002; 
Harvey et al, 1995; Malaguarnera et al, 2007a). Furthermore, p53 mutations almost 
exclusively occur in the poorly differentiated and aggressive histotypes, including 
anaplastic carcinomas (Fagin et al, 1993). These observations and the indolent 
progression of most thyroid tumours have suggested that p53 may play only a minor 
role in thyroid cancer, where mutations in p53 only serve to promote tumour 
progression to aggressive or invasive subtypes.  
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In addition to p53 inactivating mutations, it is becoming increasingly apparent that 
wild-type p53 is often functionally inactivated by viral or cellular oncogenes (Brooks & 
Gu, 2006; Meek & Anderson, 2009; Hu et al, 2006; Sherr, 2006). It is therefore 
becoming progressively more important to assess the function of p53 in those 
cancers that do not present with inactivating mutations, as this may have profound 
implications on the treatment of such tumours.  
 p53 inactivation in thyroid cancer 1.2.8.1.
In cancer types that are not normally associated with mutations in p53 or underlying 
viral infection, there is evidence for the role of cellular proteins in the functional 
inactivation of p53. For example the High-mobility group factors are nonhistone 
proteins, which participate in a variety of cellular processes including gene 
transcription, integration of retroviruses into chromatin and the promotion of 
metastatic progression (Reeves, 2001; Sgarra et al, 2004). HMGA1a and HMGA1b 
are together referred to as HMGA1 because they arise from the alternative splicing of 
a common gene (Johnson et al, 1988). HMG factors participate in specific 
protein:protein and protein:DNA interactions and initiate activity of the 
promoter/enhancer regions of genes (Reeves, 2001). Interestingly, HMG1A is 
commonly over expressed in thyroid cancers (Malaguarnera et al, 2007a). 
Subsequently the role of HGM1A in the p53 response was investigated, and the 
results are summarised below. 
In several thyroid cancer cells of different histotypes, silencing of the HMGA1 gene 
resulted in an increase in p53 transcriptional activity, measured by analysis of p21 
promoter activity (Frasca et al, 2006). In a similar vein, such studies also revealed 
that HMGA1 is able to inhibit p53 activity that would normally result in successful 
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G1/S phase arrest and apoptosis after treatment with DNA damaging agents. 
Moreover, coimmunoprecipitation experiments demonstrated direct interaction of 
HMGA1 and p53. The results of this study indicate a novel role of HMGA1 in 
regulation of the oncosuppressor function of p53 and aberrant control of this gene 
may play a central role not only in thyroid cancers but many other tumour types as 
well (Frasca et al, 2006). 
The above study, amongst others, provides evidence that over expression of other 
novel cellular proteins can result in the inhibition of p53 activity or p53 responses. 
Such proteins may be responsible for cell transformation and therefore play a central 
role in tumourigenesis. 
 Pituitary tumor transforming gene binding factor (PBF) 1.3.
Pituitary tumor transforming gene binding factor (PBF or PTTG1IP) is the poorly 
characterised interacting partner of the pituitary tumor transforming gene (PTTG) (Pei 
& Melmed, 1997; Chien & Pei, 2000). PTTG stimulates the expression of fibroblast 
growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF) (McCabe et 
al, 2002). Furthermore, PTTG is the multifunctional human securin, with an 
established role in the control of mitosis. Here, PTTG functions to prevent premature 
sister chromatid separation by inhibition of separase activity (Zou et al, 1999 and 
Figure 1.8). In addition, PTTG has also been linked with DNA repair mechanisms and 
foetal development amongst other roles (Kim et al, 2005; Boelaert et al, 2003). PTTG 
has also been implicated in numerous neoplastic conditions, and PTTG 
overexpression has been reported in tumours of the thyroid, pituitary, colon, ovary 
and breast (Stratford et al, 2005; Puri et al, 2001; Heaney et al, 2000; Shibata et al, 
2002). 
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Figure 1.8: Schematic overview of the function of PTTG as human securin and its 
relevance to human cancers. Overexpression of PTTG leads to aneuploidy: under 
normal conditions PTTG serves to inhibit the activity of separase and therefore 
prevents premature sister chromatid separation. At the metaphase-anaphase 
boundary PTTG is degraded by the anaphase promoting complex (APC) allowing 
separase to co-ordinate sister chromatid separation (and hence normal metaphase to 
anaphase transition). However, oncogenic levels of PTTG result in aneuploidy 
through the inhibition of mitosis progression by the increased repression of separase 
activity. PBF is thought to facilitate the nuclear entry of PTTG. (Figure adapted from 
Lewy et al, 2012). 
 
The mechanism by which PTTG regulates FGF-2 was determined through discovery 
and isolation of PBF. Using the yeast 2-hybrid system to identify interacting partners 
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of PTTG, PBF was isolated and characterised. PBF is located on chromosome 
21q21.3 and encodes a protein 180 amino acids in length; with a predicted molecular 
mass of 22kDa (Chien & Pei, 2000). It is interesting to note that PBF is found in the 
distal portion of chromosome 21 to which the majority of phenotypic features of 
Down’s syndrome map (Lyle et al, 2009).   
Whilst PBF appears to lack sequence homology with other human proteins, placing 
constraints on prediction of physiological role, this suggests unique functionality. 
Furthermore, PBF is ubiquitously expressed and highly conserved, implying 
significant evolutionary importance (Yaspo et al, 1998; Smith et al, 2011). The PBF 
protein consists of four functional domains including an N-terminal signal peptide, 
PSI domain, transmembrane region and a C-terminal domain containing a bipartite 
nuclear localisation signal (NLS) and sorting signal (Yaspo et al, 1998; Chien & Pei, 
2000 and Figure 1.9). The bipartite nuclear localisation signal, located towards the C-
terminus of PBF, appears important for the translocation of PTTG into the nucleus. In 
fact, ablation of the PBF NLS prevents PTTG regulation of FGF-2, suggesting that 
PBF may indirectly mediate the promotion of angiogenesis through subcellular 
distribution of PTTG (Chien & Pei, 2000).  
 
Figure 1.9: Schematic representation of the putative functional domains of the PBF 
protein. PBF contains an N-terminal signal peptide, a PSI domain (common to 
plexins, semaphorins and integrins), a bipartite nuclear localisation signal (NLS) and 
a C-terminal sorting signal. 
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1.3.1. PBF in thyroid cancer  
PBF overexpression has been characterised in thyroid and pituitary tumours, as well 
as those of the colon and breast, suggesting an oncogenic role for PBF in 
tumourigenesis (Chien & Pei, 2000; Stratford et al, 2005; Watkins et al, 2010a) 
(Figure 1.10). Additionally, PBF overexpression in thyroid tumours was found to be 
independently associated with early tumour recurrence (Stratford et al, 2005). Whilst 
PBF protein expression was significantly elevated in thyroid carcinomas, no 
mutations were found in the coding region of PBF when it was sequenced in 24 
thyroid tumours, suggesting that PBF, whilst overexpressed, does not appear to be 
mutated in thyroid cancer. PBF levels, however, significantly correlate with PTTG 
expression, where overexpression of PTTG in human primary thyrocytes and 
HCT116 cells significantly increased PBF protein expression (Stratford et al, 2005).  
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Figure 1.10: Western blotting and Real-time PCR data demonstrating significant 
elevation of PBF protein and mRNA expression in thyroid papillary carcinomas 
compared to normal tissues. Overexpression of proteins in tumours may point to an 
oncogenic role in cell transformation and/or tumourigenesis (data taken from 
Stratford et al, 2005. *** P<0.001). 
 
 More recently a study designed to assess the precise contribution of PBF to cell 
transformation and/or tumourigenesis was performed. NIH3T3 cell lines stably over 
expressing PBF, as well as wild type and mutated PTTG were constructed, and 
colony transformation assays conducted. PBF and PTTG overexpression led to 
significant colony formation, although over-expression of mutant forms of PTTG 
which were unable to stimulate PBF mRNA expression did not. The results of this 
study revealed that PBF overexpression could transform NIH3T3 cells in vitro. 
Furthermore, subcutaneous injection of NIH3T3 cells over expressing PBF elicited 
large tumours in athymic nude mice (Stratford et al 2005). Due to the dynamic 
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interaction of PBF and PTTG, the precise role of PBF in tumourigenesis remained 
unclear from this study. However, given that PTTG was not induced in a stable cell 
line of PBF overexpression it is reasonable to suggest that PBF may be a 
transforming gene in its own right (Stratford et al, 2005). 
 
.  
Figure 1.11: PBF is transforming in vitro and tumourigenic in vivo. A: Images of cell 
colony formation highlighting in vitro cell transformation of NIH3T3 cells stably 
transfected with PBF, WT PTTG, PTTG with mutated binding domain (BD-PTTG) and 
PTTG with mutated SH3 domain (SH3-PTTG) compared to VO-transfected cells. The 
graph represents the mean number of colonies/well. Both PBF and PTTG were able 
to significantly influence colony formation, but mutants of PTTG were not. B: Tumour 
growth in nude mice injected with NIH3T3 cells overexpressing PBF compared with 
VO (data taken from Stratford et al, 2005. ***p<0001). 
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 PBF and the sodium iodide symporter 1.3.1.1.
The sodium iodide symporter (NIS), under normal conditions, functions to mediate 
the uptake of iodide from the bloodstream and across the basolateral membrane of 
thyroid follicular cells, where it is utilised for thyroid hormone biosynthesis (Spitzweg 
et al, 2001). The expression of NIS, and therefore the ability to incorporate iodide, is 
a unique feature of thyroid follicular cells; and as such radioiodine has been central in 
in the treatment of thyroid tumours for the last 60 years (Shen et al, 2001). Whilst 
treatment of thyroid cancer is relatively successful, leading to particularly good 
prognosis, significant loco-regional recurrence is observed in up to 30 % of cases 
(Jonklaas et al, 2006; Mazzaferri, 1993). Interestingly, many thyroid tumours that 
express functional NIS do so at significantly diminished levels. This is due to reduced 
NIS expression and compromised targeting to, or retention at, the plasma membrane 
thereby leading to its functional inactivation. Indeed, even with the co-stimulation of 
the TSH receptor to increase iodide uptake, up to 20 % of differentiated thyroid 
cancers do not amass enough radioiodine for eradication. Thyroid cancers and their 
metastases which present as radioiodine refractory are associated with particularly 
poor prognosis; therefore, understanding the mechanisms whereby NIS regulation is 
impaired in thyroid tumours is an important consideration in the treatment of thyroid 
cancer (Kogai et al, 2006; Smith et al, 2011).  
PTTG overexpression was observed to decrease iodide uptake and reduce NIS 
expression in human primary thyrocytes. Furthermore, high PTTG expression was 
strongly associated with decreased radioiodine uptake during patient follow-up (Sáez 
et al, 2006; Heaney et al, 2001; Smith et al, 2011). These data highlighted a potential 
role for PTTG in NIS regulation and function and led to the investigation of the effects 
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of PBF on this pathway. Firstly, in a series of thyroid cancers harbouring oncogenic 
levels of PBF and PTTG, NIS expression was significantly reduced compared to 
normal thyroid (Boelaert et al, 2007). Further study revealed that both PTTG and 
PBF overexpression caused significant reduction in iodide uptake, with the greatest 
effects observed following synergistic overexpression of both PTTG and PBF. Further 
interrogation of this model revealed that PTTG mediated repression of NIS was 
severely abrogated by administration of FGF-2 antibody, suggesting that the 
mechanism of PTTG repression by NIS was, at least in part, dependent upon FGF-2 
secretion. Conversely, FGF-2 antibody treatment had no effect on PBF repression of 
iodide uptake, suggesting an independent mechanistic role for PBF in the repression 
of iodide uptake (Boelaert et al, 2007). Recently the novel mechanism of NIS 
regulation by PBF was elucidated.  Subcellular localisation studies revealed that PBF 
overexpression caused the redistribution of NIS from the plasma membrane into 
intracellular vesicles, where it was found to colocalise with the tetraspanin CD63. 
Moreover, cell-surface biotinylation assays demonstrated that PBF was able to 
significantly able to reduce the membrane expression of NIS compared to VO-
transfected controls. Critically GST-pulldown assays and co-immunoprecipitation 
assays confirmed a direct interaction between NIS and PBF in vitro. The functional 
consequence of this was examined using WT PBF and 3 deletion mutants. Whilst 
PBF significantly repressed iodide uptake, the 3 PBF mutants that showed 
significantly different subcellular expression, and did not localise to cytoplasmic 
vesicles, were unable to significantly affect NIS activity. These findings highlight a 
potentially important mechanism of NIS regulation by PBF under normal conditions, 
and highlight the possible role of PBF overexpression in resistance of a subset of 
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thyroid tumours that resist radioiodine ablation (Boelaert et al, 2007; Smith et al, 
2009). Furthermore, these findings suggest that PBF may have a number of roles to 
play in normal cellular physiology and in tumourigenesis.  
1.3.2. PBF outside the thyroid 
When the promoter region of PBF was examined, PBF was found to contain putative 
oestrogen response elements (EREs). To test whether PBF expression was 
regulated by oestrogen, ERα positive MCF-7 cells were treated with synthetic 
oestrogen analogues. Treatment with such analogues resulted in significant elevation 
of PBF protein and mRNA expression. Furthermore oligonucleotide pulldown assays 
demonstrated binding of ERα to the PBF promoter. PBF was also observed to be 
overexpressed in breast tumours, where PBF protein expression positively correlated 
with ERα status. Interestingly overexpression of PBF significantly increased the 
invasive capacity of MCF-7 cells compared to controls, when measured using 
specific Matrigel invasion assays (Watkins et al, 2010). These data highlight a 
putative role for PBF in tumour progression outside the thyroid, and suggest that PBF 
may play a diverse role in cellular physiology, encompassing a number of different 
biological functions. 
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Figure 1.12: PBF overexpression induces breast cell invasion: A: Representative 
images of invading cells (arrowed) from Matrigel invasion assays B: The mean 
number of invading cells were calculated at 24 and 48 hours and PBF 
overexpression was observed to significantly increase the invasive capacity of MCF-7 
at both time-points (data taken from Watkins et al, 2010. **p<0.01). 
 
1.3.3. Preliminary data 
Recent preliminary work from within our group has aimed at characterising the role 
and function of PBF in tumourigenesis more fully. For instance, Glutathione-S-
transferase experiments were performed to assess whether PBF and p53 interact in 
vivo. Specifically, PBF or p53 protein was GST-tagged by insertion of PBF or p53 
sequences into a GST-tagged bacterial expression vector and PBF or p53-GST 
fusion proteins were generated. Additionally, [35s]-methionine PBF or p53 was 
generated via direct in vitro translation. For the detection of the potential interaction 
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of PBF with p53, Bacterial lysates containing the p53-GST fusion protein were 
incubated with beads conjugated with glutathione to allow for the immobilisation of 
p53 to the assay beads. Following immobilisation of p53 onto the assay beads, in 
vitro translated [35s]-methionine PBF was incubated with the immobilised p53, and 
after sequential wash steps, proteins were eluted from the assay beads using 
detergent and subject to SDS-PAGE. [35s]-labelled proteins were then detected 
using X-ray film exposure. Glutathione-S-Transferase (GST) assays showed direct 
binding of PBF to p53, and through additional mutational analysis, 2 specific regions 
of p53 necessary for PBF interaction were discovered. These regions lie between 
amino acid residues 1-100 and 318-393. Conversely by disrupting PBF sequences it 
was also discovered that the N-terminal region of PBF was essential for p53 
interaction, with binding repressed by removal of 2 N-terminal regions lying between 
amino acids 28-93 and 93-149.  
 
Figure 1.13: PBF binds p53. A: Binding of [35S]-PBF to GSTp53 (1-393) and GST-
p53 deletion mutants versus a GST-only control. B: Binding of [35S]-p53 to GST-
tagged PBF (1-180) and GST-PBF deletion mutants versus a GST-only control 
(McCabe laboratory unpublished data). 
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 Other preliminary work within our group involved observing the effects of PBF on 
p53-mediated gene regulation through HDM2 promoter assays in H1299 (p53-null) 
cells. Transfection of p53 elicited a 30.7+/-2.6-fold stimulation of HDM2 promoter 
activity, whereas transfection of PBF failed to modulate promoter activity. On the 
other hand, co-transfection with PBF significantly repressed p53 transcriptional 
activity to 16.3+/-1.1-fold (Figure 1.14). Interestingly, alongside this study it was 
observed that PBF protein expression increased after exposure to gamma irradiation, 
reaching maximal levels after 24 hours in p53 positive HCT116 cells (McCabe 
laboratory unpublished data). 
 
Figure 1.14: HDM2 luciferase reporter assays in p53-null H1299 cells. A: Schematic 
representation of p53 binding to the HDM2 promoter and driving the transcription of 
the luciferase reporter gene. B: The effects of PBF on HDM2 promoter activity in 
p53-null H1299 cells. PBF was unable to influence HDM2 promoter activity in the 
absence of p53. Exogenous expression of p53 significantly increased HDM2 
promoter activity 30.7+/-2.6-fold. However, co-expression of PBF with p53 
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significantly reduced p53-mediated HDM2 promoter activity to 16.3+/-1.1-fold 
(***p<0.001, McCabe laboratory unpublished data). 
 
The preliminary observations described above are indicative of a role for PBF in the 
DNA damage response through modulation of the p53 pathway. Given that PBF is 
overexpressed in several tumours, PBF may have an important role in 
tumourigenesis by binding specifically to p53 and inhibiting downstream responses 
involved in the maintenance of cellular and genetic stability.  
The wealth of preliminary data supporting a role for PBF in tumourigenesis and more 
specifically within the context of p53-inhibition has prompted further study. The 
overall aim of my research project was therefore to characterise novel PBF 
modulation of p53 function in thyroid cancer.  
 Hypothesis  1.4.
Thyroid cancer is often caused by point mutations or chromosomal rearrangements. 
For example, the BRAF V600E mutation and RET/PTC rearrangements lead to 
aberrant activation of the MAP kinase pathway, thereby leading to aberrant cell 
growth, survival and proliferation, thus promoting neoplastic growth and cell 
transformation (Fagin, 2005; Xing, 2007; Dhomen & Marais, 2007; Ciampi & 
Nikiforov, 2007). However, in contrast to the majority of human cancers, thyroid 
carcinomas rarely display mutations in p53; and those cancers that do display p53 
mutations are almost exclusively of the poorly differentiated and aggressive 
histotypes (Vogelstein et al, 2000; Olivier et al, 2002; Malaguarnera et al, 2007a). 
p53 is a potent tumour suppressor, and when functional serves to inhibit neoplastic 
growth and cell transformation by inhibiting cell growth, promoting cell cycle arrest, 
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initiating apoptosis and driving cells into senescence, amongst other antitumourigenic 
responses (Meek, 2004; Vousden & Lane, 2007). Interestingly, through the study of 
the Chernobyl nuclear disaster and others, the thyroid gland has been observed to 
be highly sensitive to the carcinogenic effects of ionising radiation via accumulation 
of radioiodides, to which functional p53 would normally play an important protective 
role (Nikiforov et al, 1996; Nikiforov & Gnepp, 1994; Klugbauer et al, 1995).  
In addition to inactivating mutations, it is clear that p53 is also extensively inactivated 
by viral oncogenes and oncogenic expression of the negative regulators of p53 
function. Moreover, novel cellular oncogenes are emerging, that when aberrantly 
expressed significantly contribute to cell transformation and tumour progression via 
direct functional inactivation of p53 (Danovi et al, 2004; Mietz et al, 1992; Havre et al, 
1995). These findings suggest that p53 inactivation may be present in many tumours 
that express wild-type p53. The functional inactivation of p53 in thyroid cancer has 
not been comprehensively investigated, and remains controversial. Nonetheless, 
novel oncogenes are emerging, including HMG factors that when overexpressed bind 
directly to p53 and inhibit its transcriptional function (Malaguarnera et al, 2007a; 
Frasca et al, 2006).  
PBF is a relatively poorly characterised proto-oncogene found to be overexpressed in 
thyroid and other tumours (Stratford et al, 2005; Watkins et al, 2010 and our 
unpublished data). Oncogenic expression of PBF, as found in thyroid tumours 
causes transformation of cells in vitro and subcutaneous injection of cells stably 
overexpressing PBF into athymic nude mice leads to tumourigenesis in vivo 
(Stratford et al, 2005). Recently preliminary data indicate that PBF may interact 
directly with p53 and repress its transcriptional activity.  
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Given that p53 mutations are rare in thyroid cancer, yet the thyroid gland is 
particularly sensitive to the carcinogenic effects of ionising radiation, we 
hypothesised that p53 functional inactivation is common in thyroid cancers lacking 
inactivating p53 mutations. Moreover, we hypothesised that PBF overexpression (as 
observed in thyroid cancers) leads to the functional inactivation of p53 by directly 
interacting with and abrogating its tumour suppressor function in response to cell 
stress such as DNA Double strand breaks (DSBs). We further hypothesised that such 
events ultimately serve to promote cell transformation and malignant progression. 
 Aims 1.5.
The aims of this work fall into three categories: firstly, we sought to investigate the 
potential interaction of PBF and p53 in a more physiologically relevant setting, using 
co-immunoprecipitation assays. We also aimed to determine the subcellular 
localisation of PBF and p53 in thyroid cancer cell lines. Secondly, we aimed to 
assess the functional consequences of the PBF:p53 interaction on p53 biology and 
function by assessing the effects of PBF on p53 expression and p53-mediated gene 
transcription in the presence and absence of ionising radiation. Thirdly, we aimed to 
characterise the gross biological effects of PBF overexpression on cellular physiology 
in the presence and absence of ionising radiation. 
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Unless otherwise determined, all chemicals in this thesis were obtained from Sigma-
Aldrich (Poole, Dorset, UK). 
 Cell lines 2.1.
Thyroid papillary carcinoma TPC-1 cells were kindly provided by Dr Rebecca 
Schweppe (Division of Endocrinology, Metabolism, & Diabetes, University of 
Colorado Denver, Aurora, Colorado), and thyroid papillary carcinoma K1 cells were 
obtained from the Health Protection Agency Culture Collections, UK. Both TPC-1 and 
K1 papillary carcinoma cells express wild-type p53 (Messina et al, 2012; Wyllie et al, 
1999). All thyroid carcinoma cell lines were routinely cultured in RPMI 1640 (Life 
Technologies, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum 
(Invitrogen; EU approved, South American origin), penicillin (105 U/l) and 
streptomycin (100 mg/l) [Invitrogen]. Cells were passaged twice weekly. Human 
colorectal cancer HCT116 cells were obtained from the Health Protection Agency 
Culture Collections, UK. HCT116 cells also express wild-type p53 (Kaeser et al, 
2004). These cell were routinely cultured in McCoy’s 5A (Life Technologies, Grand 
Island, NY, USA) supplemented with 10 % fetal bovine serum (Invitrogen; EU 
approved, South American origin), penicillin (105 U/l) and streptomycin (100 mg/l) 
[Invitrogen]. Cells were passaged twice weekly. 
 Murine primary thyrocyte culture 2.2.
Murine primary thyrocyte culture was performed using an approach previously 
described by Jeker et al, 1999 (Jeker et al, 1999). Briefly, wild-type murine thyroids 
were aseptically dissected prior to mechanical disruption in PBS and subsequent 
digestion in 0.2 % collagenase for 45 minutes at 37 ºC. Collagenase was inactivated 
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by addition of culture medium and the cells were centrifuged for 10 minutes at 700 x 
g to obtain a pellet containing single thyroid follicles. After discarding the supernatant, 
the pellet was resuspended in 1 ml of culture medium and pipetted up and down until 
no fragments were macroscopically visible. Cells from each thyroid (2 wells for each 
WT thyroid) were seeded into 12-well plates in medium described by Ambesi-
Impiombato et al. (Ambesi-Impiombato et al, 1980), supplemented with thyrotrophin 
(300 mU/l), insulin (10 mg/ml), transferrin (5 mg/ml) [Sigma], hydrocortisone (3.5 
ng/ml) [Sigma], somatostatin (10 ng/ml) [Sigma], glycyl-L-histidyl-L-lysine acetate (2 
ng/ml) [Sigma], penicillin (105 U/l), streptomycin (100 mg/l) and 5 % fetal calf serum. 
After 72 hours, serum was omitted and experiments were performed between days 
7-14 of the culture. 
 Human primary thyrocyte culture  2.3.
Collection of thyroid specimens was with approval of the Local Research Ethics 
committee and following informed written consent from patients. All tissues were 
surplus to pathological requirement. Human thyroid follicular cells were prepared 
from surgical specimens, and consisted mainly of multinodular goitres and normal 
thyroid tissue from the contralateral lobe, as previously described (Eggo et al, 1996; 
Ramsden et al, 2002). Thyroid tissue was digested by 0.2 % type II collagenase 
(Worthington Biochemicals). Follicles were plated in 12-well plates in medium 
described previously by Ambesi-Impiombato et al.(Ambesi-Impiombato et al, 1980), 
supplemented with thyrotrophin (300 mU/l) [Sigma], insulin (100 μg/l) [Sigma], 
penicillin (105 U/l), streptomycin (100 mg/l) and 5 % fetal calf serum. Serum was 
omitted after 72 hours of culture, and experiments were performed between days 7-
11 of the culture. Generally, these cultures survive and maintain function for more 
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than 4 weeks and fibroblast as well as endothelial cell contamination is negligible 
under these conditions (Eggo et al, 1996). 
 RNA extraction and reverse transcription 2.4.
Total RNA was extracted from cells, utilising a single step acid guanidinium phenol-
chloroform extraction method [Tri-reagent (500 μl per well of a 6-well plate), Ambion, 
Austin, TX, USA] (Chomczynski & Sacchi, 1987). All samples were subjected to one 
freeze-thaw cycle at -80 °C. Subsequently, 100 μl chloroform (99+ %) was added to 
each reaction, and samples shaken vigorously for 15 seconds. After standing for 15 
minutes at room temperature, samples were centrifuged at 12,000 g for 15 minutes 
at 4°C. This separates the mixture into 3 phases. The uppermost colourless aqueous 
phase containing RNA was transferred into a fresh tube and 250 μl isopropanol (99+ 
%) was added. After mixing, the samples were left to stand at room temperature for 
10 minutes before centrifugation at 12,000 g for 10 minutes at 4 °C. The supernatant 
was discarded and the pellet washed in 500 μl 75 % ethanol then centrifuged at 7500 
g for 5 minutes at 4 °C. The ethanol was discarded and the pellet left to air dry before 
being dissolved in 30 μl of nuclease free water. 
500 nanograms of RNA (determined by spectroscopy at λ260 nm using a NanoDrop 
spectrometer (NanoDrop Products, Wilmington, DE, USA)) was reverse transcribed 
(RT) with avian myeloblastosis virus (AMV) reverse transcriptase in a total reaction 
volume of 10 μl, with 5 pmol random hexamer primers, 1 μl 10 AMV reverse 
transcriptase buffer, 1 μl deoxynucleotide triphosphate (dNTP) mix (200 μM each), 10 
units ribonuclease inhibitor (RNasin™) and 7.5 units AMV reverse transcriptase (All 
reagents from Promega, Madison, WI, USA). 
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 Qualitative polymerase chain reaction (QT- RT-PCR) 2.5.
Relative fold changes in expression of mRNAs encoding various different proteins 
were calculated in relation to control samples (that were arbitrarily assigned a value 
of 1). QT-PCR experiments were performed using an ABI 7500 Sequence Detection 
System, employing TaqMan™ chemistry for highly accurate measurement of mRNA 
levels (Wang & Brown, 1999). 
TaqMan™ probes consist of a fluorophore FAM (6-carboxy-flourescien) or VIC (full 
chemical name patent protected) covalently attached to the 5’ end, and a quencher, 
TAMRA (6-carboxy-tetramethyl-rhodamine) at the 3’ end. The quencher molecule 
suppresses the fluorescence emitted by the fluorophore when excited by the cycler’s 
light source via fluorescence resonance energy transfer (FRET). During FRET the 
high energy fluorophore acts as a donor by transferring energy to the low energy 
quencher. As the Taq polymerase extends the primer, the 5’ to 3’ exonuclease 
activity of the polymerase degrades the probe. Degradation of the probe releases the 
fluorophore from it and breaking the close proximity to the quencher, thereby 
increasing its fluorescent signal by relieving the quencher effect. Hence, fluorescence 
detected in the real-time PCR thermal cycler is directly proportional to the fluorophore 
released and therefore the amount of DNA template present in the PCR. 
Quantitative primers and probes were designed using the Primer Express™ software 
(PE Biosystems, USA). Primer design warranted a unique sequence for each gene, 
and ensured that the generated PCR product would span at least one exon-exon 
boundary (therefore avoiding genomic DNA amplification). Alternatively, pre-
optimised specific gene expression assays for QT-PCR were purchased externally 
(Applied Biosystems, Warrington, UK). 
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PCR was carried out in 25 μl volumes on 96 well plates, in a reaction buffer 
containing 1x TaqMan Universal PCR Master Mix (Applied Biosystems, Warrington, 
UK) [3 mM Mg(OAc)2, 200 μM dNTPs, 1.25 units Ampli-Taq Gold polymerase, 1.25 
units AmpErase UNG], 175 nM TaqMan probe and 900 nM primers with 1 μl of the 
RT reaction. All target gene probes were labelled with FAM, and the housekeeping 
genes, 18S and DS-CAM, with VIC. All reactions were multiplexed where possible. 
For specific gene-expression assays that were not validated for multiplexing, 
reactions were singleplexed. The 18S primers and probe are provided as a pre-
optimised control system (Applied Biosystems, Warrington, UK), eNAbling data to be 
expressed in relation to an internal reference, to allow for differences in RT efficiency. 
Reactions were as follows: 50 °C for 2 minutes, 95 °C for 10 minutes; then 44 cycles 
of 95 °C for 15 seconds and 60 °C for 1 minute. 
As per the manufacturer’s guidelines, data were expressed as Ct values (the cycle 
number at which logarithmic PCR plots cross a calculated threshold line) and used to 
determine ΔCt values (ΔCt = Ct of the target gene minus Ct of the housekeeping 
gene 18S). Measurements were carried out in duplicate for each sample. The fold 
change of mRNA in an experimental group compared to the control group is 
calculated using the equation fold change = 2-(ΔCt of experimental group – ΔCT of control group) or 2-
ΔΔCt. 
 Western blot analysis 2.6.
Proteins were prepared from thyroid tissues in lysis buffer (100 mmol/L sodium 
chloride, 0.1 % Triton X-100, and 50 mmol/L Tris, pH 8.3) containing enzyme 
inhibitors (1 mmol/L phenylmethylsulphonylfluoride, 0·3 μmol/L aprotinin, and 0·4 
mmol/L leupeptin). Protein concentration was determined using the BCA Protein 
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Assay kit (Thermo-Fisher Scientific, Rockford, IL, USA) with bovine serum albumin 
standards. 10-60 μg of protein was denatured in 4 x laemlli buffer (Bio-Rad, 
Hertfordshire, UK) for 5 minutes at 95 ºC.  
Western blot analyses were performed as we have described previously (Boelaert et 
al. 2003a; Kim et al. 2005; Smith et al. 2009). Soluble proteins (10-60 μg) were 
separated by electrophoresis in 12.5 % sodium dodedecyl sulphate polyacrylamide 
gels, transferred to polyvinylidene fluoride membranes, incubated in 5 % non-fat milk 
in tris-buffered saline with 0.1 % Tween, followed by incubation with appropriate 
primary antibodies for 16 hours at 4 °C. After washing in tris-buffered saline plus 0·1 
% Tween, blots were incubated with appropriate secondary antibodies conjugated to 
horseradish peroxidase for 1 hour at room temperature. After further washes, 
antigen-antibody complexes were visualised by the ECL plus and ECl advance 
chemiluminescence detection systems (GE Healthcare, UK) on x-ray film (Kodak, 
UK). Actin expression was determined in all Western blot analyses (monoclonal anti-
β-Actin Clone AC-15 (Sigma-Aldrich), used at 1:10 000) to assess potential 
differences in protein loading. Scanning densitometry studies were performed to 
quantify differences in protein expression (Image J Software). 
 Immunofluorescence  2.7.
COS-7, HCT116, TPC-1 and K1 cells growing on coverslips in 35 mm dishes were 
fixed at room temperature for 20 minutes in fixing solution (for 40 mls, 20 ml 0.2 M 
phosphate buffer, 0.2 M Na2HPO4 pH7.4, 0.8 g PFA (2 %), 0.8g glucose (2 %) 8 ml 
0.1% Sodium Azide (0.02%) and 12mls water). Cells were then washed in PBS and 
permeabilised in 100 % methanol for 10 minutes at -20 0C, blocked for 30 minutes in 
10% new-born calf serum in PBS and subsequently incubated in relevant primary 
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antibodies (in 1 % Bovine serum albumin-PBS). Cells were then washed and 
incubated in secondary antibodies (Alexa-fluor-594 Goat anti-rabbit and Alexa-fluor-
488 goat anti-mouse) at a concentration of 1:250 (also included was hoeschst stain 
at 1:1000 concentration) in 1% BSA and 1% NCS in PBS. Finally washes were then 
performed with PBS and coverslips were mounted onto microscope slides using 
fluorescence mounting medium (Invitrogen). Coverslips were sealed using clear nail 
varnish and cell were visualised on a confocal fluorescence microscope. 
 Statistical analysis 2.8.
Statistical analysis was only performed on data sets with a minimum of 3 
independent biological replicates Data were analysed using Sigma Stat (SPSS 
Science Software UK Ltd). The Kolmogorov-Smirnov test determined whether the 
data followed normal distribution. If the data set to be tested followed normal 
distribution, it was analysed using a two sample Student’s t-test. However, if the data 
set was non-parametric, the Mann-Whitney Rank Sum test was used for comparison 
between two groups of data. Furthermore samples with multiple variances were 
assessed via analysis of variance (ANOVA).Significance was taken as p< 0.05. For 
quantitative real time PCR, all statistics were performed on the ΔCt values to avoid 
potential bias through transformation of the data with the equation 2-ΔΔCt.  
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 Introduction 3.1.
Induction of DNA damage in TPC-1 and K1 thyroid papillary carcinoma cells and 
resulting p53 activity has not been well documented. Of the various cellular stresses 
that initiate a p53 response, the molecular mechanisms by which p53 is activated 
following DNA double strand breaks (DSBs) are perhaps the most comprehensively 
understood (Meek, 2004; Brooks & Gu, 2006). Activation of p53 by DNA damage 
occurs at 2 levels: stabilisation of the p53 protein leading to its accumulation, and 
activation of biochemical functions encompassed within the p53 protein (Meek, 
2004). DSBs are considered the most cytotoxic form of DNA lesion; and they can be 
introduced by a number of exogenous agents including γ-irradiation, topoisomerase 
poisons, radiomimetic drugs (e.g bleomycin and neocarcinostatin), and by various 
cellular processes such as V(D)J recombination and stalled replication forks 
(Mahaney et al, 2009). As described earlier, p53 is stabilised in response to DNA 
damage through inhibition of its degradation by HDM2, mediated by multi-site 
phosphorylation of both p53 and HDM2. The initial and fundamental post-
translational modification of p53 in response to DNA damage is phosphorylation of 
ser-15 by the ATM protein kinase. This initial event propagates a host of secondary 
modifications, resulting in further p53 stability and biochemical activation (Ashcroft & 
Vousden, 1999). Activated p53 acts as a node for the transduction of stress signals 
(i.e. DSBs). Predominantly p53 functions as a transcription factor to bring about 
cellular responses with the primary biological end-points of growth arrest or 
apoptosis. p53 is likely to directly regulate a plethora of different gene activity, 
although a sub-set of genes have been directly implicated with p53 regulation. Such 
genes include CDKN1A and HDM2 (involved in growth arrest and p53 regulation 
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respectively), and BAX and PUMA (both key mediators of apoptosis). As mentioned 
previously CDKN1A encodes the protein p21, which is a potent cyclin-dependent 
kinase inhibitor, transcribed by p53 in response to DNA damage to initiate a G1/S 
phase growth arrest (Waldman et al, 1995). HDM2, the human homologue of the 
mouse double minute 2 (HDM2), encodes a protein of the same name which 
contains a self and p53-specific ubiquitin ligase, binding directly to p53 and targeting 
it for degradation (Brooks & Gu, 2006). BAX (or BCL-2 associated X protein) shares 
significant amino acid homology to the anti-apoptotic BCl-2 protein. BCL-2 can form 
homodimers or heterodimers, where homodimeric BCL-2 results in anti-apoptotic 
conditions; however, when the frequency of BCL-2-BAX heterodimers increases, 
programmed cell death is accelerated and the anti-apoptotic effects of BCL-2 are 
countered (Oltval et al, 1993; Basu & Haldar, 1998; Wolter et al, 1997). Furthermore, 
the expression of BAX is upregulated by the tumour suppressor protein p53, and 
BAX has been shown to be involved in p53-mediated apoptosis (Basu & Haldar, 
1998). The p53 upregulated mediator of apoptosis (PUMA), also known as the BCL-2 
binding component 3 (BBC3), is another pro-apoptotic member of the BCL-2 protein 
family (Jeffers et al, 2003; Nakano & Vousden, 2001). As the name implies, PUMA is 
directly induced by p53 at the level of transcription (Jeffers et al, 2003). 
 In order to determine the effects of PBF on p53 function, it is necessary to 
exogenously induce DNA damage to activate the p53 pathway and bring about 
reliable and repeatable p53 responses against which the effects of PBF can be 
measured. It has been well documented that the thyroid is particularly sensitive to 
DNA damage, for example exposure of the developing thyroid to ionising radiation 
due to human disasters (Hiroshima and Chernobyl) and exposure to ionising 
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radiation as a result of medical care, lead to an increased incidence of thyroid 
papillary carcinomas (Thompson et al, 1994; Nikiforov et al, 1996; Sadetzki et al, 
2006). With this in mind, treatment of human papillary carcinoma cell lines with 
ionising γ-irradiation may be a valid and robust mechanism for inducing DNA damage 
and propagating a detectable p53 response.  
One of the first cellular responses to the introduction of DSBs is phosphorylation of 
H2AX at ser-139 to generate γ-H2AX, one of three types of histone H2A molecules in 
eukaryotic cells (Rogakou et al, 1998; Kuo & Yang, 2008), an event mediated by the 
PI3 kinase-like family of protein kinases, including DNA PKs, ATM and ATR. 
Interestingly, formation of DSBs can initiate this response, but other lesions, including 
SSBs do not (Paull et al, 2000). After treatment with DNA damaging agents, γ-H2AX 
forms foci that localise to subnuclear volumes containing damaged DNA. γ-H2AX foci 
formation precedes the formation of the Rad51-MRE11-Nbs1 complex, but appears 
to serve as an important “landing pad” for the recruitment and retention of these 
central components of DNA-repair. The importance of recruitment of γ-H2AX to sites 
of DNA breaks is highlighted following treatment of cells with Wortmannin to inhibit 
the phosphorylation of H2AX. In the absence of γ-H2AX, localisation of the central 
DNA repair machinery (RAD51-MRE11-Nbs1) is  significantly impaired, suggesting a 
causal link between γ-H2AX accumulation and subsequent colocalisation of DNA 
repair machinery (Paull et al, 2000; Kuo & Yang, 2008; Kinner et al, 2008).  
PBF has been reported to be overexpressed but not mutated in tumours of the 
thyroid, breast pituitary and colon (Stratford et al, 2005; Watkins et al, 2010 and our 
unpublished data). Furthermore at oncogenic levels, PBF has been characterised as 
transforming in vitro and tumourigenic in vivo (Stratford et al, 2005). Despite these 
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findings PBF remains a relatively uncharacterised protein associated with multiple 
cellular processes, such as nuclear entry of PTTG, FGF-2 upregulation and NIS 
mRNA expression (Stratford et al, 2005; Watkins et al, 2010b). Although the role of 
PBF in oncogenesis has not been well documented, recent preliminary data from our 
laboroatory suggests potential interaction between PBF and p53 in vitro through the 
use of GST-Pulldown assays, potentially highlighting a role for PBF in p53 activity. 
Therefore, observing the effects of DNA damage on PBF expression and determining 
whether PBF localises to sites of DNA breaks may provide useful insights into any 
potential role of PBF in the DNA damage response, which may in turn influence p53 
functionality. 
The aims of this study were therefore to explore the effects of ionising radiation on 
the induction of p53 and associated down-stream responses in thyroid papillary 
carcinoma cell lines, and establish an optimal dose response and time point at which 
p53 activity appears greatest (without inducing excessive cytotoxicity), from which 
PBF function can be measured. Furthermore, the effects of ionising radiation on PBF 
expression and localisation following ionising radiation are unknown; therefore we 
aimed to observe how PBF protein expression changes following treatment with 
ionising radiation, and to determine whether PBF localises to sites of DNA damage 
by observing its relationship with the important DNA repair protein γ-H2AX. 
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 Materials and methods 3.2.
3.2.1. Cell lines and plasmids 
Human thyroid papillary carcinoma TPC-1 and K1 cells, and human colorectal 
carcinoma HCT116 cell lines, were routinely cultured as described in Section 2.1 . 
For experiments involving ionising radiation treatment, TPC-1 and K1 cells were 
seeded into 6-well dishes at a density of 1X105/well, and HCT116 cells at 
2.5x105/well, and incubated at 37 oC for 24 hours before treatment. A Caesium-137 
γ-emitter was used to treat cells with specific doses of γ-radiation. At our time of 
research the emitter delivered 38.5 mGy of γ-irradiation per second of exposure. 
Cells were treated with the required dose and returned to incubation until harvesting 
at the relevant time point. For experiments requiring transient overexpression of PBF, 
TPC-1 and K1 cells were seeded into 6-well dishes at a density of 1X105/well and 
incubated at 37 oC for 24 hrs. After incubation human thyroid papillary carcinoma 
cells were transfected using FUGENE6™ (Roche Diagnostics Corporation, 
Indianapolis, USA), as per the manufacturer’s instructions. However an optimised 
ratio of 3 µl FUGENE6: 1 µg plasmid DNA was used (6 µl FUGENE6: 2 µg DNA in a 
6-well dish). Cells were transfected with the mammalian expression vector 
pCDNA3™ (Invotrogen™) with full length wild-type PBF cDNA with a haemaglutinin 
(HA) tag insert. Cells were then incubated for 24 hours to allow for exogenous PBF 
protein overexpression before being treated or harvested.   
3.2.2. Murine primary thyrocyte culture 
Murine primary thyrocytes were harvested and cultured using methods described in 
Section 2.2. After a minimum of 7 days in culture, thyrocytes were irradiated using a 
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Caesium-137 γ-emitter and returned to incubation before harvesting at the relevant 
time-point.  
3.2.3. SDS-PAGE/ Western blotting 
  
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see Section 2.6). Blocked membranes were subsequently 
incubated with primary antibodies. The antibodies used were, our rabbit anti-human 
PBF-8 polyclonal (1:1000). Our polyclonal antibody to PBF was generated using a 
peptide corresponding to amino acid sequence 44–57 (TNKTCEECLKNVXC). The 
antibody was purified using HPLC, and its subsequent specificity was validated 
through peptide blocking studies (Stratford et al, 2005), rabbit anti-human phosphor-
histone (ser 139) H2AX at 1:1000 (NEWENGLAND Biolabs, MA, USA), mouse anti-
human p53 (D0-1) monoclonal at 1:5000 (Santa Cruz, CA, USA), monoclonal anti-β-
actin clone AC-15, (used at 1:10,000, Sigma-Aldrich, Poole, UK). Scanning 
densitometric analysis of Western blotting assessment of PBF and p53 expression 
was normalised to β-actin.  
3.2.4. RNA extraction and Quantitative Real-time PCR 
Total RNA was extracted from TPC-1, K1, HCT116 cells and murine primary 
thyrocytes as described in Section 2.4. Reverse transcription and QT-PCR 
techniques were as described above (see Sections 2.4 and 2.5). Gene-specific 
expression assays for CDKN1A, HDM2, PUMA and BAX were purchased from 
Applied Biosystems (Warrington, UK). Primers and probes for PBF mRNA expression 
were designed according to the guide-lines mentioned in Section 2.5 and the exact 
sequences are presented in Table 3-1. 
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Table 3-1: Oligonucleotide sequences of PCR primers and TaqManTM probes used. 
Each probe possessed a 5’ FAM reporter molecule and a 3’ TAMRA quencher 
molecule. All TaqMan primers run at 59°C and yield amplicons of 70-150bp. 
 
3.2.5. Immunofluorescence  
COS-7, HCT116, TPC-1 and K1 cells were seeded onto coverslips (in 6-well dishes), 
irradiated using a Caesium-137 γ-emitter and prepared for fluorescence 
immunocytochemistry using the methods described in Section 2.7. PBF was detected 
using our rabbit anti-human PBF antibody (1:100) (Read et al, 2011), and γ-H2AX 
detected using a mouse anti-human γ-H2AX phosphor ser-139 specific antibody 
(Pierce, UK). Cells were then visualised on a fluorescence confocal microscope.  
3.2.6. Statistical analysis 
Data were analysed as described in Section 2.8. 
 
 Results 3.3.
3.3.1. Treatment with γ-irradiation: establishing an optimal dose. 
To assess the p53 response to DNA damage in TPC-1 and K1 papillary carcinoma 
cell lines, cells were treated with a range (0-40 Gy) of doses of γ-irradiation and total 
cellular protein was harvested 8 hours post treatment (Figure 3.1). A significant 
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increase in p53 protein expression was observed in TPC-1 cells at all doses of γ-
irradiation, with maximal induction of p53 protein expression observed between 
doses of 5 and 15 Gy (Figure 3.1A). At the highest dose of 40 Gy, p53 protein 
expression was elevated compared to untreated controls, but to levels below that of 
the lowest treatment dose. This dose correlated with significant levels of cytotoxicity 
that were not present at lower doses of γ-irradiation (data not shown). Similar results 
were obtained following treatment of K1 cells with ionising radiation (Figure 3.1B). 
To determine whether these effects were thyroid specific, experiments were repeated 
using the human colorectal cancer (HCT116) cell line over a dose range of 0-40 Gy. 
In these cells, again, a large and significant increase in p53 protein expression was 
observed throughout all doses of γ-irradiation. However, unlike thyroid papillary 
carcinoma cells, HCT116 cells displayed maximal p53 protein expression at the 
highest dose of 40 Gy (Figure 3.1C). 
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Figure 3.1. Induction of p53 protein expression 8 hours after treatment with a range 
of doses of γ-irradiation in TPC-1, K1 and HCT116 cell lines. A-C: Western blot 
analysis of p53 protein expression between doses of 0-40 Gy γ-irradiation in TPC-1 
and K1 and HCT116 cells respectively.  
 
In order to determine whether the increased p53 expression observed through 
treatment of different doses of γ-irradiation correlated with increased p53 activity, the 
above dose response experiments were repeated, and cellular RNA harvested 8 and 
24 hours after treatment. QT-PCR was then performed to assess the induction of 
CDKN1A mRNA expression in these cell lines. CDKN1A is a gene transcribed 
directly by p53 in response to DNA damage, giving rise to the protein p21, which 
functions as a potent cyclin-dependent kinase inhibitor, and results in G1-S-phase 
growth arrest (Vousden & Lu, 2002). 
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 CDKN1A mRNA expression in TPC-1 cells was increased in a dose dependent 
manner both 8 and 24 hours after treatment, with maximal responses occurring after 
24 hours (Figure 3.2A). CDKN1A mRNA expression was highest at 30 Gy where 
expression was increased by 5.5-fold (after 8 hours) and 6.3-fold (after 24 hours) 
compared to time matched untreated controls. At the 15 Gy dose CDKN1A mRNA 
expression was increased by 4.24-fold and 5.36-fold at the 8 and 24 hour time point 
respectively (Figure 3.2A). K1 cells displayed a somewhat different pattern of 
CDKN1A mRNA expression in response to γ-irradiation, where CDKN1A mRNA 
expression initially increased in a dose dependent manner. However, in this cell line, 
the strongest induction of CDKN1A mRNA expression was observed at the 15 Gy 
dose (5.3-fold at 8 hours Figure 3.2B). At the highest dose of 30 Gy CDKN1A was 
induced by only 4.05-fold at 8 hours. Furthermore CDKN1A expression was most 
apparent 8 hours after treatment with γ-irradiation (compared to TPC-1 cells which 
showed maximum responses at 24 hours). For example, cells treated with a 15 Gy 
dose of γ-irradiation were induced by 5.3-fold compared to untreated controls after 8 
hours, in contrast to a 3.8-fold response after 24 hours (see Figure 3.2B). 
Additionally, the broad effects of γ-irradiation on the induction of CDKN1A mRNA 
expression in non-thyroidal HCT116 cells were determined; once more, in these cells 
transcription of CDKN1A mRNA was dose dependent. At the highest dose of 40 Gy, 
HCT116 cells elicited the largest response of 7.01-fold after 24 hours (Figure 3.2C).  
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Figure 3.2: Induction of CDKN1A mRNA expression over a range of doses of γ-
irradiation 8 and 24 hours after treatment. A+B: Induction of CDKN1A mRNA 
expression in TPC-1 and K1 cells over a dose range of 0-30 Gy. C: Induction of 
CDKN1A mRNA expression over a dose range of 0-40 Gy in HCT116 cells (24 hour 
time-point only). D: Exemplar of raw Ct data in K1 and HCT116 cells demonstrating 
that ionising radiation treatment increases relative CDKN1A mRNA expression as a 
function of decreasing CDKN1A Ct threshold values as opposed to increasing 18s 
control Ct threshold values. 
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This series of preliminary experiments demonstrated that both thyroid papillary and 
human colorectal carcinoma cell lines are responsive to γ-irradiation where p53 is 
stabilised in a dose dependent manner. γ-irradiation resulted in the greatest 
responses in the thyroid carcinoma cell lines at 15 Gy (where higher doses resulted 
in visible cytotoxicity) and in the colorectal cancer cell line at 40 Gy. When p53 
activity was assessed (by observing the expression of a p53 inducible gene) in 
response to γ-irradiation, p53 activity was increased in a dose dependent manner in 
the 3 cell lines. In TPC-1 cells the greatest levels of p53 protein expression were 
observed at 15 Gy; in contrast the greatest level of p53-mediated gene induction was 
observed at 30 Gy. However, due to the observed cytotoxicity of the larger 30 Gy 
dose in these cells, and the significant induction of CDKN1A mRNA expression at the 
15 Gy dose, a dose of 15 Gy was chosen for subsequent experiments in this thesis. 
K1 cells displayed the most significant induction of p53 protein expression and p53-
mediated gene expression after 15 Gy of γ-irradiation, and so the 15 Gy dose was 
deemed optimal for these cells. Finally, in HCT116 cells, p53 protein expression and 
p53-mediated gene activation occurred at the highest treatment dose of 40 Gy and 
so in this radio-resistant cell line, a 40 Gy dose was used to induce DNA damage 
during experiments within this thesis. 
3.3.2. Treatment with γ-irradiation: establishing an optimal time-point 
With the aim of finding the time-point at which our chosen dose-response was most 
apparent, TPC and K1 cells were treated with 15 Gy of γ-irradiation and harvested 
over a 24 hour time-course at 2, 8 and 24 hours. In a similar manner to experiments 
described in Section 3.3.1 protein was extracted from cells to determine the levels of 
p53 protein expression and RNA isolated in order to monitor p53-mediated gene 
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transcription. TPC-1 cells treated with 15 Gy of γ-irradiation displayed increased p53 
protein expression from 2 hours post irradiation; levels increased at 4 hours and were 
greatest after 8 hours (Figure 3.3A). After 24 hours, irradiation induced p53 protein 
expression was apparent, but at levels considerably below that of the 8 hour time 
point (Figure 3.3A). Irradiation induced p53 protein expression was observed from 4 
hours in K1 cells and remained similarly elevated to at 8 hours; again, after 24 hours, 
p53 protein expression was only marginally increased compared to negative controls 
(Figure 3.3B). Finally, HCT116 cells were treated at the chosen higher dose of 40 Gy 
and harvested over the same time-course. p53 protein expression was induced after 
8 hours. p53 protein expression remained elevated to similar levels even 24 hours 
after irradiation (Figure 3.3C).  
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Figure 3.3: Time-course demonstrating induction of p53 protein expression in TPC-1, 
K1 and HCT116 cell lines following treatment with γ-irradiation 0, 2, 8 and 24 hours 
after treatment. A+B: p53 expression levels after treatment with 15 Gy of γ-irradiation 
in K1 and TPC-1 cells. C. Time-course displaying p53 expression levels after 
treatment with 40 Gy of γ-irradiation in HCT116 cells.  
 
TPC-1 and K1 cells were treated with 15 Gy of γ-irradiation and harvested across a 
24 hour time course as previously described. QT-PCR was then performed to assess 
the relative induction of CDKN1A expression, and hence p53 activity (Figure 3.4). 
TPC-1 cells demonstrated a robust response to irradiation from 2 hours (4.2-fold) 
compared to time-matched untreated controls. This response increased to 7-fold 
after 8 hours and remained elevated at similar levels after 24 hours (7.2-fold) (Figure 
3.4A). K1 cells showed induction of CDKN1A mRNA expression from 2 hours (3.4-
fold) which was slightly lower than that of TPC-1 cells at this time-point. After 8 hours 
the greatest induction of CDKN1A mRNA expression was observed (4.1-fold) in 
contrast to the 7.18-fold induction detected in TPC-1 cells at this time-point. After 24 
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hours CDKN1A expression was reduced to 2.9-fold suggesting a shorter length of 
p53 activity in these cells treated with a 15 Gy dose of γ-irradiation (Figure 3.4B). 
CDKN1A mRNA expression was also observed in HCT116 cells 8 and 24 hours after 
the higher treatment dose of 40 Gy. After 8 hours CDKN1A mRNA expression was 
elevated to 6-fold compared to untreated controls, and mRNA expression continued 
to increase at the 24 hour time point to 7.1-fold that of untreated controls (Figure 
3.4C).  
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Figure 3.4: Time-course demonstrating the relative induction of CDKN1A mRNA 
expression in response to treatment with γ-irradiation in TPC-1, K1 and HCT116 cells 
respectively. A+B: Fold induction of CDKN1A mRNA expression in TPC-1 and K1 
cells after treatment with 15 Gy γ-irradiation over a time-course of 0, 2, 8 and 24 
hours, compared to time-matched untreated controls. C: Fold induction of CDKN1A 
mRNA expression in HCT116 cells tretated with 40 Gy γ-irradiation 8 and 24 hours 
after treatment. 
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An optimal dose to treat the 2 thyroid papillary carcinoma cells (15 Gy) and the 
HCT116 colorectal cell line (40 Gy) were established to induce a robust p53 
response. In addition to this, time-courses established optimal time points following 
treatments to observe maximal p53 responses in each cell line. In TPC-1 cell lines, 
maximal p53 protein expression was observed 8 hours after a 15 Gy dose of γ-
irradiation, coupled with the greatest (~7-fold) induction of p53-mediated gene 
expression at both 8 and 24 hours. K1 cells showed the most significant induction of 
p53 protein expression 4 and 8 hours after treatment with γ-irradiation and maximal 
p53-mediated gene expression at 8 hours. HCT116 cells, at the higher dose of 40 
Gy, displayed the highest levels of p53 protein expression at 8 and 24 hours, and 
p53-mediated gene expression was substantially elevated at both 8 and 24 hours. 
From these data treatment of the K1 and TPC-1 cell lines with a 15 Gy dose of γ-
irradiation and harvesting cellular protein and RNA after 8 hours resulted in 
significant induction of both p53 protein expression and p53-mediated gene 
expression which could then be used to measure the effects of PBF on the induction 
of this pathway. In HCT116 cells treatment with the higher dose of 40 Gy provided 
significant induction of p53 protein expression and activity. Therefore assessing p53 
expression and activity at this dose and time-points (both 8 and 24 hours) resulted in 
optimal conditions for analysis of the effects of PBF on the induction of the p53 
response to cellular stress. 
Further to these preliminary experiments, the validity of the chosen doses and time-
points was assessed. QT-PCR was performed to determine the induction of a panel 
of p53-mediated genes, including CDKN1A. In TPC-1 cells the induction of CDKN1A, 
HDM2, BAX and PUMA mRNA expression were analysed 8 hours after treatment 
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with 15 Gy of γ-irradiation. As expected TPC-1 cells treated with 15 Gy γ-irradiation 
produced significant repeatable induction of CDKN1A mRNA expression (5.4-fold, 
n=4, p<0.001; Figure 3.5A). HDM2 mRNA expression was also significantly up-
regulated under these conditions (3.5-fold, n=4, p<0.001). The pro-apoptotic genes 
BAX and PUMA were also activated (3.1-fold, n=3, p<0.05 and 2.4-fold, n=3, p<0.05 
respectively) compared to untreated controls. CDKN1A, HDM2 and PUMA mRNA 
expression were analysed in K1 cells in a similar manner to TPC-1 cells (Figure 
3.5B). CDKN1A expression was highly elevated in response to DNA damage (4.6-
fold, n=3, p<0.01) and HDM2 mRNA expression significantly induced to similar levels 
(4.7-fold, n=3, p<0.05) compared to untreated controls. However, unlike TPC-1 cells, 
PUMA mRNA expression in K1 cells was non-significantly up-regulated in response 
to DNA damage (2.8-fold, n=3, p=NS). HCT116 cells treated with the higher dose of 
40 Gy displayed a striking increase in CDKN1A mRNA expression after 8 hours (8-
fold, n=4, p<0.001; Figure 3.5C). HDM2 and PUMA were also significantly induced 
under these conditions but at lower levels (3-fold, n=3, p<0.001 and 3.3-fold, n=3, 
p<0.001 respectively). 
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Figure 3.5: Induction of genes mediated by p53 in response to DNA damage in TPC-
1, K1 and HCT116 cells. A: Significant induction of CDKN1A (n=4, p<0.001), HDM2 
(n=4, p<0.001), PUMA (n=3, p<0.05) and BAX (n=3, p<0.05) mRNA expression 8 
hours after treatment with 15 Gy γ-irradiation in TPC-1s. B: Induction of CDKN1A 
(n=3, p<0.01), HDM2 (n=3, p<0.05) and PUMA (n=3, p=NS) mRNA expression 8 
hours after treatment with 15 Gy γ-irradiation in K1s. C: Significant induction of 
CDKN1A (n=3, p<0.001), HDM2 (n=3, p<0.001) and PUMA (n=3, p<0.001) mRNA 
expression after treatment with 40 Gy γ-irradiation in HCT116 cells (p<0.05 =*, 
p<0.01 =**, p<0.001 =***).  
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3.3.3. The effects of DNA damage on PBF expression 
The effects of DNA damage on PBF expression have not been documented. This 
thesis concerns the assessment of oncogenic PBF (as reported in tumours of the 
breast, thyroid, pituitary and colon) and its potential effects on p53 biology. We 
therefore investigated the effects of DNA damage on PBF mRNA and protein 
expression. Firstly, TPC-1 and K1 cells were treated with γ-irradiation and PBF 
protein expression was analysed over a 24-hour time course (Figure 3.6). Western 
blotting did not reveal any significant difference in PBF protein expression over the 
24 hour time-course in either TPC-1 (Figure 3.6A; n=5) or K1 cells (Figure 3.7A; 
n=5), with levels of PBF protein remaining constant in the same way as the time-
matched negative controls. In-keeping with these observations PBF mRNA 
expression remained unchanged over 24 hours (n=3) (Figure 3.6B + Figure 3.7B) in 
both cell lines. These experiments were repeated in HCT116 cells with varying 
results. Over a 24 hour time-course, PBF protein expression appeared to be elevated 
8 hours after treatment with respect to negative controls, and remained elevated at 
24 hours (Figure 3.8A). However, this result was not reliably repeatable. Furthermore 
when the effects of increasing doses of γ-irradiation on PBF protein expression in 
HCT116 cells were observed, PBF protein expression appeared to increase in a 
dose dependent manner 24 hours post irradiation treatment, from doses as small as 
10 Gy, and PBF expression was observed to increase in a similar manner to that of 
p53 (Figure 3.8B). PBF mRNA expression remained unchanged in response to 
increasing doses of γ-irradiation, suggesting that the effects of DNA damage on PBF 
protein expression are not due to upregulation of PBF at the level of gene 
transcription (Figure 3.8C).   
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Figure 3.6: The effects of DNA damage on PBF mRNA and protein expression in 
TPC-1 cells. A: PBF protein expression 0, 2, 8 and 24 hours after treatment with 15 
Gy of γ-irradiation. DNA damage did not induce any change in PBF protein 
expression at any time point (n=5). B: PBF mRNA expression 0, 2, 4, 8, and 24 
hours after treatment with 15 Gy of γ-irradiation. DNA damage similarly failed to 
induce any change in PBF mRNA expression at any time-point (n=3, p=NS). 
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Figure 3.7: The effects of DNA damage on PBF mRNA and protein expression in K1 
cells. A: PBF protein expression 0, 2, 8 and 24 hours after treatment with 15 Gy of γ-
irradiation. (n=3). B: PBF mRNA expression 0, 2, 4, 8, and 24 hours after treatment 
with 15 Gy of γ-irradiation. (n=3, p=NS). 
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Figure 3.8: The effects of DNA damage on PBF mRNA and protein expression in 
HCT116 cells. A: PBF protein expression 0, 2, 8 and 24 hours after treatment with 15 
Gy of γ-irradiation. DNA damage resulted in a non-significant increase in PBF protein 
expression 8 and 24 hours after treatment (n=3). B: PBF protein expression 
appeared to increase in a dose dependent manner 24 hours after treatment with γ-
irradiation, in a similar manner to the observed increase in p53 stability. C: PBF 
mRNA expression 0, 2, 4, 8, and 24 hours after treatment with 15 Gy of γ-irradiation. 
DNA damage did not induce any change in PBF mRNA expression at any time-point 
(n=3, p=NS). 
 
PBF overexpression has been reported in tumours of the thyroid, breast and colon 
(Stratford et al, 2005; Watkins et al, 2010b; Kim et al, 2005), and PBF is therefore 
likely to be overexpressed in both the thyroid papillary carcinoma cell lines and the 
colorectal cancer cell line. To test whether the presence of PBF over-expression in 
transformed cell lines was masking a potential PBF response to DNA damage, 
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murine primary thyrocytes were grown in culture and subsequently irradiated with 15 
Gy of γ-irradiation, and protein harvested after 24 hours. Western blotting revealed a 
significant increase in PBF protein expression 24 hours after treatment with γ-
irradiation (Figure 3.9A+B 2.17-fold, n=3, p<0.05). Critically, when PBF mRNA 
expression levels were analysed in response to ionising radiation, no significant 
difference was detected compared to time-matched untreated controls, either at 8 or 
24 hours (Figure 3.9C, n=3, p=NS), implying that PBF protein expression is 
increased in response to γ-irradiation due to an effect on protein stability rather than 
increased transcription and translation. 
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Figure 3.9: The effects of DNA damage on PBF protein and mRNA expression in 
untransformed murine primary thyrocytes. A: Western blot demonstrating increased 
PBF protein expression 24 hours after treatment with 15 Gy γ-irradiation B: Scanning 
densitometry revealed a significant increase in expression after treatment with γ-
irradiation compared to untreated controls (2.18-fold, n=3, p<0.05).C: DNA damage 
had no effect on PBF mRNA expression (n=3, p=NS).  
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3.3.4. 3 A role for PBF in the DNA damage response?  
To investigate a potential role for PBF in the DNA damage response and repair 
pathways upstream of p53 activity, the critical DNA damage protein H2AX was 
assessed to determine whether PBF localises to sites of DSBs. Firstly the optimal 
doses and time-points chosen for maximal p53 activity were challenged in light of a 
γ-H2AX response. In dose responses similar to those described earlier in this 
chapter, TPC-1, K1 and HCT116 cells were irradiated with a range of doses of γ-
irradiation, and total protein was harvested 2 hours post treatment (Figure 3.10). All 
three cell lines displayed a dose dependent increase in γ-H2AX induction following 
treatment with γ-irradiation (Figure 3.10A-C). γ-H2AX was readily detectable at the 
established dose of 15 Gy in TPC-1 cells and K1 cells and at the higher dose of 40 
Gy in HCT116 cells. When time courses were performed to assess the most suitable 
time-point for detection of γ-H2AX, all 3 cell lines displayed a robust γ-H2AX 
response to DNA damage with the most detectable levels recorded 2 hours after 
treatment (Figure 3.10D-F). The phosphorylation of H2AX is an early event in the 
DNA damage response and levels were detected at the 0 hour time-point (time taken 
to harvest cells following irradiation ~15 mins). Levels increased up to 2 hours 
following treatment, but were reduced significantly at the 8 and 24 hour time-points in 
all cell lines, most notably in K1 cells, where γ-H2AX levels were undetectable from 8 
hours along this time-course (Figure 3.10 D-F). Using the optimal doses and time-
points established, fluorescence immunocytochemistry experiments were performed 
to assess the localisation of PBF in respect to γ-H2AX foci present at sites of DSBs 
(Figure 3.11). Such studies were initially performed in green-monkey kidney COS-7 
cells, a large cell type especially amenable to immunofluorescent studies. These 
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cells, treated with 15 Gy of γ-irradiation displayed numerous sub-nuclear foci of γ-
H2AX 2 hours following treatment. PBF expression was predominantly nuclear, with 
significant levels present within the cytosol and intracellular vesicles. Interestingly 
nuclear PBF expression appeared to form distinct foci scattered through the nucleus. 
Analysis of the resultant merged image of these 2 proteins revealed a degree of 
colocalisation, whereby PBF appeared to colocalise to some γ-H2AX foci (Figure 
3.11). These experiments were repeated in TPC-1, K1 and HCT116 cells with similar 
results, where γ-H2AX foci were numerous and readily detectable, and the numerous 
PBF sub-nuclear foci appeared to colocalise with many of them. 
 
Figure 3.10: Induction of DNA damage to elicit γ-H2AX induction in TPC-1, K1 and 
HCT116 cells. A-C: Induction of H2AX expression 2 hours after treatment with a 
range of doses of γ-irradiation in TPC-1, K1 and HCT116 cells respectively. D-E: 
Time-course demonstrating maximal γ-H2AX expression in TPC-1 and K1 cells over 
a 24 hour time-course following treatment with 15 Gy γ-irradiation. F: Time-course 
demonstrating maximal γ-H2AX expression in HCT116 cells over a 24 hour time-
course following treatment with 40 Gy γ-irradiation. 
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Figure 3.11: Localisation of γ-H2AX and PBF 2 hours after treatment with I.R. in 
COS-7, TPC-1, K1 and HCT116 cells. γ-H2AX (green) forms numerous discrete sub-
nuclear foci following DNA damage, and detection is exclusively nuclear in all cell 
types. PBF expression (red) is located within the nucleus, cytosol and intracellular 
vesicles in all cell types.  The merge of the γ-H2AX and PBF imaging demonstrated a 
degree of colocalisation (yellow) of PBF to γ-H2AX sub-nuclear foci. 
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Finally, in light of the apparent colocalisation of PBF with sites of DNA damage, 
specifically to γ-H2AX foci, the effects of PBF overexpression on γ-H2AX expression 
were investigated (Figure 3.12). Thyroid papillary carcinoma cells transiently 
overexpressing exogenous PBF were treated with 15 Gy γ-irradiation and total 
protein was harvested 2 and 8 hours after treatment. TPC-1 and K1 thyroid papillary 
carcinoma cell lines exhibited a robust p53 response following treatment with I.R. 
after 2 and 8 hours, compared to untreated controls (Figure 3.12A+B). γ-H2AX 
expression was also increased in response to I.R. at both time-points However, the 
induction of γ-H2AX was not affected by PBF overexpression at any time-point 
compared to VO-transfected (VO) controls (TPC-1 n=2, K1 n=2, Figure 3.12A+B). 
Despite the apparent colocalisation of PBF with γ-H2AX foci, these preliminary data 
suggest that PBF has no effect on the γ-H2AX expression in response DNA damage. 
This initial finding was also repeated in HCT116 cells with similar results (n=1, data 
not shown). 
 
 
Figure 3.12: Western blot analysis to determine the effects of PBF overexpression on 
the induction of γ-H2AX in response to DNA damage in A: TPC-1 cells (n=2) and B: 
K1 cells (n=2).(UT= untreated). 
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 Discussion 3.4.
The effects of DNA damage, resultant p53 responses and downstream effects in 
TPC-1 and K1 thyroid papillary carcinoma cells have not been well documented. Of 
the diverse and increasing number of cellular stresses that initiate a classical p53 
response, the molecular events following the induction of DNA DSBs are the most 
fully understood (Appella & Anderson, 2001; Saito et al, 2002; Vousden & Lu, 2002). 
Exposure of the developing thyroid to ionising radiation through human disasters 
such as Hiroshima and Chernobyl, and through the administration of γ-irradiation via 
medical treatment, have revealed that the thyroid gland is highly sensitive to the 
carcinogenic effects of ionising radiation (Thompson et al, 1994; Nikiforov et al, 1996; 
Sadetzki et al, 2006). We therefore investigated the effects of DNA damage in the 
form of ionising γ-irradiation on TPC-1 and K1 cells (expressing wild-type p53) to 
attempt to establish optimal dose responses and time-points for the measurements of 
the effects of PBF on this pathway. Furthermore, the effects of DNA DSBs on the 
expression, and subcellular localisation of PBF remain uncharacterised. Therefore 
we assessed the effects of DNA damage on PBF expression and subcellular 
localisation in these cells. Finally, to determine whether responses detected were 
thyroid specific, we endeavoured to repeat our investigations in the HCT116 
colorectal carcinoma cell line. 
3.4.1. Treatment with γ-irradiation: establishing an optimal dose. 
TPC-1 and K1 papillary carcinoma cells displayed robust p53 protein accumulation 
and phosphorylation of ser-15 (data not shown), indicative of p53 activation in 
response to DNA DSBs induced by γ-irradiation. Furthermore, both cell lines 
displayed a dose dependent increase in p53 accumulation following treatment. The 
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reduced p53 accumulation observed at higher doses of γ-irradiation correlated with 
gross cytotoxicity indicative of necrosis caused by exposure to high and lethal doses 
of γ-irradiation (Raghavan et al, 2012). In HCT116 cells p53 accumulation also 
occurred in a dose-dependent manner, however, accumulation of p53 continued to 
occur even at the highest dose delivered (40 Gy) with no observable cytotoxicity. 
This suggests that TPC-1 and K1 thyroid papillary carcinoma cells, whilst displaying 
robust p53 accumulation following genotoxic stress, are more sensitive to higher 
doses of irradiation than the radio-resistant HCT116 colorectal cancer cells. p53 
activity measured as induction of CDKN1A mRNA expression was also increased in 
a dose-dependent manner in both TPC-1 and K1 cells. K1 cells displayed increasing 
CDKN1A mRNA expression in response to DNA damage up to a dose of 15 Gy after 
which, in-keeping with the cytotoxicity observed at the higher doses (above 20 Gy), 
CDKN1A mRNA expression levels began to fall. HCT116 cells displayed a dose 
dependent increase in CDKN1A mRNA expression with maximal induction at the 
highest treatment dose of 40 Gy, in direct correlation with the observed increase in 
p53 protein expression. Taken together these data indicate that the human thyroid 
papillary carcinoma cell lines, TPC-1 and K1s are responsive to a range of doses of 
γ-irradiation, resulting in a vigorous increase in p53 protein expression and activation 
of p53 as a transcription factor. The dose at which p53 accumulation and activation is 
most apparent in the thyroid papillary carcinoma cells is 15 Gy (taking into account 
the global cytotoxicity observed at higher doses) and treatment of cells with 15 Gy of 
γ-irradiation provides robust p53 activity from which the effects of PBF can be 
measured.  
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3.4.2. Treatment with γ-irradiation: establishing an optimal time-point 
In addition to observing the p53 response to DNA damage over a range of doses of 
γ-irradiation it was also necessary to determine the time-points at which maximal p53 
activity occurred. TPC-1, K1 and HCT116 cells all displayed significant induction of 
CDKN1A mRNA expression over a 24 hour time-course, with maximal responses 
observed at 8 and 24 hours in each cell-line. 
Different cell types often display different biological reactions to any given stress 
(Gudkov & Komarova, 2003), and the decision between apoptosis and growth arrest 
appears to be governed by p53 activity (Vousden & Lu, 2002). However, this process 
is by no means random, for example haematopoietic stem cells only respond to γ-
irradiation via induction of apoptosis (Vousden & Lu, 2002; Meek, 2004); and 
fibroblasts only appear to respond  even to very high doses of γ-irradiation through 
growth-arrest; apoptosis is never initiated (Gudkov & Komarova, 2003). However, 
many cell types may undergo either growth arrest or apoptosis, and the p53 
‘decision’ to drive one or both of these pathways is influenced by the levels of 
genotoxic stress sustained. TPC-1 cells are an example of a cell-type that can 
undergo either growth arrest or apoptosis depending on the level of genotoxic insult 
sustained (Abou-El-Ardat et al, 2008). We found that γ-irradiation induced p53-
mediated gene expression of the growth arrest gene CDKN1A most significantly, with 
the pro-apoptic genes BAX and PUMA significantly induced but at lower levels. 
These data correlate with the findings of Abou-El-Ardat et al, 2008, who observed 
growth-arrest as the major response to both high and low-doses of ionising radiation, 
whilst observing a degree of apoptosis in TPC-1 cells. In a similar fashion to TPC-1 
cells, K1 cells also displayed significant upregulation of CDKN1A mRNA expression, 
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suggesting that in this cell line growth arrest pathways are highly stimulated in 
response to 15 Gy of γ-irradiation. However, in contrast to the TPC-1 cell line PUMA 
mRNA expression was non-significantly upregulated (2.4-fold) following treatment, 
indicating that in these cells, induction of apoptosis may be less frequent. This result 
comes in apparent support of the finding of Challeton et al, who observed a weak 
effect of the dose rate of ionising radiation on the survival of K1 thyroid papillary 
carcinoma cells (Challeton et al, 1997).  Finally, in HCT116 cells CDKN1A mRNA 
expression was significantly elevated 40 Gy of γ-irradiation, suggesting that this dose 
is inducing a strong p53-mediated growth arrest response in this cell line. In addition, 
PUMA mRNA expression was also significantly upregulated, but to a lesser degree, 
demonstrating that at this dose, p53-mediated apoptotic pathways are also activated. 
That p53-mediated gene transcription of CDKN1A expression was significantly 
elevated in all cell lines may suggest that treatment of TPC-1 and K1 cells with 15 Gy 
and HCT116 cells with 40 Gy of γ-irradiation predominantly results in growth arrest 
responses. However, the potency of gene induction does not always reflect the 
severity of the biological response. Therefore to determine the biological outcome 
(apoptosis or growth arrest) of these doses of ionising radiation, further experiments 
are required. For instance analysis of classical BrdU staining via FACS would 
determine the extent of growth arrest exhibited by TPC-1, K1 and HCT116 cells 
following treatment with ionising radiation, and caspase 3/7 cleavage assays would 
determine the levels of apoptosis in these cells. In conclusion, whilst these data do 
not demonstrate a reliable mechanism for determining the overall cellular response to 
ionising radiation in TPC-1, K1 and HCT116 cells, they demonstrate that treatment of 
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TPC-1 and K1 cells with 15 Gy and treatment of HCT116 cells with 40 Gy 
significantly activate the p53 response to DNA damage. 
3.4.3. The effects of DNA damage on PBF expression 
The effects of ionising radiation on PBF expression are unknown. To assess whether 
PBF is responsive to DNA damage we treated TPC-1 and K1 cells with 15 Gy γ-
irradiation and harvested total cellular protein and RNA over a 24 hour time-course 
(we also repeated these experiments using HCT116 cells at the higher dose of 40 
Gy). In TPC-1 and K1 cells no detectable difference in PBF protein or mRNA 
expression was observed across a 24 hour time-course following treatment with γ-
irradiation. These cells were also subjected to a range of doses to γ-irradiation to 
observe whether the PBF response was dependent on dose (i.e. low or high dose 
response), and again, showed no change in PBF protein expression. These data 
suggest that PBF expression is not effected by γ-irradiation, and that in these cell 
lines PBF is not responsive to γ-irradiation treatment. HCT116 cells treated with 40 
Gy of γ-irradiation displayed increased PBF protein expression from 8 and 24 hours 
after treatment, but this result could not be repeated to statistical significance. 
Furthermore when dose responses were performed PBF protein expression 
appeared to increase in a dose-dependent manner, but again, these observations 
were not reliably repeatable in this cell line. PBF mRNA expression was not induced 
in response to γ-irradiation. As mentioned earlier, PBF protein is overexpressed in 
tumours of the thyroid, breast pituitary and colon, and so investigation into the effects 
of γ-irradiation in thyroid papillary carcinoma cells and human colorectal cells may 
represent a futile system of observation whereby physiological PBF responses are 
saturated. We therefore assessed the effects of PBF expression in response to γ-
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irradiation in primary murine thyrocytes. In this system, PBF protein expression was 
significantly elevated 24 hours after treatment with 15 Gy of γ-irradiation. 
Interestingly, PBF mRNA expression was unaltered in response to 15 Gy of γ-
irradiation at both 8 and 24 hours post irradiation. The lack of induction of PBF 
mRNA expression suggests that PBF protein induction in these cells occurred as a 
result of the induction of PBF protein stability rather than transcription and 
translational events. That increased PBF protein expression correlates with ionising 
radiation treatment in murine primary thyrocytes may suggest that PBF plays a role in 
the normal cellular response to genotoxic insult in the form of DNA DSBs, with 
oncogenic expression of PBF resulting in aberrant cellular responses to DNA 
damage, resulting in cell transformation or malignant progression. 
3.4.4. A role for PBF in the DNA damage response 
In order to determine the relationship between PBF, sites of DNA damage and DNA 
damage and repair proteins upstream of p53, we assessed the relationship between 
PBF and the DNA repair protein γ-H2AX. Phosphorylation of the H2AX protein at 
serine-139 (yielding γ-H2AX), mediated by ATM, is an early event following the 
induction of DNA lesions (Kinner et al, 2008). γ-H2AX was induced in a dose 
dependent manner in TPC-1 and HCT116 cells, 2 hours after treatment with ionising 
radiation. γ-H2AX was more difficult to detect in K1 cells, but was readily induced by 
DNA damage. Time-courses were also performed to ascertain the optimal time-point 
to study the relationship between PBF and γ-H2AX. In all cell lines the greatest 
accumulation of γ-H2AX occurred 2 hours after treatment, with levels readily 
detectable at time 0 (time taken to remove cells from the irradiator and harvest 
cellular protein ~15 mins). Using this information, we assessed whether PBF 
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localised to sites of DNA damage using immunofluorescence cytochemistry. 
Treatment of COS-7, TPC-1, K1 and HCT116 cells with ionising radiation induced a 
number of distinct subnuclear foci of γ-H2AX to sites of DNA lesions; PBF expression 
was located throughout the cytoplasm, intracellular vesicles and the nucleus, with 
some but not ubiquitous colocalisation with γ-H2AX foci. These data lie in support of 
the multi-functional role of PBF, for example in shuttling of PTTG into the nucleus 
and in the regulation of NIS function amongst others, where distinct isoforms of PBF 
(cleavage products or differential post-translational modifications) have distinct 
biological roles (Smith et al, 2009, 2012 and our unpublished data). However, if PBF 
plays an important role within the DNA damage response, these comments fail to 
explain why PBF does not colocalise to all sites of γ-H2AX foci preventing the 
derivation of firm conclusions concerning the relationship of PBF within the DNA 
damage response.   
Whilst this thesis concerns the relationship of oncogenic PBF levels on p53 function, 
we decided to investigate these findings further to attempt to ascertain whether PBF 
plays a role in the DNA damage response. To do this TPC-1, K1 and HCT116 cells 
were transfected with our PCDNA3-PBF plasmid to induce transient overexpression 
of PBF and the effects of PBF overexpression on the accumulation of γ-H2AX in 
response to ionising radiation were assessed. Preliminary data (TPC-1, n=2; K1, 
n=2; HCT116 n=1), demonstrated that PBF overexpression had no effect on the 
induction of γ-H2AX following treatment with γ-irradiation. These findings indicate 
that there is no functional relationship between PBF and γ-H2AX accumulation at 
sites of DNA damage.  
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3.4.5. Concluding statements 
This Chapter provides evidence that TPC-1, K1 and HCT116 cells display a robust 
p53 response to ionising radiation. For instance, p53 was highly stabilised at the 
protein level and p53-mediated gene expression was significantly elevated following 
treatment of TPC-1 and K1 cells with 15 Gy of γ-irradiation and HCT116 cells with 40 
Gy of γ-irradiation.  
Induction of DNA damage within TPC-1, K1 and HCT116 cells did not correlate with 
any significant differences in PBF protein or mRNA expression, however, in normal 
murine thyrocytes, PBF protein expression was significantly elevated in response to 
γ-irradiation. These data suggest that PBF may be activated following genotoxic 
insult in normal (non-transformed cells), and may indicate a normal cellular role for 
PBF in the cellular response to DNA damage.  
Finally, despite observing a degree of colocalisation of PBF and γ-H2AX nuclear foci, 
PBF overexpression had no effect on the induction of γ-H2AX; suggesting that whilst 
a subset of PBF nuclear foci are localise to sites of DNA breaks, PBF does not 
influence the activation of this protein in response to DNA damage. Further study into 
the DNA damage and repair pathways are required to fully elucidate the role of PBF 
in the DNA damage response upstream of p53 activity. 
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 Introduction 4.1.
As mentioned previously, p53 is inactivated by mutation in over 50 % of human 
cancers, but is also observed to be functionally inactivated by viral or cellular 
oncogenes. Indeed, numerous avenues of study implicate the functional inactivation 
of p53 with initiation and progression of tumourigenesis (Vogelstein et al, 2000; 
Vousden, 2000). Many viral oncogenes manipulate p53 function to allow for 
replication, with the outcome for the infected cell being increased susceptibility to 
transformation. For example, the viral onco-protein (HPV16) E6 counteracts cellular 
responses to unscheduled proliferation by binding directly to p53 and targeting it for 
proteasomal degradation (Havre et al, 1995; Massimi et al, 2007).  
Recently, cellular oncogenes have been characterised to inhibit p53 function in 
certain tumours. For instance, chromosomal rearrangements in acute myeloid and 
lymphoblastic leukaemias result in the generation of a chimeric protein MLL-ELL. 
Recently MLL-ELL has been shown to inhibit p53 transcriptional activity, and the 2 
proteins have been observed to colocalise within the nucleus. Furthermore, a direct 
interaction of the p53 transactivation domain and the ELL protein has been observed. 
The binding of p53 and MLL-ELL results in the disruption of numerous important p53 
interactions in response to cellular stress, including the association of p53 with its key 
transcriptional co-activator p300/CBP (Wiederschain et al, 2003). More importantly in 
thyroid papillary carcinomas, oncogenic expression of the high mobility group A 
factors (HMGA1a, HMGA1b, and HMGA2) in thyroid epithelial cells results in 
malignant transformation (Frasca et al, 2006). The mechanism by which HMGA1 
promotes transformation and tumourigenesis has been characterised, with the 
functional inactivation of p53 playing a key role. HMGA1 binds directly to p53 in the 
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region of the C-terminal oligomerisation domain, and oncogenic expression of 
HMGA1 represses the DNA binding capacity of p53 and causes the inhibition of p53 
apoptotic function (Frasca et al, 2006; Pierantoni et al, 2007; Malaguarnera et al, 
2007a).  
In some cases, the functional inactivation of p53 is brought about by its physical 
removal (sequestration) from sites of activity by another protein. For example this 
mechanism may result in p53 accumulation in the cytoplasm thereby abrogating its 
tumour suppressive action. Originally, this was discovered in mammalian models of 
viral oncogenesis. The adenovirus E1B 55 kDa protein (in conjunction with E1A and 
E1B 19 kDa proteins) contributes to cellular transformation (Yew & Berk, 1992; Yew 
et al, 1994; Hartl et al, 2008). This protein interacts directly with the transactivation 
domain (TAD) of p53 perturbing its tumour suppressive role. Whilst the E1B 55 kDa 
protein appears to disrupt p53 on many levels, it has been observed to cause the 
sequestration of p53 into cytoplasmic aggresomes (Zhao & Liao, 2003; Hartl et al, 
2008). This is a brief description of a small number of the total proteins that have 
either evolved to bypass the protective effect of p53, as in the case of viral 
oncogenes, or functionally inactivate p53 responses following oncogenic expression 
(as in the case of cellular oncogenes). Interestingly, of the p53 disruptive oncogenes 
described, all bind directly to p53 to elicit their oncogenic properties.  
Numerous cellular roles for the proto-oncogene PBF have been described. For 
instance PBF binds directly to PTTG and facilitates its transportation to the nucleus 
via its C-terminal bi-partite nuclear localisation signal. This property allows PTTG to 
function as a Securin, by inhibiting separase activity to prevent premature sister-
chromatid separation (Chien & Pei, 2000). PBF also plays a role in the regulation of 
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NIS function whereby PBF binds directly to NIS causing its redistribution from the 
plasma membrane to intracellular vesicles (Smith et al, 2009). Additionally, the 
Membrane transporter MCT-8 (a key regulator of TH secretion from the thyroid gland) 
has been observed to undergo significant subcellular relocalisation Following 
interaction with PBF (Smith et al, 2012a).  PBF has therefore been characterised with 
a number of diverse roles, suggesting that PBF is able to functionally interact with a 
number of cellular proteins.  
We hypothesised that aberrant expression of PBF promotes tumourigenesis by 
functional inhibition of p53 activity, and that, in keeping with the cellular oncogenes 
described, an interaction between the 2 proteins may be required. Given that PBF is 
known to interact functionally with other proteins we therefore assessed the potential 
interaction between PBF and p53. We have previously described an interaction 
between PBF and p53 from HCT116 cells in vitro with the use of GST pull down 
assays (see Section 1.3.3). However, in light of the fact that GST pull down assays 
represent an artificial system, where proteins may bind in a physiologically irrelevant 
manner, the observed interaction may not occur under normal cellular conditions. To 
validate or refute these preliminary GST data in a setting that is more physiological, 
we aimed to assess this interaction using the technique of co-immunoprecipitation in 
TPC-1, K1 and HCT116 cells, both in the presence and absence of ionising radiation. 
In addition to these studies, assessment of the subcellular relationship between PBF 
and p53 was investigated, both in the presence and absence of DNA damage.  We 
also aimed to characterise the effects of PBF overexpression on the subcellular 
localisation of p53, especially in light of the previously described roles for PBF in the 
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subcellular distribution of other important proteins (Chien & Pei, 2000; Boelaert et al, 
2007; Smith et al, 2009, 2012a). 
The overall aims of this chapter were therefore to determine whether PBF and p53 
interact within the intracellular environment and assess the subcellular localisation of 
PBF and p53 in the presence and absence of DNA damage.  
 Materials and methods 4.2.
4.2.1. Cell lines and plasmids 
TPC-1, K1 and HCT116 cells were routinely subcultured using the methods 
described in Section 2.1. For experiments requiring transient PBF overexpression, 
and /or γ-irradiation exposure, cells were treated using the procedures described in 
Section 3.3  
4.2.2. Co-immunoprecipitation assays  
TPC-1, K1 and HCT116  cells growing in T25 culture flasks were harvested in 500 ul 
RIPA buffer with 60 µl/ml protease inhibitor (100 mM sodium chloride, 0.1 % Triton X-
100 and 50 mM Tris (pH8.3)). Samples were then sonicated for 30 seconds on the 
medium setting of the Diagenode Bioruptor and centrifuged for 20 minutes at 13,000 
rpm (4 0C). Protein concentration was then measured using BCA estimation 
(PIERCE) and 30 µg of protein lysate were retained before addition of primary 
antibody (DO-1 at 1:100 concentration) overnight at 4 0C, with end over end mixing. 
Samples were then incubated in 50 µl of protein-G sepharose/RIPA slurry for 2 hours 
at 4 0C with end over end mixing. Beads were then pulsed and the supernatant 
discarded and unbound protein was washed using 4X500 µl RIPA buffer. 
Subsequently protein was eluted with 1:20 β-mercaptoethanol and 1 % SDS in 
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Laemlli buffer and incubation for 30 minutes at 37 0C. Equal volumes of this solution 
were added to the cell lysates and samples were loaded onto a 12 % acrylamide gel 
for subsequent analysis via Western blotting. 
4.2.3. SDS-PAGE/Western blotting 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see Section 2.6). Blocked membranes were subsequently 
incubated with primary antibodies. Antibodies used were; our rabbit anti-human PBF-
8 polyclonal (1:1000) (Stratford et al, 2005), rabbit anti-human HA (Covance) mouse 
anti-human p53 (D0-1) monoclonal at 1:5000 (Santa Cruz, CA, USA), and 
monoclonal anti-β-actin clone AC-15 (used at 1:10,000, Sigma-Aldrich, Poole, UK). 
To test for the purity and equal loading of nuclear and cytoplasmic protein 
subfractions mouse anti-human lamin  and mouse anti-human α-tubulin specific 
antibodies were used respectively (Santa Cruz, CA, USA). Scanning densitometric 
analysis of Western blotting assessment of PBF and p53 expression was normalised 
to β-actin.  
4.2.4. Immunofluorescence  
COS-7, HCT116, TPC-1 and K1 cells were seeded onto coverslips, irradiated using a 
Caesium-137 γ-emitter and prepared for fluorescence immunocytochemistry using 
the methods described in Section 2.7. PBF was detected using our rabbit anti-human 
PBF-8 antibody (1:100) and p53 detected using the mouse anti-human p53 (DO-1) 
monoclonal at 1:250 (Santa Cruz, CA, USA). Cells were then visualised on a 
fluorescence confocal microscope.  
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4.2.5. Subcellular fractionation experiments 
For subcellular fractionation experiments, cells were seeded into 6-well dishes and 
nuclear and cytosolic protein subfractions were prepared using a commercial nuclear 
extraction kit (Active Motif Europe, Rixenhart, Belgium) as per manufacturer’s 
instructions.  Protein concentration before loading was measured by the Bradford 
assay with BSA as standard. 
4.2.6. Statistical analysis 
Data were analysed as described in Section 2.8. 
 
 Results 4.3.
4.3.1. PBF and p53 interact in vitro 
To determine whether PBF and p53 interact in vitro, total cellular protein was 
harvested from TPC-1 and K1 cells and co-immunopreciptitation assays were 
performed. When compared to no antibody controls, p53 was co-immunoprecipitated 
with PBF using our PBF polyclonal antibody, in both the presence and absence of γ-
irradiation (see Figure 4.1). In the presence of γ-irradiation significantly more p53 co-
immunoprecipitated with PBF (TPC-1, 2.7 +/- 0.38 fold. n=4, p<0.05; K1, 2.1 +/- 0.13 
fold, n=4, p<0.01). p53 also co-immunoprecipitated with PBF in HCT116 cells in both 
the presence and absence of  DNA damage (see Figure 4.2A). DNA damage also 
induced a significant increase in the yield of p53 in this cell line (1.9 +/- 0.13 fold, 
n=3, p<0.01, Figure 4.2B). Further to these experiments PBF was also co-
immunoprecipitated with p53 using a specific monoclonal p53 antibody compared to 
no antibody controls (NAb) in HCT116 cells (see Figure 4.2C). Finally, an interaction 
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between PBF and p53 was observed through co-immunoprecipitation assays when 
exogenous p53 was transiently over-expressed in HCT116 cells (Figure 4.2D). These 
data demonstrate a specific and robust interaction between PBF and p53 under 
normal cellular conditions in both the presence and absence of DNA damage. 
 
Figure 4.1: PBF binds to p53 in co-immunoprecipitation assays A: Co-
immunoprecipitation of p53 with PBF in TPC-1 cells in both the absence (-) and 
presence (+) of γ-irradiation (NAb = no antibody control). Scanning densitometry 
revealed that in the presence of γ-irradiation more p53 co-immunoprecipitated with 
PBF (2.7-fold, n=3, p<0.05) compared to untreated controls. B: Co-
immunoprecipitation of PBF with p53 in K1 cells in the presence and absence of γ-
irradiation compared to NAb controls. Scanning densitometry confirmed that 
significantly more p53 co-immunoprecipitates with PBF in the presence of γ-
irradiation (2.1-fold, n=3, p<0.01) compared to untreated controls. 
Chapter 4: The relationship between PBF and p53 
 
103 
 
 
Figure 4.2: PBF binds to p53 in co-immunoprecipitation assays. A: Co-
immunoprecipitation of p53 with PBF in HCT116 cells in both the absence (-) and 
presence (+) of γ-irradiation (NAb =no antibody control). B: Scanning densitometry 
revealed that In the presence of γ-irradiation more p53 co-immunoprecipitated with 
PBF (1.9-fold, n=3, p<0.01) compared to untreated controls. C: Reverse co-
immunoprecipitatiom of PBF with p53 in the absence of DNA damage. IgG =antibody 
contamination from the immunoglobulin G light-chain. D: Co-immunoprecipitation of 
exogenous p53 with PBF. 
 
4.3.2. PBF and p53 colocalisation  
Fluorescence immunocytochemistry experiments determined the colocalisation of 
PBF and p53 in COS-7 cells, TPC-1 cells and HCT116 cells. Such studies were 
initially carried out and optimised in COS-7 cells due to their large size compared to 
the thyroid and colorectal cell lines. In COS-7 cells p53 was predominantly nuclear in 
both the presence and absence of DNA damage, indicative of a transformed cell line 
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(Hess & Brandner, 1997). Despite this, levels of p53 visibly increased in the nucleus 
following DNA damage (Figure 4.3). PBF expression appeared to be ubiquitously 
distributed throughout the cell (located within the cytosol, intracellular vesicles and 
the nucleus) However, in response to DNA damage, PBF nuclear expression visibly 
increased compared to untreated controls. PBF and p53 appeared to colocalise 
within the nucleus of COS-7 cells in both the presence and absence of DNA damage, 
with greater levels of colocalisation detected following DNA damage, in keeping with 
the apparent increase in the nuclear expression of each protein (Figure 4.3). 
Fluorescence immunocytochemistry experiments were repeated in both TPC-1 and 
HCT116 cells with similar results (Figure 4.4). In TPC-1 cells p53 was primarily 
located within the nucleus but with detectable levels within the cytoplasm (Figure 
4.4A). Following DNA damage, nuclear p53 expression was visibly increased. Again 
in these cells PBF was distributed throughout the cell, with the majority of PBF 
localised to the nucleus, and detectable levels throughout the cytosol and 
intracellular vesicles. In response to DNA damage these cells did not display 
increased PBF protein expression within the nucleus or otherwise (consistent with 
the data described in Chapter 2). PBF and p53 appeared to colocalise in these cells 
in both the presence and absence of DNA damage. In the absence of DNA damage, 
PBF and p53 colocalisation was most apparent in the cytoplasm. However, following 
DNA damage PBF and p53 appear to colocalise within the cytoplasm and compared 
to untreated controls, to a greater degree within the nucleus. Finally in HCT116 cells, 
p53 expression was predominantly nuclear, with detectable levels within the cytosol, 
and after DNA damage, p53 nuclear expression was greatly increased (Figure 4.4B). 
PBF was located predominantly in the nucleus, but also localised to the cytosol and 
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intracellular vesicles. Following DNA damage PBF nuclear expression increased 
compared to untreated controls. PBF and p53 appeared to colocalise in the nucleus 
of these cells in the presence and absence of DNA damage; although colocalisation 
was striking following DNA damage, it was minimal in the absence of DNA damage. 
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Figure 4.3: Localisation of PBF and p53 in COS-7 cells at 40x and 100x 
magnification. A: p53 and PBF localisation in a cluster of COS-7 cells in the 
presence and absence of DNA damage. p53 (green) is predominantly nuclear, with 
PBF expression (red) located throughout the cytosol, intracellular vesicles and the 
nucleus. PBF and p53 displayed significant co-localisation within the nucleus as seen 
in the merged images (yellow). In the presence of DNA damage both p53 and PBF 
nuclear expression was increased, resulting in a significant increase in nuclear co-
localisation (DAPI nuclear staining is shown in blue). B: A single COS-7 cell at 100x 
magnification displaying colocalisation of PBF and p53 in the nucleus in both the 
presence and absence of DNA damage.  
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Figure 4.4. Localisation of PBF and p53 in TPC-1 cells and HCT116 cells at 40x and 
100x magnification respectively. A: p53 and PBF localisation in a cluster of TPC-1 
cells in the presence and absence of DNA damage. p53 (green) was predominantly 
nuclear, with detectable levels within the cytosol. PBF (red) was ubiquitous 
throughout the cell. PBF and p53 displayed significant co-localisation within the 
nucleus as observed in the merged images (yellow). DNA damage resulted in greater 
p53 nuclear expression, resulting in a significant increase in nuclear co-localisation. 
B: p53 (green) and PBF (red) subcellular localisation in both the presence and 
absence of ionising radiation in HCT116 cells. Following treatment with ionising 
radiation p53 nuclear localisation significantly increased resulting in increased co-
localisation of PBF and p53 in the nucleus (DAPI nuclear staining is shown in blue). 
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4.3.3.  PBF does not affect the subcellular localisation of p53 
Previous data in this chapter demonstrated that PBF binds directly to p53, and that 
the 2 proteins colocalise within the cell both in the presence and absence of DNA 
damage. It was therefore of interest to determine whether PBF effects the subcellular 
localisation of p53. To do this PBF was overexpressed in thyroid papillary carcinoma 
cell lines and the colorectal cancer cell line, both in the presence and absence of 
DNA damage, and gross cytosolic and nuclear proteins were harvested. In the 
cytoplasmic fraction of TPC-1 cells, p53 levels remained constant when PBF was 
overexpressed compared to VO-transfected controls (Figure 4.5). p53 protein 
expression was increased following DNA damage as expected but there was no 
significant difference in p53 levels when PBF was overexpressed compared to 
controls. PBF overexpression had no significant effect on p53 levels within the 
nucleus, either in the presence or absence of DNA damage (Figure 4.5A; TPC-1 
cells; n=3). HCT116 cells displayed similar results, where p53 levels in either fraction 
were unaltered in response to PBF overexpression in the presence or absence of 
DNA damage. (Figure 4.5B; HCT116 n=5).  
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Figure 4.5: The effects of PBF overexpression on p53 subcellular localisation in A: 
TPC-1 (n=3) and B: HCT116 cells (n=5) in the presence and absence of DNA 
damage (TPC-1 15 Gy, and HCT116 40 Gy). Assessment of relative total protein 
loading and purity of the Nuclear and cytoplasmic fractions were determined using 
specific lamin and α-tubulin antibodies respectively. (VO = vector only controls, UT = 
untreated). 
 
 
 
 
Chapter 4: The relationship between PBF and p53 
 
110 
 
 Discussion  4.4.
4.4.1. PBF and p53 interact in vivo 
Of the diverse range of viral and cellular oncogenes that have been characterised to 
functionally interact with p53 most elicit their functional properties via a direct 
physical interaction. Indeed, in thyroid papillary carcinomas, overexpression of 
HMGA factors in thyroid epithelial cells leads to cell transformation, by directly 
interacting with the C-terminal oligomerisation domain of p53, thereby functionally 
inactivating it (Frasca et al, 2006; Malaguarnera et al, 2007a; Pierantoni et al, 2007). 
Whilst remaining a relatively uncharacterised protein, PBF has an emerging 
repertoire of cellular roles, providing evidence for its multi-functionality (Chien & Pei, 
2000; Smith et al, 2009; Watkins et al, 2010a; Read et al, 2011). Additionally, 
oncogenic expression of PBF has been reported in thyroid tumours, with 
overexpression resulting in cell transformation in vitro and tumourigenesis in vivo 
(Stratford et al, 2005). We hypothesised that functional inactivation of p53 plays a 
role in transformation and progression of thyroid papillary carcinomas when p53 
mutations are not present. Given the transforming and tumourigenic properties 
observed when PBF was overexpressed; we investigated the relationship between 
PBF and p53 in thyroid papillary carcinoma cells. 
We recently demonstrated a potential interaction between PBF and p53 in vitro with 
the use of recombinant PBF and p53 protein. Initial GST pull-down assays 
demonstrated that L-α-[35S]-methionine-labelled PBF interacts with the tumour 
suppressor protein p53 (Figure 1.13). Therefore to determine whether PBF and p53 
interact within TPC-1, K1 and HCT116 cells, we performed co-immunoprecipitation 
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assays designed to explore potential interaction between endogenous PBF and p53. 
Numerous cellular conditions and protocols were used to optimise the conditions of 
the co-IP assays for ideal detection of the potential interaction between PBF and p53 
(data not shown). Using the conditions described in Section 4.2.2, p53 was 
successfully co-immunoprecipitated with PBF when PBF was immunoprecipitated 
with our PBF antibody in TPC-1, K1 and HCT116 cells. Significantly more p53 was 
observed on Western blots 8 hours after cells were subjected to ionising γ-irradiation 
treatment. These data do not indicate that the stringency of interaction between PBF 
and p53 is increased following DNA damage, because more p53 is available for the 
interaction due to its stabilisation; however it does indicate that PBF and p53 interact 
within the intracellular environment in both the presence and absence of DNA 
damage. To provide further evidence that PBF binds directly to p53 we were able to 
co-immunoprecipitate PBF with p53 using the DO-1 p53 specific antibody, and also 
co-immunoprecipitate exogenous p53 with PBF. These data are in support of the 
GST-pulldown assays performed recently with our group. The interaction of viral and 
cellular proteins with p53 commonly results in the modulation of p53 function, and 
whilst evidence for the interaction between PBF and p53 is robust, the functional 
consequence of the interaction of PBF and p53 remains to be characterised.  
4.4.2. PBF and p53 colocalisation 
We demonstrated a direct interaction between PBF and p53 in TPC-1, K1 and 
HCT116 cells in both the presence and absence of DNA damage. Therefore to 
analyse the subcellular relationship between PBF and p53 we performed 
fluorescence immunocytochemistry experiments in both the presence and absence 
of γ-iradiation.  
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An increasing number of roles are being attributed to the PBF protein, and as such 
PBF is found throughout the cell, at the plasma membrane, within the cytosol, 
intracellular vesicles, and the nucleus (Chien & Pei, 2000; Smith et al, 2009, 2012a). 
We first analysed the subcellular relationship between PBF and p53 in COS-7 African 
green monkey kidney cells as these cells are much larger than TPC-1 or HCT116 
cells, thus allowing optimal visualisation of subcellular localisation. In a manner 
typical of transformed cells lines, p53 was observed to be predominantly nuclear in 
COS-7, TPC-1 and HCT116 cells, with some cytosolic p53 within TPC-1 and HCT116 
cells (Moro et al, 1995). Under normal cellular conditions (the absence of DNA 
damage) PBF and p53 appeared to colocalise within the nucleus of COS-7 cells and 
the nucleus and cytoplasm of TPC-1 cells. However, in contrast to the co-
immunoprecipitation data, colocalisation between PBF and p53 was minimal in 
HCT116 cells in the absence of DNA damage. Following the induction of DNA 
damage, colocalisation of PBF with p53 was apparent and increased in all 3 cell 
lines, and this effect is most likely due to increased stability and accumulation of p53. 
The colocalisation of PBF with p53 in COS-7, TPC-1 and HCT116 cells supports the 
co-immunoprecipitation data generated in Section 4.3.1 and demonstrates that PBF 
and p53 colocalisation is predominantly nuclear following ionising radiation, indicating 
that PBF may functionally interact with p53 in the nucleus of these cells. It would be 
of great interest to observe the relationship between PBF and p53 in normal thyroid 
epithelial cells to determine the normal distribution and subcellular localisation of PBF 
and p53. 
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4.4.3. PBF does not affect the subcellular localisation of p53 
Viral oncogenes, including the adenovirus E1B 55 kDa protein sequester p53 to 
cytoplasmic aggresomes by actively promoting nuclear export of p53, thereby 
inhibiting its function (Zhao & Liao, 2003; Mihara et al, 2003; Hartl et al, 2008). 
Aberrant expression of cellular oncogenes including the deubiquitinylating enzyme 
HAUSP also results in p53 sequestration in the cytoplasm due to impaired interaction 
with p53 (Moll et al, 1995; Becker et al, 2007).  
We have characterised a robust interaction between PBF and p53 in our cell lines in 
both the presence and absence of γ-irradiation. Given the subcellular distribution of 
PBF and its characterised role in the subcellular distribution of important proteins  
(Chien & Pei, 2000; Smith et al, 2009, 2012a; Lewy et al, 2012) we aimed to assess 
the effects of PBF overexpression on the subcellular distribution of p53. To do this 
we performed subcellular fractionation studies aimed to isolate total cytoplasmic and 
nuclear proteins in TPC-1, K1 and HCT116 and determine total levels of p53 in each 
fraction following PBF overexpression in both the presence and absence of ionising 
radiation. After numerous independent observations we did not detect any difference 
in p53 subcellular localisation following PBF overexpression in the presence or 
absence of DNA damage in any of the cell lines. In keeping with the fluorescence 
immunocytochemistry experiments in Section 4.2.4, these data indicate, that whilst 
PBF and p53 colocalise and interact in TPC-1, K1 and HCT116 cells, PBF does not 
specifically alter p53 subcellular localisation despite having other characterised roles 
in the nuclear import of PTTG and the internalisation of NIS at the plasma membrane 
(Chien & Pei, 2000; Smith et al, 2009, 2012a). It would be useful to investigate 
whether specific mutants of PBF, such as one lacking the bipartite nuclear 
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localisation signal and which is sequestered within the cytoplasm, could alter p53 
subcellular distribution. 
4.4.4. Concluding statements 
This chapter provides evidence that PBF interacts with both in the presence and 
absence of DNA damage within the intracellular environment. These findings support 
existing observations that recombinant PBF and p53 interact in cell-free GST-
pulldown assays. The interaction of PBF with p53 suggests that in thyroid cancers 
where PBF is overexpressed, PBF may bind to p53, potentially abrogating its 
function in the absence of p53 mutations. Furthermore, PBF and p53 appear to 
colocalise within the nucleus of COS-7, TPC-1 and HCT116 transformed cells. 
Subcellular fractionation studies confirmed that the overexpression of PBF within 
TPC-1, K1 or HCT116 cells did not significantly alter p53 subcellular localisation, 
suggesting that the functional consequence of the interaction of PBF with p53 does 
not concern the subcellular redistribution of p53, as is the case with many cellular 
oncogenes. Data in the following chapters explore the functional consequences of 
the newly characterised interaction of PBF with p53 in thyroid cancer. 
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 Introduction 5.1.
p53 acts as a node or pivot for incoming stress signals, which are then transduced 
largely through the ability of p53 to act as a transcription factor to bring about a 
plethora of cellular responses that ultimately provide preventative measures against 
malignant transformation (Vogelstein et al, 2000; Meek, 2004; Brooks & Gu, 2006). 
For example, in its role as a master regulator, p53 transcriptional control expands 
across a large number of genes encompassing a diverse range of biological 
activities. These genes amongst others, control DNA metabolism, cell cycle arrest, 
angiogenesis, senescence and apoptosis (Vogelstein et al, 2000). However, in its 
function as a tumour suppressor the primary roles of p53 are in DNA repair, cell cycle 
arrest and apoptosis (Meek, 2004). As described extensively in Section 1.2, p53 is 
rapidly stabilised due to multi-site phosphorylation of both HDM2 and p53 following a 
genotoxic insult. In the case of DNA DSBs after exposure to ionising radiation, p53 is 
initially phosphorylated at ser-15 by the DNA damage kinase ATM. This event is 
crucial for the inhibition of p53 degradation and allows further post-translational 
modification of p53 to bring about its activity. Initial phosphorylation of Ser-15 primes 
the p53 protein for a subsequent cascade of post translational modifications (as 
many as 17 sites undergo phosphorylation and acetylation) which disrupt the 
interaction of p53 with HDM2. Furthermore, post-translational modification of p53 
stimulates recruitment of transcription factors including p300 and CBP. These factors 
are not only responsible for the transcriptional stimulation of p53 target genes, but 
also acetylate critical lysine residues within the p53 protein that are normally 
ubiquitinated as part of the negative regulation of p53. Other residues are 
posttranslationally regulated in response to DNA DSBs. For example many residues 
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within the N and C-terminus of the protein are deemed important for specific 
promoter selectivity and for site-specific DNA binding. 
Many viral and cellular oncogenes are responsible for the disruption of p53-mediated 
gene transcription.  For instance aberrant expression or mutation of HDM2, MDMX, 
ARF  and USP10 results in disruption of p53 activity by altering its stability (Lee & 
Gu, 2009; Gilkes et al, 2006; Yuan et al, 2010).  ARF, by example, is a tumour 
suppressor protein with a role in p53-mediated gene transactivation. ARF activation 
results in the disruption of the E3 ligase activity of HDM2, causing p53 stabilisation 
and increasing p53 transcriptional activity. Furthermore, disruption of the p53 
pathway and related transcriptional activities are associated with loss of ARF function 
(Sherr, 2006; Kamijo et al, 1998; Pomerantz et al, 1998). Additionally the oncogene 
MDMX directly associates with HDM2 to perform distinct yet co-operative functions in 
p53 inactivation (Shvarts et al, 1996; Hu et al, 2006). For example, MDMX augments 
the ubiquitin ligase activity of HDM2, and despite possessing no intrinsic ubiquitin 
ligase (E3) activity, can still inhibit p53 functionality (Okamoto et al, 2009). These 
findings were determined using the potent p53 activator Nutlin, where administration 
of Nutlin to transformed cells overexpressing HDMX was not sufficient to activate p53 
(Hu et al, 2006). Such examples, coupled with the oncogenes described in Section 
4.1, demonstrate that p53 inactivation can occur in the absence of p53 mutation, and 
significantly affect the ability of p53 to transcribe target genes in response to cellular 
stresses such as DNA DSBs.  
PBF is a novel regulator of NIS expression and function, and despite functionally 
interacting with NIS to alter its subcellular distribution, also directly represses NIS 
mRNA expression, thereby abrogating the efficiency of radioiodide uptake when 
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overexpressed (Smith et al, 2009; Read et al, 2011; Smith et al, 2012a, 2011). Data 
in 0 demonstrate the physical interaction between PBF and p53 in TPC-1, K1 and 
HCT116 cells, and that this interaction may occur within the nucleus of these cells. 
To determine the effects that such an interaction might have on the activity of p53, 
the effects of PBF overexpression on the ability of p53 to drive the transcription of 
target genes was analysed. To do this we aimed to make use of a p53 signalling 
pathway PCR array (SA biosciences, Qiagen). This array profiles the expression of 
84 p53 related genes involved in the processes of apoptosis, the cell cycle, cell 
growth, proliferation, differentiation and DNA repair using real-time PCR. 
The overall aims of this chapter were therefore to determine the functional 
consequences of the interaction between PBF and p53 with regard to p53 
transcriptional activity, both in the presence and absence of ionising radiation, using 
focused microarrays and TaqMan based assays. 
 Materials and methods 5.2.
5.2.1. Cell lines and plasmids 
TPC-1, K1 and HCT116 cells were routinely subcultured using the methods 
described in Section 2.1. For experiments requiring transient PBF overexpression, 
and /or γ-irradiation exposure, cells were treated using the procedures described in 
Section 3.3. For PBF siRNA knockdown experiments, K1 and TPC-1 cells were 
seeded into 6-well dishes at a density of 1x105 cells per well and incubated for 24 
hours prior to siRNA delivery. siRNA was delivered at a concentration of 100 nM 
(either scrambled, negative control #1 siRNA or PBF specific siRNA #14399 and 
#147350 mixed in equal quantities, Ambion, Grand Island NY, USA) in serum free 
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optiMEM™. Cells were incubated in 1 ml of serum free optiMEM™ 30 minutes prior 
to transfection. siRNA and Lipofectamine (6 µl Lipofectamine per reaction) were 
prepared in separate 100 µl volumes of serum free optiMEM™ for delivery into 6-well 
dishes. The 2 solutions were incubated at room temperature for 5 minutes before 
combining siRNA- optiMEM™ with lipofectamine 2000™- optiMEM™.  After 15 
minutes of incubation the siRNA-lipofectamine 2000™ complexes were delivered 
drop-wise on to cells in serum free optiMEM™. Cells were then incubated for a 
minimum of 72 hours to encourage maximal knockdown of PBF (Watkins et al, 
2010a; Read et al, 2011). 
5.2.2. SDS-PAGE/Western blotting 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see Section 2.6). Blocked membranes were subsequently 
incubated with primary antibodies. Antibodies used were our rabbit anti-human PBF-8 
polyclonal (1:1000) (Stratford et al, 2005), rabbit anti-human HA (Covance) Mouse 
anti-human p53 (D0-1) monoclonal at 1:5000 (Santa Cruz, CA, USA), monoclonal 
anti-β-actin clone AC-15, (used at 1:10,000, Sigma-Aldrich, Poole, UK). 
5.2.3. RNA extraction and QT-PCR 
Total RNA was extracted and quantified from TPC-1, K1 and HCT116 cells as 
described in Section 2.4 for eventual use with TaqMan based assays. To ensure the 
quality and purity of RNA for use within focused microarrays, Total cellular RNA was 
isolated from TPC-1 cells using an RNeasy Minikit (Qiagen, UK), as per the 
manufacturer’s instructions. This Kit incorporates and additional DNase step to 
irradicate possible genomic and plasmid DNA carry over, providing greater quality 
RNA samples.  
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Reverse transcription and QT-PCR techniques were as described in Sections 2.4 
and 2.5. Primers and probes for PBF mRNA detection were designed as described 
above (see Section 2.5) and the sequences are given in Table 3-1. Gene-specific 
expression assays for CDKN1A, HDM2, E2F3, FAS, APAF-1, NF-1 and BRCA2 were 
purchased from Applied Biosystems (Warrington, UK). 
5.2.4. Focused Microarrays 
p53 pathway specific focused microarrays (SA Biosciences, Qiagen, UK) were 
performed with 1µg of cDNA per sample as per the manufacturer’s instructions. 384-
well focused microarray plates were analysed using the ABI PCR 7900 Sequence 
Detection System.  
5.2.5. Statistical analysis 
Data were analysed as described in Section 2.8. 
 
 Results 5.3.
5.3.1. The effects of PBF overexpression on CDKN1A and HDM2 mRNA 
expression 
In order to determine the effects of PBF overexpression on p53-mediated gene 
induction, TPC-1 cells were transiently transfected with our PBF-pCDNA3 plasmid for 
24 hours to allow overexpression of PBF protein before treatment with 15 Gy of 
ionising radiation. Total cellular RNA was then harvested 8 hours post treatment for 
measurement of p53-mediated gene activation. SDS-PAGE/Western blotting was 
used to confirm that all samples were successfully overexpressing PBF protein and 
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that p53 protein expression was induced following DNA damage (Figure 5.1A); and 
the assessment of PBF overexpression on the induction of CDKN1A and HDM2 
mRNA expression was then measured using QT RT-PCR. PBF overexpression in 
TPC-1 cells had no significant effect on CDKN1A mRNA expression in the absence 
of DNA damage (n=4; p=NS, Figure 5.1B). CDKN1A mRNA expression was 
significantly induced in VO-transfected TPC-1 cells 8 hours after treatment with 15 
Gy γ-irradiation at levels similar to those observed in Figure 3.5 (5.17-fold; n=4; 
p<0.001; Figure 5.1B). Interestingly when PBF was overexpressed a repeatable 20 
% reduction in CDKN1A mRNA expression was observed compared to VO-
transfected controls (reduced to 4.15-fold; n=4; p=NS). However, this result did not 
reach statistical significance. Additionally the effects of PBF overexpression on the 
induction of HDM2 mRNA expression were assessed. Once again PBF 
overexpression alone did not significantly affect HDM2 gene activity in the absence 
of ionising radiation (n=4; p=NS, Figure 5.1C). HDM2 mRNA expression was 
significantly elevated in response to ionising radiation (3.9-fold; n=4; p<0.001). 
Transient overexpression of PBF had no effect on the induction of this gene, where 
cells overexpressing PBF exhibited a 3.6-fold induction of HDM2 mRNA expression 
in response to ionising radiation (n=4; p=NS; see Figure 5.1C).  
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Figure 5.1: The effects of PBF overexpression on p53-mediated induction of 
CDKN1A and HDM2 mRNA expression in response to DNA damage in TPC-1 cells.  
A: Representative Western blot demonstrating successful induction of p53 stability 
and phosphorylation at serine-15 in response 8 hours after treatment with 15 Gy γ-
irradiation, and successful transient overexpression of PBF (n=4). B: The effects of 
PBF overexpression on the induction of CDKN1A mRNA expression following 
ionising radiation treatment. PBF overexpression alone had no effect on CDKN1A 
mRNA expression (n=4, P=NS). Treatment with ionising radiation significantly 
induced CDKN1A mRNA expression (5.17-fold; n=4; p<0.001), CDKN1A expression 
was reduced by ~20 % following PBF overexpression, but this effect did not reach 
statistical significance. C: The effects of PBF overexpression on the induction of 
HDM2 mRNA expression following ionising radiation treatment. Again, PBF 
overexpression alone had no effect on HDM2 mRNA expression (n=4; p<0.05). 
HDM2 expression was significantly induced following treatment with ionising radiation 
(3.9-fold; n=4; p<0.001). However, overexpression of PBF did not affect the induction 
of this gene (3.6-fold; n=4; p<0.01). 
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 The effects of PBF siRNA knockdown on CDKN1A mRNA 5.3.1.1.
expression 
In addition to analysing the effects of PBF overexpression on the induction of 
CDKN1A mRNA expression in response to ionising radiation, the effects of PBF 
knockdown via delivery of specific siRNAs was assessed in HCT116 cells (Figure 
5.2). Previous studies from our laboratory confirm that PBF protein is depleted 
significantly 72 hours after delivery of a combination of PBF-specific siRNAs (Read et 
al, 2011; Watkins et al, 2010a). CDKN1A mRNA expression was assessed both 72 
hours and 96 hours after PBF siRNA delivery, and 8 hours after exposure to 40 Gy γ-
irradiation. PBF mRNA expression was confirmed to be significantly reduced even 96 
hours after siRNA delivery with 92 % knockdown of PBF after 72 hours (n=3; 
p<0.001) and 83 % at 96 hours (n=3; p<0.001) compared to cells transfected with a 
scrambled siRNA control (see Figure 5.2A) . Despite achieving desirable levels of 
PBF knockdown in HCT116 cells, there was no significant effect on p21 mRNA 
expression after DNA  damage, where CDKN1A mRNA expression was increased to 
1.02-fold (n=3; p=NS) after 72 hours and to 1.4-fold after 96 hours (n=3; p=NS) 
compared to Scr-siRNA treated controls (Figure 5.2B). 
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Figure 5.2: The effects of PBF siRNA knockdown on the induction of p21 mRNA 
expression following treatment with 40 Gy of γ-irradiation in HCT116 cells. A: PBF 
mRNA was significantly reduced following siRNA delivery 96 hours after transfection 
(92% reduction after 72 hours and 83 % at 96 hours; n=3; p<0.001). B: QT-PCR 
revealed that siRNA depletion of PBF did not have a significant effect on the 
induction of p21 mRNA expression in response to 40 Gy of γ-irradiation.  
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5.3.2. Analysis of the effects of PBF overexpression on p53-mediated gene 
induction using focused microarrays 
TPC-1 lysates were thus confirmed to be overexpressing PBF at the protein level, 
and to have significantly elevated levels of p53 protein expression in response to 
treatment with ionising radiation, along with the induction of ser-15 phosphorylation, a 
hallmark of p53 activity. Furthermore, analysis of CDKN1A and HDM2 mRNA 
expression in these samples revealed that both CDKN1A and HDM2 expression 
were significantly induced following treatment with ionising radiation, consistent with 
activation of p53 as a transcription factor. From these initial data and analysis of 
purified RNA, the quality of sample was deemed acceptable for use in a series of 
focused microarrays aimed at assessing the effects of PBF overexpression on the 
modulation of 84 p53-mediated genes in both the presence and absence of DNA 
damage (Section 5.1 and 5.2.4). CDKN1A and HDM2 were both present within the 
focused microarrays. Therefore we next gauged the technical consistency of our test 
samples using TaqMan gene expression assays and the focused microarrays (Figure 
5.3). In keeping with the data in Figure 5.1, PBF overexpression had no effect on 
CDKN1A or HDM2 mRNA expression in the absence of DNA damage. Following 
treatment with 15 Gy γ-irradiation both CDKN1A and HDM2 mRNA expression were 
significantly induced to levels consistent with those detected using the TaqMan 
based assays (CDKN1A, 5.38-fold; n=3; p<0.001 and HDM2, 3.9-fold; n=3; p<0.01; 
Figure 5.3A+B). PBF overexpression did not significantly affect the magnitude of 
either CDKN1A or HDM2 mRNA expression in response to ionising radiation, where 
both genes remained significantly elevated (CDKN1A, 4.8-fold, n=3; p<0.001 and 
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HDM2, 4.09-fold, n=3; p<0.01; Figure 5.3A+B). These data indicate technical 
consistency between the cDNA array and TaqMan RT-PCR analysis.   
 
 
Figure 5.3: The effects of PBF overexpression on the induction of CDKN1A and 
HDM2 mRNA expression using data generated from the focused microarray. A: PBF 
alone had no effect on the expression of CDKN1A transcription. In response to 
ionising radiation, CDKN1A mRNA expression was significantly elevated (5.4-fold; 
n=3; p<0.001). However, when PBF was overexpressed the magnitude of CDKN1A 
mRNA induction was reduced (4.8-fold; n=3; p<0.001) but this effect was not 
significant. B: Again, PBF overexpression alone did not affect the expression of 
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HDM2. In response to ionising radiation, HDM2 expression was significantly induced 
(3.88-fold; n=3; p<0.01). However, there was no significant effect on HDM2 induction 
following treatment with γ-irradiation when PBF was overexpressed, with HDM2 
induced to the same magnitude as VO controls (4-fold; n=3; p<0.01). 
 
  Analysis of focused microarray data 5.3.2.1.
With the integrity of TPC-1 samples persisting between both TaqMan gene 
expression assays and the focused microarray data, we analysed the effects of PBF 
overexpression on the induction of 84 important genes mediated directly by p53 in 
response to ionising radiation (Figure 5.4). Surprisingly, PBF overexpression had 
minimal effect on the 84 p53 mediated genes, and based on 3 separate focused 
microarray plates PBF had no significant effect on the magnitude of p53-mediated 
gene transcription. Whilst PBF had no significant effect on the 84, 8 genes (APAF-1, 
BRCA2, FASLG, E2F3, EGR1, EI24, MYC and NF-1) from the microarray are 
represented in figure 5.4. Of the 84 genes assessed, these 8 genes appeared to be 
the most altered in response to PBF overexpression (Figure 5.4). 
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Figure 5.4 Expression data representing the most altered genes based on the 
average of 3 separate focused microarrays in TPC-1 cells. A: The effects of PBF 
overexpression on the gene expression of APAF-1, BRCA2, FASLG and E2F3 in the 
presence and absence of ionising radiation B: The effects of PBF overexpression on 
the gene expression of EGR1, EI24, MYC and NF-1 in the presence and absence of 
ionising radiation. The effects of PBF on the expression of these genes did not reach 
statistical significance (n=3). 
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 APAF-1 (apoptotic peptidase activating factor) is a central component of the intrinsic 
pathway of apoptosis. This protein is released along with cytochrome C from the 
mitochondrial membrane during the onset of apoptosis, resulting in its 
oligomersiation to form a multi-protein complex known as the apoptosome (Li et al, 
1997; Robles et al, 2001; Soengas et al, 1999). Whilst the effects of PBF on APAF-1 
expression did not reach statistical significance, a reduction in APAF-1 expression 
was observed when PBF was overexpressed following exposure to γ-irradiation by 
an average of  70 % compared to VO controls, although the standard error for these 
samples was high. PBF overexpression alone had no apparent effect on APAF-1 
mRNA expression compared to negative controls (see Figure 5.4A).  
BRCA2 (breast cancer 2 susceptibility protein), first identified in 1994 (Wooster et al, 
1994), has an established role in tumourigenesis. For instance germline mutations in 
BRCA1 or BRCA2 account for 20-60% of breast cancer cases in families where 
multiple individuals are affected, equating to ~2-6% of all cases reported (Nathanson 
et al, 2001). BRCA2 is a reported transcriptional target of p53; however, in TPC-1 
cells exposed to 15 Gy of γ-irradiation, BRCA2 mRNA expression remained similar to 
those of untreated controls, indicating that BRCA2 gene activity is unaltered at this 
dose of ionising radiation. Interestingly, when PBF was overexpressed a 1.9-fold 
induction of BRCA2 mRNA expression was detected, in the absence of DNA 
damage, indicating that PBF overexpression alone may influence BRCA2 mRNA 
expression (Figure 5.4A).  
FASLG, a member of the tumour necrosis factor (TNF) family, encodes a type II 
transmembrane protein (FASL) with an established role in the regulation of the 
immune system through induction of apoptosis. The death receptor FAS (also known 
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as CD95) is activated by interaction with FASL, leading to the induction of pro-
apoptotic responses. Interestingly in TPC-1 cells, FASL was repressed when PBF 
was overexpressed, compared to VO-transfected controls in the absence of DNA 
damage. This repression persisted following treatment with γ-irradiation, suggesting 
that PBF may alter the transcription of this gene (Figure 5.4A).  
The E2F family of transcription factors including the E2F3 protein have been 
characterised with an important role in the control of cellular proliferation by directly 
regulating the activity of genes that mediate progression through the cell cycle, 
specifically via regulation of the G1/S phase transition (Sharma et al, 2006; Shan & 
Lee, 1994). PBF overexpression alone did not modify E2F3 gene transcription; 
however, ionising radiation treatment resulted in non-significant repression of this 
gene by ~33%. This effect was completely reversed following overexpression of PBF, 
where a 1.5-fold induction of E2F3 was observed, suggesting that normal repression 
of E2F3 activity in response to DNA damage may be perturbed by PBF 
overexpression (Figure 5.4A). 
EGR-1 is a p53-mediated gene implicated in tumour progression. For instance, in 
prostate cancer (the most common malignancy in men, and frequent cause of cancer 
death) EGR-1 is frequently overexpressed and increasing expression levels correlate 
strongly with malignant progression (Scharnhorst et al, 2000, -1; Virolle et al, 2003, -
1). TPC-1 cells were observed to express detectable levels of EGR-1 mRNA. PBF 
overexpression in these cells resulted in a minor increase in EGR-1 mRNA 
expression compared to VO-transfected controls in the absence of DNA damage 
(~1.4-fold; n=3; p=NS), thus indicating little or no effect of PBF on EGR-1 expression 
under normal conditions. Following induction of DNA damage, EGR-1 mRNA 
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expression was reduced by ~25 % in response to DNA damage in VO-transfected 
controls, and by 53 % in those cells overexpressing PBF (Figure 5.4B).  
Etoposide inducible factor 2.4 is a DNA damage response gene, discovered following 
the characterisation of NIH3T3 cells treated with etoposide to induce apoptotic 
pathways (Lehar et al, 1996). NIH3T3 cells express wild-type p53 and as such 
undergo p53-mediated apoptosis following treatment with etoposide or γ-irradiation. 
Treatment with such DNA damaging agents revealed a clear association between 
p53 and EI24 expression (Gu et al, 2000). As expected EI24 mRNA expression was 
increased following induction of DNA damage via γ-irradiation treatment in both cells 
overexpressing PBF and in VO-transfected cells, to a similar magnitude (~2-fold; 
n=3). However in the absence of DNA damage, PBF overexpression resulted in a 
1.5-fold increase in EI24 expression (n=3; p=NS; Figure 5.4B). 
C-MYC is a proto-oncogene reported to be negatively regulated by p53.  This proto-
oncogene is a transcription factor with established roles in important cellular 
processes such as cell proliferation and apoptosis (Liao & Dickson, 2000). C-MYC 
mRNA expression was reduced by ~50 % in VO-transfected TPC-1 cells following 
DNA damage (n=3; p=NS). In cells overexpressing PBF, C-MYC expression was 
elevated in the absence of DNA damage to 1.4-fold and subsequent repression of C-
MYC expression on response to DNA damage was attenuated to only 27 % (n=3; 
p=NS; Figure 5.4B). 
Finally, the NF-1 tumour suppressor gene was analysed with regard to PBF 
overexpression in TPC-1 cells. PBF overexpression resulted in a 1.4-fold increase in 
NF-1 mRNA expression compared to controls, in the absence of DNA damage.  
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However, following genotoxic insult, VO-transfected cells displayed a ~90% reduction 
in NF-1 mRNA expression; by contrast, no repression of NF-1 mRNA expression was 
observed in cells overexpressing PBF (n=3; Figure 5.4B). 
 Validation of focused microarray results 5.3.2.2.
Despite successfully overexpressing PBF in TPC-1 cells and inducing DNA damage 
by administration of 15 Gy of γ-irradiation, we observed no significant effects of PBF 
overexpression on any of the 84 p53-mediated genes within the focused microarrays 
in the presence or absence of ionising radiation, based on 3 separate focused 
microarrays. To confirm that PBF overexpression had no effect on p53-mediated 
gene transcription in our system, we chose 5 of the 8 genes presented in Figure 5.4 
based on the magnitude of the effect of PBF and the importance of the p53-mediated 
gene in cell transformation and tumourigenesis, and assessed the validity of the 
findings from the microarray using specific TaqMan gene expression assays in TPC-
1, K1 (not shown) and HCT116 cells (Figure 5.5). Those genes that were 
investigated further were APAF-1, FASLG, NF-1, E2F3 and BRCA2. These genes 
were analysed both 8 and 24 hours after induction of DNA damage in TPC-1 and 
HCT116 cells. Data representing the effects of PBF overexpression on the 5 array 
genes 8 hours post γ-irradiation treatment are presented in Figure 5.5. No significant 
effects of PBF overexpression were found.  
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Figure 5.5: Assessment of 5 of the 8 most altered genes from the focused microarray 
using specific Taqman-based assays. A: TPC-1 cells (n=3) and B: HCT116 cells 
(n=3). No gene was validated to statistical significance.     
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 Discussion 5.4.
The data in this chapter demonstrate an investigation in to the effects of PBF 
overexpression on the induction of p53-mediated gene expression in the presence 
and absence of ionising radiation. Overexpression of PBF and induction of p53 
following treatment with γ-irradiation was confirmed in samples via SDS-
PAGE/Western blotting, and the induction of the p53-mediated genes CDKN1A and 
HDM2 were observed using TaqMan based assays. Samples displaying significant 
induction of PBF overexpression following transfection, and consistent induction of 
p53 activity following γ-irradiation treatment, were chosen for use within a p53 
signalling pathway PCR array (SA Biosciences, Qiagen) so that the global effects of 
PBF overexpression on p53 transcriptional activity could be measured.  
5.4.1. The effects of PBF overexpression on CDKN1A and HDM2 mRNA 
expression 
Many interacting partners of p53 when expressed at oncogenic levels serve to 
functionally inactivate p53 by inhibition of p53-mediated gene transcription (Lee & 
Gu, 2009; Gilkes et al, 2006; Yuan et al, 2010a). For example, overexpression of 
HGMA1 results in repression of CDKN1A transcription that would normally result in 
successful G1/S phase arrest after treatment with DNA damaging agents, thus 
serving to functionally inactivate p53 (Frasca et al, 2006; Malaguarnera et al, 2007a).  
In light of previous cellular examples, the functional consequences of the interaction 
between PBF and p53 on p53-mediated gene transcription were interrogated. Firstly 
the effects of PBF overexpression on the induction of CDKN1A and HDM2 mRNA 
expression were investigated in TPC-1 cells, as these genes were significantly 
induced at a dose of 15 Gy γ-irradiation (see Figure 3.5A), and are amongst the most 
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common genes transcribed by p53 in response to DNA damage. CDKN1A mRNA 
expression was significantly elevated in response to 15 Gy γ-irradiation (consistent 
with levels reported in Section 3.3.2). PBF overexpression resulted in a ~20 % 
repression of CDKN1A mRNA expression following DNA damage, but this effect did 
not reach statistical significance. PBF also had no effect on p53-mediated HDM2 
induction. When specific PBF siRNAs were used to deplete PBF protein in HCT116 
cells, PBF knockdown did not significantly alter the magnitude of CDKN1A induction 
in response to ionising radiation. These data suggest that despite interacting with 
p53, PBF has no significant effect on CDKN1A or HDM2 mRNA expression under the 
conditions reported. To thoroughly examine the effects of PBF overexpression on 
global p53 transcriptional activity, focused microarrays were used to test the 
induction of 84 p53 mediated genes when PBF was overexpressed. 
5.4.2. The effects of PBF overexpression on p53-mediated gene induction 
Samples for use within the p53 signalling array were tested for genomic DNA 
contamination using spectrophotometry, and viable samples were then selected for 
use within separate focused microarrays. Many genes were altered following a 15 Gy 
dose of ionising radiation, but the induction of only a small number of p53 related 
genes was affected by PBF in TPC-1 cells. The most altered of these genes were 
APAF-1, BRCA2, E2F3, EGR1, EI24, MYC and NF-1. However, statistical analysis of 
the effects of PBF overexpression on the activity of these p53-mediated genes 
confirmed that these changes were not statistically significant.  
Given the importance of the transcriptional activities performed by p53 in the 
maintenance of cellular and genetic stability (Levine et al, 2001), 5 of the most 
altered genes from the focused microarray were chosen to be assessed using 
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TaqMan based assays; in an attempt to determine whether these effects were real. 
We therefore assessed the effects of PBF overexpression on APAF-1, BRCA2, 
FASL, E2F3 and NF-1 mRNA expression using TaqMan based expression assays.  
APAF-1 is a critical downstream effector of p53-mediated apoptosis and silencing of 
the APAF-1 gene would appear to support oncogenesis and malignant progression. 
in fact, loss of APAF-1 has been reported in approximately half of all metastatic 
melanomas (Furukawa et al, 2005; Soengas et al, 2001). Furthermore in the context 
of thyroid cancer, a study by Aratake et al revealed that APAF-1 immunostaining was 
significantly reduced in histological samples within the more aggressive 
undifferentiated regions of thyroid cancer specimens compared to those areas that 
were well-differentiated, indicating that APAF-1 may play a role in thyroid tumour 
aggressiveness (Aratake et al, 2006). In TPC-1 thyroid papillary carcinoma cells, 
expression of APAF-1 was readily detectable, and therefore in response to ionising 
radiation it may be expected that APAF-1 mRNA expression would be significantly 
induced. However, in VO-transfected TPC-1 cells, APAF-1 mRNA expression was 
non-significantly elevated to ~1.5-fold, suggesting that 15 Gy of γ-irradiation does not 
significantly induce this gene in TPC-1 cells. APAF-1 expression is repressed in 
thyroid cancers and correlates with tumour aggressiveness (Aratake et al, 2006; 
Soengas et al, 2001). Therefore, given the important role of APAF-1 as a central 
component of the apoptotic pathway, loss or inhibition of p53-mediated APAF-1 
upregulation would lead to impaired apoptotic responses to genotoxic insult. 
Interestingly, in cells overexpressing PBF, APAF-1 mRNA expression was reduced in 
response to ionising radiation treatment, suggesting that PBF overexpression may 
result in the repression of this gene. However, subsequent investigations using 
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TaqMan based assays confirmed that PBF overexpression had no significant effect 
on the modulation of APAF-1 gene activity in TPC-1, HCT116 or K1 cells. These 
results imply that PBF overexpression does not significantly affect the ability of p53 to 
modulate APAF-1 gene activity following treatment with 15 Gy of γ-irradiation. 
.We next investigated the effects of PBF overexpression on the gene expression of 
the important DNA repair protein BRCA2. The function of BRCA2 was elucidated 
following the observation of BRCA2 deficient cells in culture; these cells were found 
to display increased sensitivity to ionising radiation. Furthermore, BRCA2-deficient 
cells accumulate chromosomal breaks and aberrant mitotic exchanges during culture 
(Marmorstein et al, 1998a; Moynahan et al, 2001). BRCA2 has also been observed 
to functionally interact with other well characterised DNA repair proteins, including 
RAD51, providing further evidence that BRCA2 plays a central role in DNA repair 
following the induction of DSBs, for example after exposure to ionising radiation 
(Marmorstein et al, 1998; Venkitaraman, 2001). As one would expect, VO-transfected 
TPC-1 cells displayed a ~2-fold increase in BRCA2 expression following the 
induction of DNA DSBs through administration of 15 Gy of γ-irradiation. However 
following PBF overexpression, the induction of BRCA2 in response to ionising 
radiation was not observed, indeed levels were similar to that of untreated controls. 
This result would imply that PBF represses p53 induction of BRCA2 expression 
following genotoxic insult. Further investigations into the effect of PBF 
overexpression on BRCA2 mRNA modulation following DNA damage were 
performed using specific BRCA2 TaqMan assays. However, no significant effects 
were observed in TPC-1, HCT116 or K1 cells. Again, these results imply that PBF 
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overexpression does not significantly affect the modulation of BRCA2 gene activity in 
response to ionising radiation. 
Furthermore, TaqMan based assays confirmed that PBF had no effect on, FASL, 
E2F3 or NF-1 expression in the presence and absence of ionising radiation, in TPC-
1, K1 and HCT116 cells both 8 and 24 hours post irradiation treatment. These results 
would suggest that the effects of PBF on p53-mediated gene expression are minimal, 
and that the interaction between PBF and p53 does not alter p53 transcriptional 
activity. Before utilising samples for analysis of the effects of PBF overexpression on 
p53-mediated gene expression, PBF was confirmed to be overexpressed using SDS-
PAGE/Western blotting and the activation of p53 was visualised using the total p53 
antibody DO-1. Furthermore samples for use within focused microarrays were 
assessed for the both PBF overexpression and p53 stabilisation, along with 
assessment of CDKN1A and HDM2 induction. Given that CKN1A and HDM2 were 
present within the focused microarray technical consistency between samples was 
therefore easily independently verified confirming the integrity and reliability of 
samples. This suggests that the results were reliable; and to further confirm that PBF 
had no significant effects on p53-mediated gene transcription 5 of the most altered 
genes from the focused microarray were assessed using TaqMan based assays. 
Taken together these results demonstrate a thorough investigation in to the effects of 
PBF on the induction of p53-mediated genes in both the presence and absence of 
ionising radiation. To further characterise the effects of PBF on p53-mediated gene 
expression it would be of interest to repeat these p53 signalling arrays in normal 
thyrocytes to determine the effects of PBF in untransformed cells. Furthermore, 
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assessment of the effects of PBF on p53-mediated gene expression in cell stably 
overexpressing PBF would alleviate the problem of transient transfection efficiency.  
Whilst the principal molecular function of p53 concerns its action as a transcription 
factor, there are nonetheless well characterised and important transcriptional 
independent roles of p53, and aberrant control of these has significant implications in 
human cancers (Vousden & Prives, 2009; Speidel et al, 2006; Moll et al, 2005). Most, 
but not all, transcriptional independent roles appear to be heavily involved with the 
onset of apoptosis (Moll et al, 2005; Galy et al, 2001). For instance, p53 mutants 
lacking the ability to influence gene transcription have been characterised to promote 
apoptosis; most notably, p53 can directly activate the pro-apoptotic protein BAX 
(Brady & Attardi, 2010; Chipuk et al, 2004). These examples suggest that the 
interaction between PBF and p53, whilst having no effect on p53-mediated 
transcription, may prompt further study of the transcriptional independent roles of 
p53. 
5.4.3. Concluding statements 
Despite confirming that PBF was overexpressed in TCP-1 samples through Western 
blotting, and confirming p53 activity through Western blotting and TaqMan gene 
expression assays, PBF overexpression had no significant effect on 84 p53-mediated 
genes in the presence or absence of DNA damage (TPC-1; n=3), Furthermore, 5 of 
the most altered genes in the focused microarray were investigated further through 
TaqMan based assays in TPC-1, HCT116 and K1 cells, and no significant effects 
were observed. These results indicate that PBF overexpression does not significantly 
affect p53-mediated gene expression in TPC-1, HCT116 or K1 cells, and that the 
functional consequence of the interaction of PBF and p53 in these cells does not 
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aberrantly affect p53 transcriptional function. The next chapters explore the effects of 
PBF on p53 metabolism and assess the effects of PBF on transcription independent 
p53 functions 
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 Introduction  6.1.
p53 is by necessity an intrinsically unstable protein, undergoing perpetual 
degradation by E3 ubiquitin ligases including HDM2. Continually transcribed and 
translated, p53 rapidly accumulates following a genotoxic insult due to inhibition of its 
degradation by HDM2 and other E3 ligases (Chen et al, 1993; Oliner et al, 1993; 
Kubbutat et al, 1997).  HDM2 engages in a high affinity interaction with p53, by virtue 
of its large N-terminal p53 binding domain (see Figure 1.6). The functional interaction 
between the HDM2 and p53 proteins is necessary for p53 inactivation, where apart 
from ubiquitinating both itself and p53 (bringing about the proteasomal degradation of 
each protein), HDM2 masks the DNA binding domain of the p53 protein, also 
preventing p53 from acting as a transcription factor (Vogelstein et al, 2000; Brooks & 
Gu, 2006). HDM2 is considered the major physiological antagonist of p53 activity, 
although other proteins are emerging with characterised physiological role in p53 
regulation such as HDMX/MDMX (or HDM4/MDM4), ARF and USP10. Clearly 
dysregulation of p53 metabolism has drastic consequences for cell physiology. 
Indeed oncogenic expression or mutation of HDM2, MDMX, ARF  and USP10 results 
in disruption of p53 activity by altering its stability (Lee & Gu, 2009; Gilkes et al, 2006; 
Yuan et al, 2010).   
Interestingly, in thyroid papillary carcinomas oncogenic expression of HDM2 itself has 
been reported to interfere with wild-type p53 function (Malaguarnera et al, 2007a). 
For example, in a large study involving a series of well-differentiated thyroid papillary 
cancer specimens, HDM2 was highly overexpressed, and expression levels 
correlated with poor clinical outcome (Horie et al, 2001; Jennings et al, 1995). 
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Oncogenic expression of HDMX (a potent agonist of p53 activity) has been reported 
in up to 20 % of colon and breast cancers and 65 % of retinoblastomas (Toledo & 
Wahl, 2007). Furthermore in glioblastoma multiforme (GBM), the most common form 
of primary brain tumour in adults, HDMX amplification occurs solely in the absence of 
p53 mutations, resulting in the functional inactivation of p53 by preventing p53 
transactivation and targeting it for degradation via the ubiquitin pathway. That HDMX 
amplification occurs solely in the absence of p53 mutations in GBM demonstrates the 
potency of this oncogene in the functional inactivation of p53 in these tumours (Jin et 
al, 2010). More recently the protein USP10 has been characterised to interact directly 
with p53 and bring about its stabilisation. USP10 causes increased p53 stability by 
virtue of its ubiquitin specific protease activity. This activity causes the 
deubiquitination of p53 in the cytoplasm, thus bringing about the reversal of HDM2 
mediated p53 degradation. USP10 overexpression was associated with increased 
p53 accumulation and decreased p53 ubiquitination (measured using anisomycin 
half-life assays and MG132 ubiquitin assays respectively). USP10, in fact, has been 
observed to be downregulated in a high percentage of clear cell carcinomas and 
overexpression leads to reduced cell growth in tumours expressing wild-type p53 
(Yuan et al, 2010). This pertinent example demonstrates that novel cellular proteins 
are still emerging that bind to and modulate p53 function and when aberrantly 
expressed negatively affect p53 stability resulting in increased susceptibility to 
cellular transformation and tumourigenesis. The results from such studies have led to 
increased speculation that oncogene inactivation of p53 may, in fact, represent an 
earlier event in the progression of some cancers. However, an improved 
understanding of the biological consequences following disruption of p53 by different 
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oncogenes is still required before the sequence of molecular events in 
tumourigenesis can be better defined, especially in thyroid papillary carcinomas 
where mutations in p53 are rare.  
We have previously determined that PBF is overexpressed in thyroid papillary 
cancers, and that oncogenic expression of PBF is transforming in vitro; and 
tumourigenic in vivo (Stratford et al, 2005). Data in Chapter 4 provide evidence to 
demonstrate that PBF acts as a novel binding partner of p53 (through co-
immunoprecipitation assays and fluorescence immunocytochemistry assays) in 
human thyroid papillary carcinoma cell lines and a human colorectal carcinoma cell 
line. To follow on from these observations we aimed to characterise the effects of 
PBF on p53 metabolism. Thus, we attempted to assess the effects of PBF 
overexpression on p53 using classical anisomycin p53 half-life assays, and 
attempted to determine the effects of PBF overexpression on p53 ubiquitination using 
MG132 ubiquitin assays. Furthermore, given the close relationship between p53 and 
its master regulator HDM2, we performed co-immunoprecipitation assays to 
investigate the specific relationship between PBF and HDM2 in thyroid papillary 
carcinoma cell lines.  
 Materials and methods 6.2.
6.2.1. Cell lines, plasmids and siRNAs 
TPC-1, K1 and HCT116 cells were routinely subcultured using the methods 
described in Section 2.1. For experiments requiring transient PBF overexpression, 
and / or γ-irradiation exposure, cells were treated using the procedures described in 
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Section 3.3. For PBF siRNA experiments, PBF specific siRNA was delivered into 
TPC-1 and K1 cells using the methods described in Section 5.2.1.  
6.2.2. p53 half-life assays 
TPC-1, K1 and HCT16 cells were seeded into 6 well dishes at a density of 7.5x104, 
1x105 and 2.5x105 cells/well respectively. Cells were then transiently transfected with 
pCDNA3-PBF-HA, pCDNA3-PBF, pCDNA3-PBF-M13 (PBF-M13 contains a Y174A 
substitution thereby inhibiting the action of the NLS region) and pCDNA3 only or PBF 
specific siRNA or scrambled controls. Half-life assays to determine the effects of PBF 
on p53 stability were then performed 24 hours after transient overexpression of PBF 
or 72 hours after PBF specific siRNA delivery, to allow for maximal overexpression 
and knockdown of PBF respectively. Serum containing media was then removed and 
replaced with Anisomycin, delivered at a final concentration of 100 mM in 1 ml of 
serum free optiMEM™ per well at specific time-points (0, 60, 90 and 120 minutes). At 
the end of the 2 hour time-course, total cellular protein was promptly harvested and 
samples prepared for analysis via SDS-PAGE/Western blotting. 
6.2.3. p53 ubiquitin assays 
TPC-1, K1 and HCT16 cells were seeded into 6 well dishes at a density of 7.5x104, 
1x105 and 2.5x105 cells/well respectively. These cells were then transiently 
transfected with pCDNA3-PBF-HA and pCDNA3 to allow for the potential effects of 
PBF overexpression on p53 ubiquitination to be measured. Cells were subsequently 
treated with 20 µM MG132 (Sigma-Aldrich Poole, Dorset, UK), over a 120 minute 
time-course in a similar fashion to the anisomycin half-life assays described in 
Section 6.2.2. Protein was then promptly harvested and prepared for analysis via 
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SDS-PAGE/Western blotting in the manner described in Section 2.6. Ubiquitinated 
p53 was detected using the mouse anti-human p53 specific antibody DO-1.  
6.2.4. Co-immunporecipitation assays 
TPC-1, K1 and HCT116  cells growing in T25 culture flasks were harvested in 500 ul 
RIPA buffer with 60 µl/ml protease inhibitor (100 mM sodium chloride, 0.1 % Triton X-
100 and 50 mM Tris (pH8.3)). Co-immunprecipitation assays were performed in a 
similar manner to Section 4.2.2. HDM2 was immunoprecipitated using a mouse anti-
human HDM2 polyclonal antibody (HDM2 2αB, Courtesy of Dr Andrew Turnell, 
University of Birmingham, School of Cancer Sciences) at a concentration of 1:50 
(antibody to lysate volume). The presence of co-immunoprecipitated PBF was 
detected via SDS-PAGE/Western blotting using our PBF specific antibody. Proteins 
from pre immunoprecipitated lysates were used to identify co-immunoprecipitated 
protein bands detected by the PBF antibody.  
6.2.5. SDS-PAGE/Western blotting 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see Section 2.6).  Blocked membranes were subsequently 
incubated with primary antibodies against p53 (DO-1, 1:1000), PBF (our PBF-8 
polyclonal rabbit anti-human PBF specific antibody 1:1000) and HDM2 (2αB, 
courtesy of Dr Andrew Turnell, School of Cancer Sciences, University of 
Birmingham). After washing in TBS-T, blots were incubated with appropriate 
secondary antibodies conjugated to horseradish peroxidise (Dakocytomation, UK) for 
1 hour at room temperature before being visualised by the techniques described in 
Section 2.6. 
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6.2.6. RNA extraction and QT-PCR 
Total RNA was extracted from TPC-1, K1 and HCT116 cells as described in Section 
2.4. Reverse transcription and QT-PCR techniques were as described in Sections 
2.4 and 2.5. Primers and probes for PBF mRNA detection were designed as 
described above (see Section 2.5) and the sequences are given in Table 3-1. Gene-
specific expression assays for p53 (Hs01034249_m1) were purchased from Applied 
Biosystems (Warrington, UK). 
6.2.7. Statistical analysis 
Statistical analysis was performed using the methods described in Section 2.8. 
 Results 6.3.
6.3.1. The effects of PBF on p53 protein expression and turnover 
Given that a direct interaction between PBF and p53 was observed through the use 
of GST-pulldown and co-immunopreciptitation assays (Chapter 4), we considered the 
effects of PBF on p53 protein stability by performing p53 half-life assays. PBF was 
transiently transfected into TPC-1, K1 and HCT116 cells (with pCDNA3 vector-only 
controls) for 24 hours before replacing basal media with optiMEM™ containing 100 
µM anisomycin (an inhibitor of de novo protein synthesis). Protein was then 
harvested from cells overexpressing PBF or vector-only 0, 60, 90 and 120 minutes 
after delivery of anisomycin, and the levels of total cellular p53 were observed via 
SDS-PAGE and Western blotting. VO-transfected TPC-1 cells displayed detectable 
levels of p53 across the 120 minute time-course, with levels of p53 decreasing at 
each time-point (Figure 6.1A). However, overexpression of PBF resulted in 
significantly increased turnover of p53 protein in TPC-1 cells, where levels of p53 
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were visibly lower on Western blots from 90 minutes of this time-course compared to 
vector only controls. Scanning densitometry confirmed a significant difference in p53 
levels at 120 minutes, with cells overexpressing PBF having 10-fold lower p53 
expression (n=4; p<0.05) than time-matched VO controls (Figure 6.1A). p53 
expression was markedly different in K1 cells, appearing to remain constant 
throughout the 120 minute time course, suggesting that p53 may be more stable in 
this cell line. Again, Western blotting revealed that p53 turnover was increased 
following PBF overexpression, with levels reduced from 90 minutes. Scanning 
densitometry confirmed that p53 levels were significantly lower in cells 
overexpressing PBF after 120 minutes (~17-fold; n=4; p<0.01) when compared to VO 
controls (Figure 6.1B). 
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Figure 6.1: Western blot analysis and scanning densitometry to determine the effects 
of PBF overexpression on p53 half-life following treatment of cells with anisomycin to 
block de novo protein synthesis. Ai: Western blot representing the effects of PBF 
overexpression on p53 stability in TPC-1 cells compared to vector only controls. Aii: 
Scanning densitometry revealed that PBF significantly reduced p53-half-life 120 
minutes after administration of anisomycin (~10-fold; n=4; p<0.05). Bi: Western blots 
representing the effect of PBF overexpression on p53 half-life in K1 cells. Bii. 
Scanning densitometry confirmed that PBF overexpression also reduces p53 half-life 
in these cells after 120 minutes (~17-fold; n=4; p<0.01). 
Chapter 6: The effects of PBF overexpression on p53 expression 
 
150 
 
The effects of PBF overexpression on p53 stability in HCT116 cells were also 
analysed (Figure 6.2). In a similar manner to K1 cells, p53 levels did not drop 
significantly over the 120 minute time-course, suggesting that p53 in these cells is 
also more stable than in TPC-1 cells. However, following PBF overexpression, p53 
levels were rapidly reduced from 90 minutes of this time-course. In these cells 
scanning densitometry revealed that when PBF was overexpressed p53 levels were 
significantly reduced from 90 minutes (~2-fold at 90 minutes, n=4; p<0.05, and ~10-
fold at 120 minutes, n=4; p<0.01) compared to time-matched VO controls (Figure 
6.2). To investigate whether the effects of PBF overexpression were a result of 
reduced protein stability, or altered mRNA repression, the levels of p53 mRNA 
expression were observed following PBF overexpression in TPC-1 and HCT116 
cells. QT RT-PCR did not reveal any significant difference in p53 mRNA expression 
when PBF was overexpressed in either cell line (TPC-1, 1.13-fold; n=3; p=NS, 
HCT116, 1.47-fold; n=3; p<0.05 and Figure 6.2A) compared to VO controls, 
indicating that PBF overexpression does indeed effect p53 half-life at the level of 
protein stability, and not mRNA expression (see Figure 6.2).  
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Figure 6.2: Western blot analysis and scanning densitometry to determine the effects 
of PBF overexpression on p53 half-life following treatment of HCT116 cells with 
anisomycin to block de novo protein synthesis, and real-time PCR to determine the 
effects of PBF overexpression on p53 mRNA expression. Ai: Western blot 
representing the effects of PBF overexpression on p53 stability in HCT116 cells 
compared to vector only controls. Aii: Scanning densitometry revealed that PBF 
significantly reduced p53-half-life from 90 minutes after administration of anisomycin 
(~2-fold at 90 minutes, n=4; p<0.05, and ~10-fold at 120 minutes, n=4; p<0.01) 
compared to time-matched VO controls. B: QT RT-PCR did not reveal any significant 
difference in p53 mRNA expression following PBF overexpression in either TPC-1 or 
HCT116 cells (TPC-1, 1.13-fold; n=3; p=NS, HCT116, 1.47-fold; n=3; p=NS).  
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To interrogate the effects of PBF on p53 half-life further, we depleted PBF using 
specific PBF-siRNAs and assessed the stability of p53 in order to observe whether 
the inverse relationship held true (Figure 6.3).  The most significant levels of PBF 
knockdown were achieved in K1 cells, where PBF was consistently knocked down by 
~75 % or more even after 72 hours (n=4; p<0.001; Figure 6.3A). K1 cells were 
transfected with PBF-specific siRNAs before performing anisomycin half-life as 
described earlier in this Section. Interestingly, K1 cells transfected with PBF siRNAs 
displayed an increase in p53 protein expression at every stage of this time-course 
compared to scrambled siRNA treated controls (Figure 6.3B). Scanning densitometry 
revealed that PBF depletion was associated with a significant increase in p53 half-life 
from 60 minutes (n=4; p<0.05), resulting in a >3-fold increase in p53 levels (n=4; 
P<0.01) compared to scrambled controls after 120 minutes.  
PBF specific siRNA delivery into TPC-1 cells resulted ~60 % depletion in PBF mRNA 
expression after 72 hours (n=4; p<0.05; Figure 6.3A). In keeping with the reduced 
potency of PBF knockdown, TPC-1 cells transfected with PBF-specific siRNAs did 
not display an obvious increase in p53 expression at time 0 (Figure 6.3C). However, 
PBF knockdown in TPC-1 cells did result in an observable increase in p53 half-life. 
For instance in TPC-1 cells treated with scrambled siRNA controls, p53 levels 
decreased rapidly over the 120 minute time course, in keeping with our previous data 
(Figure 6.3A). Nevertheless, TPC-1 cells treated with PBF specific siRNAs displayed 
increased levels of p53 from 90 minutes of this time-course, with levels remaining 
highly detectable even after 120 minutes (n=3;Figure 6.3C). These experiments were 
also repeated in HCT116 cells with similar results obtained (n=1, data not shown).  
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Figure 6.3: the effects of PBF siRNA knockdown on p53 half-life in K1 and TPC-1 
cells measured through the use of anisomycin half-life assays. A: QT RT-PCR 
revealed that PBF specific siRNA knockdown in K1 and TPC-1 resulted in significant 
knockdown of PBF mRNA expression even after 72 hours (K1, ~75 %; n=4; p<0.001, 
TPC-1, ~60 %; n=3; p<0.05). B: Representative Western blot demonstrating the 
effects of PBF knockdown on p53 stability in K1 cells.  Bii: scanning densitometry 
revealed a significant increase in p53 half-life from 60 minutes resulting in > 3-fold 
increase in p53 levels after 120 minutes (n=4; p<0.001). C: representative Western 
blot displaying the effects of PBF knockdown on p53 stability in TPC-1 cells (n=3).  
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Finally, we investigated the effects of a specific mutant of PBF (PBF-M13) to further 
describe the effects of PBF on p53 stability. PBF-M13 (courtesy of Dr Vicki Smith, 
School of Clinical and Experimental Medicine, University of Birmingham), contains a 
single amino acid substitution at tyrosine 174 (Figure 6.4A). This mutation prevents 
the phosphorylation of PBF by specific tyrosine kinases and causes sequestration of 
PBF at the plasma membrane, an area we did not associate with p53 co-localisation 
(Dr Vicki Smith unpublished data and Section 4.3.2). Our previous data strongly 
suggests that PBF binds directly to p53 and affects its half-life. Therefore, we 
repeated anisomycin half-life assays in TPC-1 cells following overexpression of PBF-
M13, and observed its effects on p53 stability compared to overexpression of WT 
PBF and VO controls. Overexpression of WT PBF resulted in a visible decrease in 
p53 half-life, compared to VO controls; with p53 levels once more appearing reduced 
90 minutes after treatment with anisomycin (Figure 6.4B). Overexpression of PBF-
M13 however, had no effect on the turnover of p53, when compared to VO controls, 
where p53 levels were reduced at each time-point in a similar fashion to VO controls 
(Figure 6.4C). When the p53 expression levels of cells overexpressing WT PBF were 
observed against those of cells overexpressing PBF-M13 significant differences were 
observed. p53 turnover was highly increased in cells overexpressing WT PBF 
compared to those overexpressing PBF-M13. Indeed, at the exposure presented in 
Figure 6.4D, p53 levels were undetectable from 60 minutes when PBF was 
overexpressed, whilst overexpression of PBF-M13 resulted in detectable levels of 
p53 at each time-point. These data suggest that sequestration of PBF away from its 
sites of interaction with p53 prevents the effects of PBF on p53 turnover (Figure 
6.4A-D). 
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Figure 6.4: Western blot analysis of the effects of PBF-M13 on the turnover of p53 
measured through the use of anisomycin half-life assays across a 120 minute time-
course. A: Schematic showing the location of the Y174A within the C-terminal sorting 
signal of the PBF protein. B: Representative Western blot demonstrating that PBF 
overexpression is associated with increased p53 turnover. C: The effects of PBF-
M13 overexpression on p53 stability compared to VO-transfected controls D: The 
effects of WT PBF overexpression vs PBF-M13 overexpression on p53 stability. 
  
6.3.2. PBF overexpression results in increased p53 ubiquitination 
Given that modulation of PBF expression was associated with significantly altered 
p53 stability, we next examined p53 ubiquitination in cells treated with the 
proteasome inhibitor MG132 (MG132 facilitates the accumulation of ubiquitinylated 
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proteins by preventing their degradation). Treatment of TPC-1 and HCT116 cells with 
20 µM MG132 resulted in a stepwise accumulation of p53 ubiquitin isoforms over a 
120 minute time-course (data not shown). When PBF was overexpressed, the level 
of p53 ubiquitintation was increased in both TPC-1 cells and HCT116 cells Figure 
6.5). Immunoprecipitation of p53 and subsequent Western blot analysis revealed that 
accumulation of p53 ubiquitin chains was greater in cells overexpressing PBF 
immediately after administration of MG132, with maximal levels of p53 ubiquitination 
occurring from 90 minutes, compared to VO controls (Figure 6.5Ai). p53 ubiquitin 
chains are routinely detected via SDS-PAGE/Western blotting using the p53 specific 
antibody DO-1 and appear as laddered bands above the classical 53 kDa band of 
native p53 (see Section 6.2.3). We were able to reliably repeat the observation that 
PBF overexpression correlates with increased p53 ubiquitination 90 minutes after 
treatment of TPC-1 cells with 20 µM MG132 via p53 immunoprecipitation and 
subsequent Western blot analysis (TPC-1; n=4; Figure 6.5A+B). In light of the 
observations that overexpression of PBF resulted in a detectable increased in p53 
ubiquitination immediately after MG132 administration, PBF was transiently 
overexpressed for 24 hours in TPC-1 cells and total cellular protein was harvested. 
Western blotting revealed that PBF overexpression resulted in increased 
accumulation of ubiquinated p53 in a dose dependent manner, compared to VO-
transfected controls (Figure 6.5B). A significant increase in p53 ubiquitination was 
also observed when PBF was overexpressed in HCT116 cells 90 minutes after 
treatment with MG132 (Figure 6.5C, HCT116; n=3). 
Chapter 6: The effects of PBF overexpression on p53 expression 
 
157 
 
 
Figure 6.5: PBF increases ubiquitination of p53. Ai+ii: Extracts from TPC-1 cells 
transfected with the indicated vectors for 24 hours and treated with 20 μM MG132 
were immunoprecipitated with an anti-p53 antibody, then analysed by Western 
blotting with the same antibody. PBF and β-actin were determined by Western 
blotting on the pre-immunoprecipitated lysates. B: Western blots representing the 
detection of p53 ubiquitin isoforms following PBF overexpression on whole-cell 
lysates in the absence of MG132 in TPC-1 cells. C: Extracts from HCT116 cells 
transfected with the indicated vectors for 24 h and treated with 20 μM MG132 were 
analysed by Western blotting with the indicated antibodies. 
 
6.3.3. The relationship between PBF and HDM2 
The previous data in this chapter describes a role for PBF in the modulation of p53 
stability. Specifically, when wild-type PBF is overexpressed (in thyroid or colorectal 
cell lines) p53 turnover is significantly increased as measured by anisomycin half-life 
assays, and these findings correlate with increased p53 ubiquitination. As previously 
described, p53 protein expression is controlled not by the rate of gene transcription, 
but by the rate of its protein degradation. Under normal physiological conditions, p53 
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is continually transcribed and translated; however, levels remain low due to the 
action of the E3 ubiquitin ligase HDM2. HDM2 binds directly to p53 and ubiquitinates 
both itself and p53, thus targeting each protein for degradation in the proteasome. It 
was initially hypothesised that PBF may be an E2 ubiquitin ligase, but experiments 
performed by our collaborator, Dr Pascal Lopez, Lyon, France, disproved this 
hypothesis, as in vitro ubiquitin assays confirmed that PBF was unable to ubiquitinate 
itself in isolation (personal communication). From these observations, it is unlikely 
that PBF is directly responsible for the increased p53 ubiquitination observed 
following its overexpression. Therefore given the important role of HDM2 in the 
negative regulation of p53 protein expression under physiological conditions, and 
given the direct interaction between PBF and p53, we sought to determine the 
relationship between PBF and HDM2 in our cell lines through the use of co-
immunoprecipitiation assays. Endogenous HDM2 was successfully 
immunoprecipitated using the antibody 2αB (the MDM2 2AB antibody is a mouse 
polyclonal antibody which detects total MDM2 and HDM2, courtesy of Dr Andrew 
Turnell, University of Birmingham) in TPC-1, K1 and HCT116 cells. Subsequent 
probing for the presence of co-immunoprecipitated PBF in TPC-1 cells using our PBF 
specific antibody revealed the presence of specific bands in co-immunoprecipitation 
samples, that were not present in either the no antibody controls (NAb), or IgG 
controls, indicating that PBF may indeed be interacting with HDM2 (Figure 6.6). 
However, further analysis of pre-immunoprecipitated lysates suggests that the bands 
detected in the Co-IP samples are apparently of a slightly lower molecular weight 
when compared with these lysates (Figure 6.6A). Using our PBF antibody to assess 
the presence of co-immunoprecipitated PBF in K1 cells did not result in detectable 
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bands in the co-IP samples, suggesting that whilst HDM2 was successfully 
immunoprecipitated in these cells, PBF was not co-immunoprecipitated and therefore 
no interaction was apparent (Figure 6.6B). Finally, in HCT116 cells, successful 
immunoprecipitation of HDM2, and subsequent immuno-detection of PBF revealed 
specific bands within our co-IP test samples, with no detectable bands present in the 
negative controls (NAb control, or IgG control), indicating a possible interaction 
between the 2 proteins. Subsequent analysis of PBF from the pre-
immunoprecipitated lysates again revealed that bands detected in the co-IP test 
samples ran at a slightly lower molecular weight on SDS-PAGE/Western blots 
(Figure 6.6C). 
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Figure 6.6: Representative Western blots to assess whether PBF co-
immunoprecipitates with HDM2 in A: TPC-1, B: K1 and C: HCT116 cells. Cell-lines 
were tested for successful immunoprecipitation of HDM2 and protein from the pre 
immunoprecipitated lysates was used for the identification of Co-immunoprecipitated 
proteins. No antibody controls (NAb) and igG controls were used as negative controls 
to assess the ability of proteins to bind in a non-specific manner to sepharose G 
beads and antibody fragments respectively. (S1 +S2 represent 2 separate co-IP 
expermients). 
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 Discussion 6.4.
Data in Chapter 4 probed the relationship of PBF and p53; specific co-
immunoprecipitation assays confirmed that PBF is a novel interacting partner of p53 
in both the presence and absence of ionising radiation (inactive or active p53) in 2 
thyroid papillary carcinoma cell lines (TPC-1 and K1 cells) and the HCT116 colorectal 
carcinoma cell line. These data correlated with colocalisation of PBF and p53 within 
the nucleus of TPC-1, COS-7 and HCT116 cells. Despite the physical interaction 
between PBF and p53, PBF had no effect on the subcellular distribution of p53 using 
specific subcellular fractionation assays. Data in Chapter 5 therefore were aimed at 
characterising the functional outcome of the PBF:p53 interaction on p53-mediated 
gene transcription using p53 specific focused microarrays and TaqMan based 
assays. Regardless of successful PBF overexpression through transient transfection, 
and the induction of p53 activity following treatment with ionising radiation, PBF had 
no significant effect on p53-mediated gene transcription within our cell lines. The data 
in 6 therefore were aimed at determining the effects of PBF on p53 biology. 
p53 is a potent tumour suppressor, bringing about a plethora of important cellular 
effects (for example growth arrest or apoptosis) in response to genotoxic insults 
(Vogelstein et al, 2000; Meek, 2004; Meek & Anderson, 2009; Vousden & Prives, 
2009). By necessity, such influential effects must be tightly regulated, to prevent 
aberrant regulation of such important cellular processes (Brooks & Gu, 2006; Meek & 
Hupp, 2010; Meek & Anderson, 2009). Furthermore, p53 is rendered inactive despite 
being transcribed and translated at relatively high levels at all times. This effect is 
mediated through the action of HDM2, the E3 ligase. In addition to the action of 
HDM2 novel cellular proteins are emerging that bind directly to p53 and effect p53 
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metabolism, and when aberrantly expressed contribute to its functional inactivation in 
human cancers (Lee & Gu, 2009; Sherr, 2006; Gilkes et al, 2006; Yuan et al, 2010). 
A recent paper by Yuan et al described the effects of the deubiquitinylating enzyme 
USP10 on p53 stability, reporting its interaction with p53 and increased rate of down 
regulation in clear cell carcinomas (Yuan et al, 2010). With the observed 
overexpression of PBF in thyroid and other cancers, the established oncogenic 
nature of PBF, and the recently characterised interaction between PBF and p53, we 
characterised the effects of PBF overexpression on p53 metabolism, and assessed 
the functional association of PBF with the master regulator of p53, HDM2.  
6.4.1. The effects of PBF overexpression on p53 metabolism 
Treatment of TPC-1 cells with anisomycin to block de novo protein synthesis 
revealed that despite being a transformed cell line (where increased p53 stability is 
observed compared to normal cells) p53 levels decreased over the 120 minute 
timecourse. However, following the transient overexpression of PBF, p53 expression 
levels were significantly reduced from 120 minutes. Furthermore, in K1 cells, where 
p53 appeared to be much more stable across the 120 minute time course than TPC-
1 cells, PBF still had a potent effect on p53 turnover, with p53 levels also significantly 
reduced from 90 minutes. To test whether this observation was thyroid specific, 
anisomycin half-life assays were performed in HCT116 cells. In this cell line p53 was 
particularly stable across the 120 minute time course, with no visible decrease in p53 
levels even after 120 minutes. Nonetheless, PBF overexpression significantly 
increased the turnover of p53 from 90 minutes. The direct interaction of PBF with p53 
may therefore increase the rate of p53 degradation, an effect that has profound 
implications on the ability of p53 to function normally in response to genotoxic insult. 
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The ability of PBF to bring about significant alterations in p53 metabolism strongly 
suggests that PBF should join a growing number of cellular oncogenes that 
negatively affect the stability of p53 when aberrantly expressed. 
Given the potential importance of the observation that PBF is a novel mediator of p53 
metabolism, the effects of PBF on p53 half-life were characterised further. Firstly, the 
mRNA expression of p53 was monitored in the presence and absence of PBF 
overexpression, where we found that there was no significant difference in p53 
mRNA expression following PBF overexpression in either TPC-1 or HCT116 cells. 
These data suggest that the increase in p53 turnover observed in Figure 6.1 and 
Figure 6.2 occurs solely as a function of post-translational events and not as a 
consequence of TP53 gene repression. Secondly, given the probable overexpression 
of PBF in the cell lines used for study, investigation into the effects of transient PBF 
overexpression on p53 function may be, if at all, less sensitive than the depletion of 
PBF through siRNA knockdown in these cells. To that end, we used specific siRNAs 
to deplete PBF in K1 and TPC-1 cells and determined whether this would reverse the 
finding that PBF overexpression reduces p53 half-life. siRNA depletion in TPC-1 and 
K1 cells resulted in a significant repeatable increase in p53 half-life, further 
strengthening the observation that PBF is a novel mediator of p53 metabolism. Such 
an increase in p53 half-life on depletion of PBF protein may point to the importance 
of PBF in the maintenance of p53 homeostasis under normal conditions. However, 
when expressed at oncogenic levels PBF may cause the functional inactivation of 
p53. We found it difficult to directly implicate the physical interaction of PBF and p53 
with the turnover of p53. However, we were able to provide evidence that PBF must 
be in close proximity to p53 to affect its half-life with the use of a specific mutant of 
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PBF which is sequestered at the plasma membrane. Transient overexpression of this 
mutant did not alter the rate of p53 turnover; indeed the rate of p53 metabolism 
closely matched those of time-matched VO-transfected controls, providing evidence 
(albeit indirect) that PBF and p53 must physically interact to bring about the 
modulatory effect on p53 metabolism. That PBF can bind to and modulate the rate of 
p53 turnover indicates that PBF is a novel mediator of p53 stability, and when 
overexpressed may play a pivotal role in the functional inactivation of p53 in thyroid 
papillary carcinomas and other tumours where p53 mutations are rare.  
6.4.2. PBF overexpression results in increased p53 ubiquitination 
p53 turnover is mediated by ubiquitination (Brooks & Gu, 2006; Chen et al, 1993; Lee 
& Gu, 2009), and therefore observation of p53 ubiquitination following PBF 
overexpression  was necessary to provide greater meaning to the p53 half-life 
studies performed in Section 6.3.2. p53 ubiquitination was measured in TPC-1 cells 
and HCT116 cells, and in keeping with the anisomycin half-life assays, MG132 
ubiquitin assays confirmed that PBF overexpression correlated with increased p53 
ubiquitination. These data indicate that PBF modulates p53 physiology by increasing 
p53 turnover specifically via the ubiquitin proteasomal route. Oncogenic expression 
of PBF therefore has the potential to disrupt p53 regulation by altering its stability in 
thyroid and colorectal carcinomas. 
Despite the prominent effects of PBF on p53 metabolism, specific ubiquitin assays 
performed by our collaborator Dr Lopez (Lyon), confirmed that PBF was unable to 
incorporate ubiquitin, and was thus unlikely to possess ubiquitin ligase activity. This 
result suggests that PBF is not directly responsible for p53 ubiquitination, and 
therefore we hypothesised that PBF may bind directly to p53, influencing the ability of 
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HDM2 to bind to p53 and modulate its turnover. Recent work within our laboratory 
has been aimed at discerning the mechanism by which PBF influences p53 
ubiquitination. For example, experiments performed by Mr Gavin Ryan (University of 
Birmingham) using the HDM2 antagonist/ p53 activator Nutlin-3 (a compound that 
prevents HDM2 activity by preventing the direct interaction between p53 and HDM2 
(Vassilev et al, 2004)), revealed that PBF was unable to influence p53 turnover in the 
absence of HDM2 activity in TPC-1 cells. These data provide independent 
verification of the effects of PBF on p53 half-life in TPC-1 cells and demonstrate that 
that PBF influences p53 half-life in an HDM2 dependent manner.  
The data revealing that PBF can bind to, and negatively regulate, p53 expression by 
increasing its ubiquitination in an HDM2 dependent manner are suggestive that PBF 
may play the role of a co-factor, for example facilitating the docking of HDM2 or 
increasing the stability of the p53:HDM2 interaction to bring about optimal 
ubiquitination of p53 and HDM2. There are examples of co-factors of p53 and HDM2 
that serve to negatively regulate p53 homeostasis. For example the E3/E4 ligase 
UBE2B directly associates with p53 and HDM2, increasing its p53 degradation. 
Interestingly this protein has a characterised role in brain tumours (for example 
medulloblastoma) where amplification of UBE2B expression results in the functional 
inactivation of p53 (Wu et al, 2011). Furthermore, in line with the absence of ubiquitin 
ligase activity exhibited by PBF, the transcription factor Ying Yang 1 (YY1) has no 
intrinsic ubiquitin ligase activity, but is able to negatively influence p53 protein 
expression and bring about its ubiquitination. The mechanism whereby YY1 induces 
the turnover of p53 has  been characterised by Sui et al, 2004. Briefly YY1 Is able to 
induce HDM2-mediated degradation of p53 (in the absence of YY1 transcriptional 
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activation of target genes), and the basis for the regulation of p53 turnover by YY1 is 
primarily due to the ability of YY1 to facilitate or stabilise the interaction between p53 
and HDM2 (Sui et al, 2004; Atchison et al, 2011; Zhang et al, 2011). These relatable 
examples indicate that PBF may indeed facilitate HDM2 mediated degradation of p53 
by virtue of its direct interaction with p53 and HDM2. 
6.4.3. The relationship between PBF and HDM2 
With the data described in the previous Sections, it was important to assess the 
potential interaction of PBF with HDM2, as it may be that PBF binds to p53 and 
facilitates the action of HDM2. Co-immunoprecipitation assays were therefore 
performed to assess the potential interaction between PBF and HDM2 in TPC-1, K1 
and HCT116 cells. Co-immunoprecipitation reactions were inconclusive, but provided 
potential evidence for the interaction between PBF and HDM2. For example, in TPC-
1 and HCT116 cells, successful immunoprecipitation of HDM2 was followed by the 
detection of bands of ~23 kDa in size using our PBF specific antibody, that were not 
present in the NAb or IgG controls, indicating that the bands detected were not a 
result of antibody fragments or of proteins binding non-specifically to various 
components of the co-immunoprecipitation assay. However, in both cells lines the 
bands detected were of a different size to those which appeared on the pre-
immunoprecipitated lysates. The discrepancy in band size detracts from the validity 
of these findings, although provides potential supporting evidence of the GST-
pulldown assays that initially revealed an interaction between recombinant PBF and 
HDM2 in vitro (Dr Andrew Turnell, School of Cancer Sciences, University of 
Birmingham –unpublished data). We were unable to detect the interaction between 
HDM2 and PBF in K1 cells using the conditions described in Section 6.2.4. 
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Interestingly there are numerous lines of evidence that PBF exists in a number of 
distinct isoforms within the cell. For instance specific use of mutants lacking putative 
glycosylation sites are found to run at different sizes to endogenous WT PBF.  
 Concluding statements 6.5.
The data within this chapter provide evidence that PBF is a novel regulator of p53 
metabolism. For example oncogenic expression of PBF in thyroid cancer cells results 
in a marked increase in p53 turnover, correlating with increased ubiquitination of p53. 
A specific mutant of p53, which remains sequestered at the plasma membrane away 
from the observed interaction with p53, was unable to influence p53 half-life. These 
data suggest that the interaction of PBF with p53 is necessary for the increase in p53 
turnover observed. Furthermore, independent experiments confirm that PBF 
decreases p53 half-life in an HDM2 dependent manner, and our preliminary data 
indicate that PBF may also interact with HDM2. These findings demonstrate that PBF 
may be a novel co-factor serving to promote HDM2-mediated degradation of p53.  
In conclusion this chapter provides evidence for a novel potential mechanism of 
tumourigenesis in thyroid papillary carcinomas, whereby PBF binds directly to p53, 
and oncogenic expression of PBF perturbs p53 function by increasing its turnover in 
an HDM2 dependent manner. 
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 Introduction 7.1.
As previously described, the functional inactivation of p53 has been extensively 
linked to the initiation and progression of human cancer. PBF overexpression may 
therefore result in a biological change in p53 biology that might predispose the cell to 
malignant transformation and tumourigenic progression. Whilst the data in chapter 5 
demonstrate that PBF had no significant effect on p53-mediated gene transcription 
(as measured through the use of p53-specific focused microarrays), p53 also has 
well characterised roles as a tumour suppressor independently of its role as a 
transcription factor. For instance, p53 directly mediates apoptosis induction following 
genotoxic insult by rapidly translocating to the mitochondria (Moll, Wolff, Speidel, & 
Deppert, 2005). P53 mitochondrial translocation occurs very rapidly, and precedes 
cytochrome c release, the collapse of the mitochondrial membrane potential and 
caspase-3 activation (Marchenko, Zaika, & Moll, 2000). The majority of mitochondrial 
p53 localizes to the outer membrane (Sansome, Zaika, Marchenko, & Moll, 2001), 
although a subfraction is found in complex with the major mitochondrial import 
proteins mthsp70 and mt hsp60 in the mitochondrial matrix (Dumont, Leu, Pietra, 
George, & Murphy, 2003; Mihara et al., 2003). The importance of p53 in the initiation 
of the release of cytochrome C and subsequent caspase cascade were highlighted 
using p53 fusion proteins. Specifically, Targeting of p53 to mitochondria by fusing it 
with mitochondrial address peptides, thereby bypassing the nucleus, was found to be 
sufficient to launch acute apoptosis and chronic colony suppression directly from the 
mitochondrial platform (Mihara et al., 2003; Moll et al., 2005; Sansome et al., 2001). 
Such studies highlight that the p53 tumour suppressor can directly initiate apoptosis, 
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and demonstrate that the potential effects of PBF on p53 function may involve the 
suppression of p53 transcription independent functions. 
The data in chapter 6 describes the effect of PBF on p53 turnover, where oncogenic 
expression of PBF results in significant reduction of p53 half-life, causing increased 
degradation of p53 via the ubiquitin-proteasomal pathway. To investigate the gross 
effects of PBF on cell physiology, we used MTT cell viability assays to determine the 
overall effects of PBF overexpression on relative cell survival following exposure of 
ionising radiation to induce DNA DSBs. Furthermore, given the importance of the 
apoptotic pathway in the induction and progression of tumours, we assessed the 
effects of PBF overexpression on the mRNA and protein expression of 3 important 
regulators of apoptosis, BAX, PUMA and BCl-2, which are controlled directly by p53. 
We aimed to make use of specific caspase 3/7 cleavage assays to determine the 
overall levels of apoptosis following overexpression of PBF in thyroid papillary 
carcinoma cells.  
Recently a murine model of targeted PBF overexpression in the thyroid was 
generated and characterised. Mice overexpressing PBF in the thyroid were found to 
exhibit normal thyroid function but presented with a striking enlargement of the 
thyroid gland associated with hyperplastic and macrofollicular lesions (Read et al, 
2011). Thyroid cell growth is governed by a series of well-defined kinase pathways, 
which are commonly disrupted in thyroid neoplasia; therefore investigations into the 
expression of proteins involved in the mitogen activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K) pathways were undertaken to gain mechanistic 
insights to the growth effects observed. Whilst MAPK was found to be unaltered in 
PBF transgenic mice when compared to wild-type counterparts, the important PI3K 
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target Akt was significantly induced by phosphorylation at ser-473 (a critical residue 
for AKT activation). In accordance with PBF overexpression causing the activation of 
AKT, the total levels of AKT in murine transgenic thyroids was unaltered (Read et al, 
2011). These data indicate that PBF may induce AKT activation, a critical mediator of 
cellular proliferation and novel mediator of p53 turnover and ubiquitination (Gottlieb et 
al, 2002; Boehme et al, 2008; Ogawara et al, 2002). In light of these recent data, we 
also aimed to assess the effects of PBF overexpression on AKT in human primary 
thyrocytes and thyroid papillary carcinoma cells. 
The overall aims of this Chapter were therefore to observe the gross biological 
effects of PBF overexpression, and potentially elucidate the potential mechanism 
whereby PBF affects p53 function. 
 
 Materials and methods 7.2.
7.2.1. Cell lines and plasmids 
TPC-1, K1 and HCT116 cells were routinely subcultured using the methods 
described in section 2.1. For experiments requiring transient PBF overexpression, 
and / or γ-irradiation exposure, cells were treated using the procedures described in 
section 3.2. Human primary thyrocytes were cultured as described in Section 2.3 
(Thyrocytes were transfected using Fugene as directed in Section 3.2) 
7.2.2. SDS-PAGE/Western blotting 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see Section 2.6). Blocked membranes were subsequently 
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incubated with primary antibodies. Antibodies used were our rabbit anti-human PBF-8 
polyclonal (1:1000) (Read et al, 2011), rabbit anti-human HA (Covance) Mouse anti-
human p53 (D0-1) monoclonal at 1:5000 (Santa Cruz, CA, USA), monoclonal anti-β-
actin clone AC-15, (used at 1:10,000, Sigma-Aldrich, Poole, UK). Antibodies used for 
detection of apoptotic proteins were, rabbit anti-human BAX (#2774), BCL-2 (#2870) 
and PUMA (#4976) purchased from Cell-Signaling Technology (New England 
Biolabs, Ipswich, Massachusetts, USA). Observation of AKT and p-AKT ser-473 
protein expression was determined using rabbit anti-human Akt Antibody #9272, and 
Phospho-Akt (Ser473) (D9E) XP® antibody #4060 purchased from Cell-Signaling 
Technology (New England Biolabs, Ipswich, Massachusetts, USA). 
7.2.3. RNA extraction and QT-PCR 
Reverse transcription and QT-PCR techniques were as described in Sections 2.4 
and 2.5. Specific primers and probes for assessment of BAX, BCL-2 and PUMA 
mRNA expression were purchased from Applied Biosystems (Warrington, UK). 
7.2.4. MTT cell-viability assays 
The rate of cellular proliferation of TPC-1, K1 and HCT116 cells following transient 
PBF overexpression and treatment with ionising γ-irradiation was assessed by 
internalisation and reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT). Cells were seeded into 6-well dishes, and incubated for 24 hours 
before transient overexpression of PBF, using the methods described in section 3.3. 
After 24 hours thyroid cells lines and the colorectal cell line were treated with 15 Gys 
and 40 Gys γ-irradiation respectively and returned to incubation. Following treatment 
with γ-irradiation cells were trypsinised, counted and seeded into 96-well dishes at a 
density of 7500 cells/well and incubated for 24 hours. Cells were incubated with 0.8 
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mg/ml MTT (Sigma-Aldrich, UK) for the last 3 hours of culture incubation. Cells were 
then washed with cold PBS before formazan crystals were solubilised by addition of 
100 μl dimethyl sulfoxide for 15 minutes. The absorbance at 540 nm was measured 
using a Wallac 1420 Victor plate-reader (Perkin-Elmer, Massachusetts, USA). 
7.2.5. Caspase 3/7 cleavage assays  
The effects of PBF overexpression on the gross levels of apoptosis were assessed 
using specific caspase 3/7 cleavage assays (CaspaseGlo 3/7 assay, Promega). The 
luminogenic substrate within the assay is cleaved by caspases 3 and 7 to yield a 
substrate for luciferase. Relative levels of apoptosis were then measured using a 
luminometer. Cells were seeded into 6-well dishes and treated as above (7.2.4), and 
were seeded into 96-well plates at a density of 1x105 per well, incubated for 24 hours 
before application of CaspaseGlo 3/7 substrate as per manufacturer’s instructions. 
Luminescence was measured using a Wallac 1420 Victor plate-reader (Perkin-Elmer, 
Massachusetts, USA). 
7.2.6. Statistical analysis 
Statistical analysis was performed using the methods described in Section 2.8. 
 
 Results 7.3.
7.3.1. The biological effects of PBF overexpression 
To investigate the physiological relevance of our finding that PBF decreases p53 
stability by targeting it for ubiquitination, we examined the influence of manipulating 
PBF expression on cell survival in response to ionising radiation (I.R). We used MTT 
Chapter 7: The biological effects of PBF on cell survival, growth and apoptosis 
 
174 
 
assays to assess the effects of PBF overexpression on cell viability 24 hrs after 
treatment with γ-irradiation. VO transfected TPC-1 cells displayed a significant, 
repeatable reduction in cell viability (17.9%+/-1.3 %; p<0.05; n=3; Figure 7.1A). 
However, TPC-1 cells overexpressing PBF alone did not show any significant 
reduction in cell viability, resulting in a significant difference in cell viability following 
exposure to ionising radiation (Figure 7.1A; n=3; p<0.001). A similar result was 
observed in K1 cells where VO-transfected cells displayed a ~20 % reduction in cell 
viability compared to cells overexpressing PBF, which displayed only a 7 % decrease 
in cell viability compared to untreated controls. The increase in cell survival observed 
when PBF was overexpressed in K1 cells following treatment with γ-irradiation did 
not reach statistical significance (n=4; p=NS; Figure 7.1B). MTT cell viability assays 
were also assessed following the transient overexpression of PBF in HCT116 cells. 
In this cell line VO controls displayed a repeatable ~25 % reduction in cell viability in 
response to γ-irradiation. However when PBF was overexpressed no reduction in cell 
viability was observed, and hence PBF overexpression resulted in a significant 
difference in cell viability in response to γ-irradiation (Figure 7.1C, n=4; p<0.001). 
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Figure 7.1: MTT cell viability assays representing the effects of transient PBF 
overexpression on the relative change in cell viability 24 hrs after treatment with γ-
irradiation compared to untreated controls. A: TPC-1 cells transiently overexpressing 
PBF displayed a significant increase in cell viability in response to 15 Gy γ-irradiation 
treatment (n=3; p<0.0001). B: K1 cells transiently overexpressing PBF showed a 13 
% reduction on cell viability in response to 15 Gy γ-irradiation (n=4; p=NS). C: 
HCT116 cells transiently overexpressing PBF displayed a significant increase in cell 
viability in response to 40 Gy γ-irradiation treatment (n=4; p<0.001). Representative 
Western blots demonstrating p53 induction in response to ionising radiation and 
levels of transient overexpression of PBF were obtained from lysates from cells 
treated in parallel with cells seeded for the MTT viability assays. D: Raw data 
exemplar of absorbance readings at 540 nm for HCT116 MTT cell viability data 
(n=3). 
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In order to assess whether the effects of PBF overexpression were directly linked to 
the effects of PBF on p53 metabolism, MTT cell viability assays were repeated in the 
p53 null SW1736 anaplastic thyroid cell line. Preliminary data suggest that the 
significant differences observed in cell viability in TPC-1 cells and HCT116 cells are 
lost in p53 null SW1736 cells. In this cell line DNA damage induced a ~10 % 
reduction on cell viability in VO-transfected controls, with cells overexpressing PBF 
displaying a similar decrease in cell survival of ~12 % (preliminary data; n=2; Figure 
7.2), suggesting that the effects of PBF overexpression on cell survival may indeed 
be p53 specific.  
 
Figure 7.2: Preliminary MTT assay data demonstrating the effects of PBF 
overexpression on cell viability/ survival following exposure to ionising radiation in 
p53  null SW1736 anaplastic thyroid carcinoma cells (n=2). 
 
7.3.2. The effects of PBF on the p53-mediated apoptotic pathway 
Given the potential survival advantage conferred by PBF overexpression in response 
to ionising radiation, we aimed to define the biological pathway responsible. In this 
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Section we specifically focused on 2 key pro-apoptitic factors, BAX and PUMA and 1 
important anti-apoptotic factor BCL-2, and determined the effects of PBF 
overexpression on the gene and protein expression of these factors following 
induction of DNA damage by ionising radiation. Furthermore, specific caspase 3/7 
cleavage assays were performed to assess the effects of PBF on the levels of 
apoptosis following DNA damage. 
 The effects of PBF on BAX and PUMA expression 7.3.2.1.
BAX and PUMA (described more fully in Section 3.1) are both pro-apoptotic genes, 
directly induced by p53 activity in response to cellular stress. The protein products of 
these genes directly interact with the anti-apoptotic protein BCL-2 (the expression of 
which is also mediated by p53 at the level of transcription), to bring about the onset 
of the apoptosis pathway. For instance, the presence of BCL-2 homodimers 
constitute an anti-apoptotic environment, but on activation of BAX, BCL-2:BCL-2 
interactions are displaced by BCL-2:BAX heterodimers, resulting in the initiation of 
apoptosis. PUMA also interacts with BCL-2 and specifically inhibits its function, 
paving the way for BAX activity, and ultimately the onset of apoptosis via the 
mitochondrial cytochrome C pathway.  
The effects of PBF overexpression on the induction of BAX, BCL-2 and PUMA 
expression were analysed in both the presence and absence of ionising radiation in 
TPC-1 cells and HCT116 cells (Figure 7.3). BAX mRNA expression was not affected 
by PBF alone (n=3; p=NS; Figure 7.3A), but was significantly induced by the 
administration of 15 Gy γ-irradiation in cells transiently overexpressing PBF and 
those expressing the vector only compared to untreated cells (elevated to 1.84-fold 
and 1.88-fold respectively, n=3; p<0.05). However, there was no significant 
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difference in BAX induction following PBF overexpression. The expression of the 
anti-apoptotic BCL-2 was not effected by PBF overexpression alone. Administration 
of γ-irradiation resulted in a predictable repression of BCL-2 expression in both the 
presence and absence of PBF overexpression (both by ~40%, n=3; p=NS; Figure 
7.3A), indicating that PBF also has no effect on the activity of this gene in this cell 
line. Again, PBF overexpression had no effect on PUMA mRNA expression in either 
the presence or the absence of ionising radiation, although PUMA mRNA expression 
was significantly elevated in response to ionising radiation (~3-fold; n=3; p<0.001; 
Figure 7.3A).  
Experiments were repeated in HCT116 cells and similar results were obtained 
(Figure 7.3B), BAX was non-significantly elevated following treatment with ionising 
radiation and PBF overexpression had no significant effect on BAX expression in the 
presence or absence of ionising radiation (n=3). Again, BCL-2 was non-significantly 
repressed in response to ionising radiation, with PBF having no effect on the 
induction of this gene (n=3; p=NS). Finally, PUMA mRNA expression was 
significantly elevated in response to ionising radiation (~3.2-fold: n=3; p<0.001), but 
PBF overexpression did not significantly affect the induction of this gene (see Figure 
7.3B). 
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Figure 7.3: The effects of PBF overexpression on the mRNA expression of the 
apoptotic factors BAX, PUMA and BCL-2 in the presence and absence of DNA 
damage in HCT116 and TPC-1 cells A: In TPC-1 cells, BAX and PUMA mRNA 
expression were significantly induced by ionising radiation, but PBF had no effect on 
this. BCL-2 expression was not significantly affected by ionising radiation, and was 
not significantly affected by PBF overexpression. B: Within HCT116 cells, PUMA was 
the only gene significantly elevated in response to ionising radiation, but PBF had no 
significant effect (n=3, *p<0.05, **p<0.01, ***p<0.001).  
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 The effects of PBF overexpression on the protein expression of 7.3.2.2.
BAX, PUMA and BCL-2 in the presence and absence of ionising radiation 
In support of the data described in Section 7.3.2.1, no significant differences in the 
protein expression of PUMA or BCL-2 were detected in response to PBF 
overexpression, either in the presence or absence of genotoxic insult, in TPC-1 or 
HCT116 cells (Figure 7.4). We were unable to detect BAX protein expression in TPC-
1 or HCT116 cells using the antibody described in Section 7.2.2 (Figure 7.4A+B). An 
increase in PUMA protein expression was observed in both TPC-1 and HCT116 cells 
following γ-irradiation, in support of the mRNA data generated by QT-PCR, 
demonstrating that PUMA mRNA expression was significantly upregulated in 
response to DNA damage in these cell lines (Figure 7.4).  
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Figure 7.4: The effects of PBF overexpression on the protein expression of BAX, 
PUMA and BCL-2 in the presence and absence of ionising radiation in TPC-1 and 
HCT116 cells. A: Representative Western blots displaying the effects of PBF 
overexpression on PUMA and BCL-2 protein expression in TPC-1 cells. PBF had no 
effect on the expression of these proteins (n=3) B: Representative Western blot 
displaying the effects of PBF overexpression on PUMA and BCL-2 protein 
expression in HCT116 cells. PBF also had no effect on the expression of these 
proteins (n=3). Immunoblots for p53 and PBF were included to represent successful 
induction of DNA damage and PBF overexpression, with β-actin used as a loading 
control. We were unable to detect BAX protein using the antibody described in 
Section 5.2.2. 
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 The effects of PBF overexpression on gross levels of apoptosis in 7.3.2.3.
the presence and absence of ionising radiation 
PBF overexpression had no effect on the induction of 3 important mediators of 
apoptosis, BAX, BCL-2 and PUMA, providing evidence that PBF does not affect 
these important apoptotic factors in thyroid cancer. However, given the reported 
transcriptional independent roles of p53 in the induction of apoptosis, total levels of 
apoptosis were measured following PBF overexpression in the presence and 
absence of DNA damage compared to mock transfected controls. 
The relative levels of apoptosis can be accurately measured in transformed cells in 
culture by assessing the activity of caspase 3 and 7 enzyme activity. Apoptosis 
assays incorporate the use of a pro-luminescent caspase 3/7 substrate containing 
the tetrapeptide sequence DEVD, which is cleaved to aminoluciferin, a substrate of 
luciferase, by the activity of caspase 3 and 7. Relative levels of apoptosis of cells in 
culture can be accurately measured by measuring the levels of luminescent signal 
produced using a luminometer.  
TPC-1, K1 and HCT116 cells were seeded into 96-well dishes and PBF was 
overexpressed for 24 hours using the methods described in Section 2.1. Thyroid 
carcinoma cells and HCT116 cells were then treated with 15 Gy and 40 Gy γ-
irradiation respectively and returned to incubation for 24 hours, with caspase 3/7 
GLO substrate added in the final 3 hours of culture incubation, and measurement of 
apoptosis was performed after 24 hours (Figure 7.5). TPC-1 cells overexpressing 
PBF displayed a repeatable decrease in apoptosis, which was statistically significant 
(18 % +/- 4.5 % decrease; n=3; p<0.01; Figure 7.5A), suggesting that PBF causes a 
decrease in apoptosis in this cell line in the absence of DNA damage. Surprisingly, 
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treatment with 15 Gy γ-irradiation did not significantly elevate the rate of apoptosis in 
TPC-1 cells (Figure 7.5A), despite the earlier observation that 15 Gy ionising 
radiation significantly elevates the mRNA and protein expression of pro-apoptotic 
factors in this cell line. It would appear, as mentioned in Chapter 3, that the 
predominant response of TPC-1 cells to 15 Gy γ-irradiation is growth-arrest, rather 
than the induction of apoptosis. When the levels of apoptosis were measured in 
HCT116 cells PBF was observed to have no effect on the levels of apoptosis in the 
absence of DNA damage, in contrast to the data generated in TPC-1 cells (see 
Figure 7.5A+B). The levels of apoptosis were also unaltered in HCT116 cells treated 
with 40 Gy γ-irradiation (Figure 7.5B). Again, the main biological response of 
HCT116 cells treated with such a dose of ionising radiation appears to be growth 
arrest, rather than apoptosis, despite the apparent induction of proapoptotic factors in 
response to this treatment. Furthermore, as described in TPC-1 cells, PBF had no 
apparent effect on apoptosis in the presence of DNA damage (Figure 7.5B). Similar 
results were obtained in K1 cells, where PBF was observed to have no effect on 
apoptosis in either the presence or absence of ionising radiation (n=2, data not 
shown).  
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Figure 7.5: The effects of PBF overexpression on the relative levels of apoptosis in 
TPC-1 and HCT116 cells in the presence and absence of ionising radiation. A PBF 
overexpression significantly repressed apoptosis in the absence of DNA damage 
(~18 % +/- 4.5 %; n=3; p<0.05). Ionising radiation did not affect the basal levels of 
apoptosis in this cell line, and PBF had no effect on apoptosis in the presence of 
DNA damage. B: The relative levels of apoptosis in HCT116 cells; PBF 
overexpression did not affect apoptosis levels in the presence or absence of ionising 
radiation. Furthermore, treatment of HCT116 cells with 40 Gy γ-irradiation did not 
significantly affect the induction of apoptosis (n=3; p=NS). 
 
7.3.3. PBF and PKB/AKT activity 
With PBF overexpression linked with increased turnover and ubiquitination of p53, 
and increased cell survival following short-term exposure to ionising radiation, the 
effects of PBF overexpression on p-AKT induction were investigated in human 
primary thyrocytes and thyroid papillary carcinoma cells. In keeping with the findings 
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of Read et al, 2011, human primary thyrocytes transiently transfected with pCDNA3 
for 24 hours demonstrated significant phosphorylation (and therefore activation) of 
AKT at Ser-473 compared to VO-transfected controls (Figure 7.6). In addition, those 
samples that displayed significant induction of AKT phosphorylation at Ser-473 did 
not display any significant increase in total AKT expression compared to VO-
transfected controls (Figure 7.6). 
 
 
Figure 7.6: Representative Western blot demonstrating the effects of PBF 
overexpression on the induction of p-AKT in human primary thyrocytes. β-actin was 
used as a total protein loading control, and total AKT levels were monitored to assess 
the effects of PBF overexpression on total AKT expression.  
 
The effects of PBF overexpression on AKT were investigated using TPC-1, K1 and 
HCT116 cell lines. In agreement with the data obtained using human primary 
thyrocytes, no significant difference in total AKT protein expression was observed in 
any of our cell lines (Figure 7.7A). Moreover, the effects of PBF overexpression on p-
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AKT (Ser-473) were investigated in TPC-1 cells in the presence and absence of 
ionising radiation. Preliminary data suggested that PBF overexpression results in an 
increase in p-AKT levels in the absence of ionising radiation, to a similar level 
observed in normal thyrocytes. In the presence of ionising radiation, phosphorylation 
of AKT appears to be induced in both the presence and absence of PBF 
overexpression compared to time matched untreated controls (Figure 7.7B). 
However, the phosphorylation of AKT appeared to be greatest in cells 
overexpressing PBF (Figure 7.7B, preliminary data).  
 
Figure 7.7: The effects of PBF overexpression on AKT expression: A: Representative 
Western blots to assess the effects of PBF overexpression on total AKT protein 
expression in TPC-1, K1 and HCT116 cells (n=3). B: Preliminary data displaying the 
effects of ionising radiation and PBF overexpression on the expression of p-ser-473 
AKT in the presence and absence of ionising radiation in TPC-1 cells. Detection of 
PBF confirmed successful overexpression of PBF following transient overexpression, 
and β-actin was used as a protein loading control.  
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 Discussion 7.4.
7.4.1. The biological effects of PBF overexpression 
In light of the observed effects of PBF on p53 biology, we sought to determine the 
gross biological effects elicited by PBF overexpression in the presence and absence 
of ionising radiation in TPC-1, K1 and HCT116 cells through the use of MTT cell 
viability/survival assays. PBF overexpression alone did not have a significant effect 
on cell viability or survival in the absence of DNA damage. However, following 
treatment with ionising radiation to induce DNA damage, TPC-1 and HCT116 cells 
overexpressing PBF demonstrated a significant, repeatable increase in cell survival 
24 hours after the induction of DNA damage by ionising radiation treatment, 
compared to VO-transfected controls. MTT assays performed in K1 cells 
demonstrated a similar trend, where PBF overexpression resulted in an overall ~13 
% increase in cell survival/viability following DNA damage, but this trend was not 
found to reach statistical significance. Data in Chapter 4 provide evidence for a direct 
interaction between PBF and p53 in the presence and absence of ionising radiation 
and Sections 6.3.1 and 6.3.2 present data to suggest PBF overexpression negatively 
influences p53 half-life by increasing its turnover via the ubiquitin proteasomal route. 
In accordance with this data, MTT cell viability assays revealed that PBF 
overexpression correlates with a significant increase in cell survival following 
exposure to γ-irradiation. The MTT survival data cannot be directly associated with 
the effects of PBF on p53 metabolism, but provides evidence that PBF 
overexpression has a gross biological effect that potentially promotes 
tumourigenesis. To address this issue we attempted to make use of the p53-null 
SW1736 anaplastic thyroid carcinoma cell line. These cells are functionally p53 null 
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by virtue of a striking down regulation of p53 mRNA expression (Blagosklonny et al, 
1998). Our preliminary data indicate that PBF does not affect cell viability following 
DNA damage in these p53-null cells, implying that PBF affects cell physiology by 
modulating the activity of p53. To confirm that the cell viability effects are due to the 
functional interaction of PBF with p53, future experiments would assess the effects of 
PBF on cell viability in SW1736 cells expressing exogenous wild-type p53. These 
data suggest that PBF overexpression may inhibit mechanisms of growth arrest or 
apoptotic pathways, usually activated by p53 in response to DNA damage. 
7.4.2. The effects of PBF overexpression on the p53-mediated apoptotic 
pathway 
Given the overwhelming evidence linking the aberrant control of apoptosis to tumour 
progression (Cotter, 2009), the effects of PBF overexpression on the induction of 3 
prominent mediators of apoptosis (BAX, PUMA and BCL-2) were analysed. BAX and 
PUMA are both pro-apoptotic factors, and aberrant expression of these proteins has 
been extensively characterised in cell transformation and tumourigenesis (Basu & 
Haldar, 1998; Ionov et al, 2000; Frenzel et al, 2009), along with BCL-2, the 
antiapoptotic factor (Oltval et al, 1993; Frenzel et al, 2009). As expected, following 
treatment of TPC-1 cells with γ-irradiation the 2 pro-apoptotic factors BAX and PUMA 
were significantly upregulated, and the antiapoptotic factor BCL-2 non-significantly 
repressed by ~50 %. These findings imply that 15 Gy γ-irradiation is sufficient to 
influence p53-mediated expression of these genes, as reported in Section 3.3.2. 
However, following PBF overexpression there was no observed effect on the 
expression of BAX, BCL-2 and PUMA expression. In accordance with these 
observations, PBF overexpression had no effect on any of the 3 apoptotic genes in 
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HCT116 cells treated with 40 Gy of γ-irradiation. Furthermore, Western blotting data 
suggested that PBF has no effect on PUMA protein expression. We were unable to 
detect BCL-2 protein expression via Western blotting in either the presence or 
absence of ionising radiation, despite readily detecting BCL-2 mRNA expression, 
although this may reflect the avidity of the antibody used.  
 The effects of PBF on the gross levels of apoptosis  7.4.2.1.
In light of the evidence to demonstrate that p53 performs transcription independent 
roles in the response to DNA damage, the effects of PBF overexpression on the 
gross levels of apoptosis in the presence and absence of DNA damage were 
assessed (Vousden & Prives, 2009; Speidel et al, 2006; Moll et al, 2005) . There 
were no significant effects of PBF overexpression on the levels of apoptosis following 
treatment with DNA damage in TPC-1 or HCT116 cells. Interestingly, despite 
significant induction of the proapoptotic factor PUMA (at both the mRNA and protein 
level, Section 7.3.2), there was no significant induction of apoptosis following DNA 
damage in ether VO-transfected or PBF transfected cells. These data suggest that, 
as described in 0, the predominant response of TPC-1 and HCT16 cells to 15 and 40 
Gy γ-irradiation respectively may be that of growth arrest and not apoptosis. In the 
absence of DNA damage however, TPC-1 cells displayed a significant 18 % 
decrease in apoptosis levels in response to PBF overexpression compared to those 
of VO-transfected controls. Such findings indicate that PBF may influence the levels 
of apoptosis in the absence of DNA damage, and therefore the presence of inactive 
p53. However, in light of the fact that PBF overexpression had no effect on apoptosis 
in the presence of DNA damage, this finding was deemed to be of no consequence. 
Furthermore, there was no effect of PBF overexpression on apoptosis in the absence 
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of DNA damage in K1 or HCT116 cells. These data demonstrate that it is unlikely 
that apoptosis is responsible for the survival effects determined through the use of 
MTT cell viability assays.  
Separate from the transcription independent control of apoptosis orchestrated by 
p53, there are reports of transcription independent modulation of cell growth. For 
example a study by Galy et al, 2001 confirmed that p53 is able to inhibit human 
fibroblast growth factor 2 in the absence of transcriptional activity. This report 
provides evidence that transcription independent functions of p53 are emerging, and 
demonstrate that the effects of PBF on p53 may be entirely valid. It is interesting to 
note that PBF is required for PTTG activation of FGF-2 (Ishikawa et al, 2001; Chien & 
Pei, 2000). Therefore it may be of interest to assess the effects of PBF p53-mediated 
FGF-2 inhibition in future investigations.  
7.4.3. PBF and the PKB/AKT pathway 
Targeted overexpression of PBF in murine thyroids results in striking enlargement of 
the thyroid gland, with associated hyperplastic and macrofollicular lesions. Further 
analysis revealed that PBF transgenic thyroids displayed significant repeatable 
induction of p-AKT (Ser-473) compared to their wild-type counterparts (Read et al, 
2011). These findings were relevant, as AKT is strongly associated with the p53 
pathway. For instance, AKT, whilst having no effect on the transcription of p53, 
directly promotes p53 turnover via the ubiquitin proteasomal pathway (Ogawara et al, 
2002). The mechanism whereby AKT promotes p53 turnover and inactivation 
appears to be due to HDM2 activation, and several independent studies have 
confirmed that AKT directly activates HDM2 by phosphorylation of Ser-186 (Ogawara 
et al, 2002; Mayo & Donner, 2001; Zhou et al, 2001). Following transient 
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overexpression of PBF in human primary thyrocytes, PBF expression correlated with 
activation of AKT at Ser-473. These data hint that PBF and AKT may co-operate to 
bring about the observed effects of PBF overexpression on p53 biology. We 
attempted to assess the effects of PBF overexpression on the induction of p-AKT in 
our cell lines, and confirmed that PBF overexpression had no effect on the 
expression of total AKT protein expression in TPC-1, K1 or HCT116 cells. Preliminary 
data suggest that ionising radiation induces Ser-473 phosphorylation of AKT in TPC-
1 cells, consistent with previous studies (Li et al, 2009; Viniegra et al, 2005; Jung et 
al, 2010), and that PBF overexpression may increase the levels of p-AKT. Further 
studies to verify or refute these initial findings may point to or eliminate a novel 
potential mechanism of p53 functional inactivation based on the co-operation of PBF 
and AKT to increase p53 degradation. 
 Concluding statements 7.5.
Experiments in this chapter attempted to assess the gross biological effects of PBF 
overexpression in thyroid cancer cells. Such data revealed that PBF overexpression 
correlated with an increase in cell viability following treatment with ionising radiation, 
implying that PBF might confer a survival advantage under these conditions. 
However, PBF had no effect on the gross levels of apoptosis, suggesting that the 
mechanism of increased cell survival following PBF was unlikely to have targeted the 
apoptotic pathway. Preliminary data suggest that PBF expression positively 
correlates with phosphorylation of Akt at ser-473, leading to its activation, further 
characterisation of the effects of PBF on the Akt pathway in thyroid cancer cell lines 
may provide a mechanism whereby PBF affects cell survival.  At present the pathway 
targeted by PBF to bring about the observed effects remains to be elucidated. 
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The research described within this thesis demonstrates investigations into the 
relationship between the poorly characterised proto-oncogene PBF and the tumour 
suppressor protein p53. Specific research included assessing the potential 
interaction between PBF and p53 and determining the effects of PBF on p53 
homeostasis and function in thyroid papillary carcinoma cells. Investigations were 
founded on the observations that p53 mutations are rare in thyroid cancer, yet the 
thyroid gland is particularly sensitive to the carcinogenic effects of ionising radiation 
(Olivier et al, 2002; Malaguarnera et al, 2007b; Nikiforov et al, 1996; Klugbauer et al, 
1995). We therefore hypothesised that p53 functional inactivation is common in 
thyroid cancers lacking inactivating p53 mutations, and that PBF overexpression (as 
observed in thyroid cancers) leads to the functional inactivation of p53 by directly 
interacting with and abrogating its tumour suppressor function in response to cell 
stresses such as DNA double strand breaks (DSBs).  
 PBF directly interacts with p53 8.1.
Primary research aimed to assess the potential interaction of PBF and p53 using co-
immunoprecipitation assays. Initial data within the McCabe laboratory demonstrated 
that PBF may interact with p53 in vitro. Such data were generated through GST-
pulldown assays, which are known to provide artificial proximity of proteins, thus 
allowing for the potential interaction of proteins in a physiologically irrelevant manner. 
Through co-immunoprecipitations assays, we observed PBF to interact directly with 
p53 in 2 thyroid papillary carcinoma cell lines (TPC-1 and K1) expressing wild-type 
p53, both in the presence and absence of DNA damage. Therefore the interaction of 
PBF with p53 in these cells occurred both when p53 was inactivated, and when p53 
Chapter 8: Final discussion and future work 
 
194 
 
was activated by DNA DSBs. Furthermore, the interaction of PBF and p53 was 
observed HCT116 cells, suggesting that the interaction was not specific to the 
thyroid. Such data were consistent with subcellular colocalisation of PBF and p53 
using fluorescence immunocytochemistry assays. The interaction of PBF and p53 
may point to a functional consequence of PBF on p53 function. Oncogenic 
expression of viral or cellular proteins has been reported to sequester p53 away from 
sites of interaction and to therefore inhibit its function (Hartl et al, 2008; Becker et al, 
2007). In light of the established roles of PBF in the subcellular redistribution of 
important cellular proteins (Chien & Pei, 2000; Smith et al, 2009, 2012), we 
hypothesised that p53 subcellular distribution might be affected by PBF. However, 
using subcellular fractionation studies, we were unable to detect significant 
subcellular redistribution of p53 following overexpression of PBF. These data indicate 
that whilst PBF binds to p53, oncogenic expression of PBF does not result in p53 
subcellular redistribution, and hence, this does not appear to be a mechanism 
whereby PBF might functionally inactivate p53. To further characterise the effects of 
PBF on p53 subcellular localisation, future studies could make use of specific 
mutants of PBF. For instance, a mutant lacking the bipartite NLS, and observed to 
remain within the cytoplasm, could be assessed with regard to p53 subcellular 
localisation. Conversely, a mutant p53 lacking a functional NLS could be employed to 
observe the effect of WT PBF on p53 localisation, and thus determine whether PBF 
can affect the nuclear localisation of p53. It would be of interest to utilise human 
primary thyrocytes to assess the relationship between PBF and p53 in normal, 
untransformed cells. This could be achieved through use of proximity ligation assays 
(PLAs). PLAs allow protein:protein interactions to be detected and quantified using a 
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small number of cells. This technique also reveals the subcellular localisation of such 
interactions (Weibrecht et al, 2010). 
 PBF does not alter p53-mediated gene expression  8.2.
p53 is a potent transcription factor, and this functional role of p53 has been 
extensively characterised with regard to tumour suppression (Vogelstein et al, 2000; 
Wu & Levine, 1997; Meek, 2004). We used focused microarrays to assess the effects 
of PBF on the expression 84 p53-mediated genes. Surprisingly, PBF did not 
significantly alter p53-mediated transcriptional activity in the presence or absence of 
DNA damage. These data contrast with preliminary data demonstrating the effects of 
PBF on p53-mediated gene transcription using specific luciferase reporter assays (Dr 
Martin Read, University of Birmingham). Such data demonstrate that PBF 
significantly represses p53 as a transcription factor. Retrospectively, transfection 
efficiencies in TPC-1 cells may have been sub-optimal. Furthermore, given that PBF 
is overexpressed in thyroid cancers, the potential effect of PBF on p53 transcription 
may have been saturated. Future work would aim to further investigate the effects of 
PBF on p53-mediated gene transcription, as p53 primarily functions as a transcription 
factor. The sensitivity of detection could be improved by generating cell lines to stably 
overexpress PBF, and thus discard transfection issues. Furthermore, these focused 
microarrays could be performed in normal untransformed thyrocytes to prevent 
problems arising from high background PBF expression. 
 PBF affects p53 homeostasis 8.3.
Apart from its role as a transcription factor, p53 is also capable of tumour 
suppression by transcription independent mechanisms (Vousden & Prives, 2009; 
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Speidel et al, 2006; Moll et al, 2005). Many viral or cellular oncogenes functionally 
inactivate p53 by direct interaction, causing disruption of p53 homeostasis and 
metabolism (Lee & Gu, 2009; Gilkes et al, 2006; Yuan et al, 2010b) . Overexpression 
of PBF led to a significant increase in p53 turnover in thyroid and colorectal 
carcinomas. Critically, this effect was reversed when PBF was depleted through the 
administration of specific siRNAs. These findings indicate that, under normal 
conditions, PBF might play a physiological role in maintenance of p53 homeostasis 
(Figure 8.1). For example, given that the binding of PBF and p53 may increase 
following γ-irradiation, PBF may be responsible for mediating p53 expression levels 
by increasing p53 turnover following successful maintenance of genome integrity in 
response to DNA damage. The mechanism by which PBF affects p53 turnover 
appears to involve the E3 ligase HDM2. For instance, specific ubiquitin assays 
revealed that PBF overexpression correlated with increased ubiquitination. 
Additionally, other ubiquitin assays indicate that PBF does not possess ubiquitin 
ligase activity, and could not therefore cause p53 ubiquitination directly. Moreover, 
recent data point to an interaction between PBF and HDM2, through co-
immunoprecipitation assays, and continuation of this work by Mr Gavin Ryan 
(University of Birmingham), revealed that the effect of PBF on p53 turnover was 
impaired when HDM2 activity was inhibited following administration of Nutlin. These 
data imply that PBF may function as a novel co-factor of p53, binding to p53 and 
facilitating the interaction of HDM2 thereby increasing the efficiency of p53 turnover 
(Figure 8.1). Therefore, PBF might increase the efficiency of the interaction between 
p53 and HDM2, allowing p53 or HDM2 docking (Figure 8.1). Oncogenic expression 
of PBF may perhaps enhance this function, leading to increased p53 degradation, 
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and potential impairment of p53 function in thyroid cancer. Also, PBF could interact 
with specific regions within the p53 molecule that result in uncoupling of p53 and 
HDM2 following genotoxic insult, thereby allowing PBF and HDM2 to re-associate 
(Figure 8.1). 
 
Figure 8.1: PBF influences p53 protein turnover. A: PBF potentially binds to p53 and 
HDM2 and facilitates HDM2-mediated degradation of p53, serving to keep p53 levels 
low in the absence of cell stress. p-AKT may also play a role in this process. B: 
Oncogenic expression of PBF causes increased p53 turnover, potentially bringing 
about the impairment of p53 responses to cellular stress. 
 
 PBF confers a survival advantage after genotoxic insult 8.4.
Given the effects of PBF on p53 expression, we observed the effects of PBF 
overexpression on cell fate. MTT assays revealed that PBF overexpression 
correlated with increased cell viability or survival after DNA damage, which may be 
not due to inhibition of apoptosis. These findings imply that oncogenic expression of 
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PBF prevents normal cellular responses to DNA damage, thereby potentially allowing 
the incorporation genetic alterations within the genome (Figure 8.2).  
Recently, in a murine model of targeted PBF overexpression within the thyroid, mice 
presented with striking enlargement of the thyroid with significant hyperplastic 
regions. Such findings are indicative of a PBF-mediated growth effect in vivo (Read 
et al, 2011). These mice however, did not develop thyroid tumours following PBF 
overexpression alone (Read et al, 2011, and McCabe laboratory unpublished data). 
Therefore, future experiments could be aimed at assessing tumour formation in these 
PBF transgenic mice following exposure to ionising radiation.  
Interestingly, a potential mechanism for the altered cell growth in these transgenic 
mice was elucidated following the observation that PBF overexpression correlated 
with increased phosphorylation of AKT at ser-473 and hence activation of the AKT 
cell growth pathway (Read et al, 2011). We observed increased activation of AKT 
through serine-473 phosphorylation in human primary thyrocytes and assessed AKT 
activity in thyroid cancer. Our preliminary data suggest that PBF overexpression may 
also induce AKT activity in the presence and absence of ionising radiation. These 
data hint at a potential mechanism for the effect of PBF on cell survival in thyroid and 
colorectal cancer cells. Future studies would continue to assess the effects of PBF 
on AKT activation in thyroid carcinoma cells, to determine whether this effect was 
real. Furthermore, p-AKT appears to play an important role in p53 homeostasis by 
promoting p53 degradation through direct interaction with, and phosphorylation of, 
HDM2 (Ogawara et al, 2002). Therefore, investigating the relationship between PBF, 
p53, HDM2 and AKT, via 2-step co-immunoprecipitation assays, may serve to 
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elucidate the exact mechanisms whereby PBF effects p53 protein expression (Figure 
8.1). 
 
Figure 8.2: Oncogenic expression of PBF causes increased cell survival. PBF 
overexpression increases the HDM2-mediated degradation of p53. This finding 
correlates with an increase in cell survival following genotoxic insult. However, the 
exact functional consequence of PBF overexpression on the p53 pathway in thyroid 
cancer cells remains to be elucidated. 
. 
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 Concluding statements 8.5.
PBF binds to p53 and reduces its half-life in thyroid and colorectal cancer cell lines. 
Lacking intrinsic ubiquitin ligase activity, PBF appears to reduce p53 protein 
expression by bringing about its ubiquitination in an HDM2 dependent manner. The 
mechanism whereby PBF affects p53 expression may in part be due to activation 
and recruitment of p-AKT. Therefore, PBF may serve as a novel co-factor of p53 and 
HDM2 under normal conditions. However, oncogenic expression of PBF may lead to 
aberrant regulation of p53 turnover in thyroid cancer. Surprisingly, our data indicated 
that these effects of PBF on p53 homeostasis did not significantly affect the 
transcriptional functions of p53 in thyroid cancer cell lines. Nonetheless, 
overexpression of PBF conferred a significant survival advantage following DNA 
damage, indicating that oncogenic expression of PBF results in a gross biological 
effect that might potentially facilitate neoplastic growth and tumourigenesis. p53 
tumour suppressor functions encompass a wide range of biological functions, and do 
not always involve gene transcription. PBF may therefore serve to promote p53 
functional inactivation independently of its function as a transcription factor. However, 
the exact consequences of increased p53 degradation in response to oncogenic 
expression of PBF on p53 function remain to be elucidated.  
In conclusion, oncogenic expression of PBF may result in a novel mechanism of p53 
functional inactivation whereby PBF increases the degradation of p53 utilising the 
master regulator of p53, HDM2. These events may serve to increase cell survival 
following DNA damage, ultimately promoting cell transformation and tumorigenesis in 
thyroid cancers expression wild-type p53. 
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